

## RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

(A Govt. of Rajasthan Undertaking)

Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India Tel No: 0141-2228066, 2228064, E-mail: edprmsc@rajasthan.gov.in

# E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF FIRMS FOR DRUGS AND MEDICINES

(Rate Contract for the period ending on 30.09.2027)



LAST DATE OF SUBMISSION OF ONLINE BIDS	05.06.2025 & 06.00 PM
DATE AND TIME OF OPENING OF ONLINE TECHNICAL BIDS	06.06.2025 & 11.00 AM

Signature yalid



Digitally signed by Maroj Kumar Designation, Executive Director Date: 2025.05.06 1 .53:38 IST Reason: Approve

## मुख्यमंत्री निःशुल्क दवा योजना



## RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

(A Govt. of Rajasthan Undertaking)

Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur - 302005, India

Phone No: 0141-2228066, 2228064 Website: www.rmsc.health.rajasthan.gov.in CIN:U24232RJ2011SGC035067 E-mail: edprmsc@rajasthan.gov.in

Ref. No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/871

Dated:- 06.05.2025

## NOTICE INVITING E-Bids

e- Bids are invited by RMSCL, Jaipur from bonafide MANUFACTURERS / LOAN LICENSEE / IMPORTERS / CO-MARKETERS with sole marketing rights for imported proprietary items for rate contract cum supply and empanelment of bidders for Drugs & Medicines. The last date of submission of duly filled up form along with documents on e-proc i.e http://eproc.rajasthan.gov.in and submission of fees is upto 6.00 PM of 05.06.2025 Details of NIB may be seen at the website of State Public Procurement Portal <a href="https://sppp.rajasthan.gov.in/">http://eproc.rajasthan.gov.in.</a>, <a href="https://sppp.rajasthan.gov.in/">http://eproc.rajasthan.gov.in/</a>, http://rmsc.health.rajasthan.gov.in and may be downloaded from there.

Estimated Value (Rs): - 178.37 Crore

UBN No. -

Executive Director (Proc), RMSCL

Signature valid

Digitally signed by Maroj Kumar Designation Execution Date: 2025.05.06 Reason: Appro

## RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

## E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF FIRMS FOR SUPPLY OF DRUGS AND MEDICINES

(Rate Contract for the period ending on 30.09.2027)

Bid Reference No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-

01/2025/871 Dated:-06.05.2025

Date and time for downloading bid document 06.05.2025 from 06.00 PM

Pre- bid conference 13.05.2025 at 11.30 AM (Board room)

Last date and time of submission of online 05.06.2025 up to 06:00 PM

bids

Date and time of opening of Online technical 06.06.2025 at 11:00 AM

bids

Estimated bid Cost Rs. 178.37 Crore

Cost of Bid Document Rs. 2,360/- (including GST @ 18%)

Cost of Bid Document For MSME Unit of Rs. 1,180/- (including GST @ 18%)

Rajasthan

RISL Processing Fees Rs. 2950/- (including GST @ 18%)

Bid Security Fees @2% (for MSME unit of Rajasthan @ 0.5%) of

Estimated Bid value for each quoted item as per

Annexure VIII)

Empanelment Fees (Optional) Rs. 5,900/- (including GST @ 18%)

Signature yalid

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.06.06 17.53:38 IST

Reason: Approve

# INDEX

S.NO	PARTICULARS
	General instruction for bidders
1.	Last date for receipt of bids, bid document fees, Bid Security Deposit, RISL processing fees and empanelment fees
2.	Eligibility criteria
3.	Purchase preference
4.	General conditions
5.	Technical bid
6.	Price bid
7.	Opening of technical and financial bid.
8.	Bid security deposit
9.	Other conditions
10.	Acceptance of bid
11.	Performance Security
12.	Agreement
13.	Supply conditions
14.	Logograms / markings
15.	Packing
16.	Quality testing
17.	Payment provisions
18.	Deduction in payments:
19.	Quality control deduction & other penalties:
20.	Empanelment of bidders
21.	Saving clause
22.	Jurisdiction Jurisdiction
23.	Correction of arithmetic errors
24.	
25.	Procuring entity's right to vary quantity
	Dividing quantities among more than one bidder at (in case of procurement of goods):
26.	Grievance redressal during procurement process:
27.	Compliance with the code of integrity and no conflict of interest:
28.	Fall Clause
29.	Applicability of Rules
5	Annexure-I Bank Challan
Annexure	Annexure -II Format of Affidavit
Ĕ	Annexure -III Annual Turn Over Statement
₹	Annexure -IV Agreement
	Annexure - V Check List
	Annexure - VI Check List of Details Regarding Products Quoted
	Annexure - VII Declaration & Undertaking
	Annexure - VIII List of Drugs With Specifications
	Annexure - IX Guidelines for Blacklisting/Debarring of Product or Supplier/Company
	Annexure - X Memorandum of Appeal Under The Rajasthan Transparency In Public Procurement Act, 2012
	Annexure -XI Undertaking For Empanelment
	Annexure -XII Supplier Consolidated Invoice
	Annexure -XIII Analytical Report Regarding Quality
	Annexure -XIV Performance Security form (Bank guarantee)
	Annexure -XV Land Border Country Registration Requirement
	Annexure –XVI Performance Security Declaration
	Annexure –XVII BIDDER'S AUTHORIZATION CERTIFICATE
	Annexure -XVIII Cianoturo valid
	Annexure –XVIII Annexure –XIX Bid Security Form (Bank Guarantee)  Signature valid

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 17:53:38 IST Reason: Approver

## GENERAL INSTRUCTIONS FOR BIDDERS

The bidders are instructed to read the complete bid document carefully. The following points may be noted so that mistakes/lapses/shortcomings during Bid submission can be avoided.

- 1. It is expected from all bidders that they will ensure that documents to be used in bid set will be given to a reliable person only, and that only a fully reliable person shall be authorized for DSC. So that the confidentiality of your bid/ rates can be maintained upto bid opening & that your documents are not put to any misuse.
- 2. In case you are given any assurance of any advantage in RMSC, by anybody or if you are directly or indirectly threatened or intimidated of harming your bidding & subsequent work in RMSC, please inform immediately about the same to MD, RMSC or ED (Proc.) RMSC. It would be better if evidence of such unfair activity of such person is produced so that action can be taken against such person / institution and their details can be put on the website.
- 3. It is advisable for bidder to authorize only those persons for RMSCL tender who are employed in your company on salary basis.
- 4. The turnover should be as per bid conditions. Do not submit Bid if the turnover of the firm is less.
- 5. Quote only for the products for which Product Permission meets the Bid specifications. Do not quote if it differs with regard to any parameter.
- 6. Quote rate in BOQ for the packing unit exactly given in annexure VIII.
- Highlight the quoted items in the documents like Product Permission and Market 7. Standing Certificate, and also mark the item code no. at appropriate place in the documents.
- 8. The uploaded product permission and other documents should be clearly legible. Date of issue of the documents should be clearly legible.
- 9. Upload the Bids on the e-portal well in advance so that failure in uploading can be avoided and no desired document remains un-uploaded.
- 10. In case there is any suggestion regarding Bid conditions/specifications/shelf life, strength, packing/turn over etc. The suggestions should be submitted/sent/E -Mailed one/two days earlier from the date of pre bid meeting so that the representation of the bidders may be well processed and decision could be taken well in time. Bidders may submit their representations within one working day after pre-bid meeting. Representations received after that would not be entertained.
- One person can only be authorized by one bidder for a particular item. In 11. case, it is found that one person is authorized representative of more than one bidder for a particular item then all such bidders shall be disqualified on the ground of conflict of interest. Signature valid

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 11.53:38 IST Reason: Approve

 If there is any query regarding terms and conditions in Bid document, you may contact:-

Sh. Krishna Pratap Singh, Senior Accounts Officer (Proc)

Ph.0141-2228064, Mob. No. 9953092656

Smt. Swati Sethi, Senior Manager (Drug)

Ph.0141-2228064, Mob. No. 7340662491

If any condition or term which is contrary to RTPP Act 2012 or RTPP Rules 2013, then provisions of RTPP Act 2012 or RTPP Rules 2013 shall prevail and be binding on bidders

Signature yalid

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 17.53:38 IST Reason: Approve

## RAJASTHAN MEDICAL SERVICES CORPORATION LTD. RAJASTHAN

Rajasthan Medical Services Corporation Ltd., (hereinafter referred to as Bids Inviting Authority unless the context otherwise requires) invites E-BID FOR RATE CONTRACT CUM SUPPLY AND EMPANELMENT OF DRUGS AND MEDICINES.

# 1. <u>LAST DATE FOR RECEIPT OF BIDS AND BID FEES, BID SECURITY, RISL PROCESSING FEES AND EMPANELMENT FEES</u>

- (a) E-Bids in two separate bid (Technical bid & Price Bid) can be submitted till up to 06.00 P.M. 05.06.2025 on e-proc portal i.e. https://eproc.rajasthan.gov.in/, for the rate contract cum supply and empanelment for supply of drugs and medicines. (Rate Contract for the period ending 30.09.2027)
- (b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity period for an additional specified period of time. The Bidder may refuse extension of bid validity, and in such a case its Bid security deposit shall not be forfeited.
- (c) The Bids will be received on e-procurement web-portal of Govt. of Rajasthan. Every Bidder will be required to pay the following fees:

S. No.	Fee / Security	In favour of	Mode	Amount (In Rs.)
1	2	3	4	5
1	Bid Processing fee	M.D. RISL	Only DD/ BC	2950/-
2	Bid form fee	M.D. RMSCL	D.D. / BC/ NEFT/ RTGS /IMPS/ Bank challan*	2,360/- (for MSME unit of Rajasthan @ 50% of Bid form fee)
3	Bid Security	M.D. RMSCL	D.D. / BC/ NEFT/ RTGS /IMPS/BG/ e-BG/ Bank challan / Insurance Surety Bonds	@2% (for MSME unit of Rajasthan @ 0.5%) of Estimated Bid value for each quoted item as per Annexure VIII)
4	Empanelment fee (Optional)	M.D. RMSCL	D.D. / BC/ NEFT/ RTGS /IMPS/ Bank challan	5,900/-

### Note:-

- Bank challan\* (format enclosed in Annexure-I) in any branch of the BANK OF MAHARASHTRA Account no.-60460019022 & IFSC Code no. MAHB0000389 throughout country.
- 2. S. No. 1, 2 & 4 fee amounts including GST @ 18% (as applicable).

All D.D. / Banker cheque/copy of all the recension of the recension of the check of

Digitally signed by Mar of Kumar Designation Executive Director Date: 2025.06.06 17.53:38 IST

Reason: Approve

Insurer registered with the Insurance Regulatory and Development Authority of India (IRDA) for transact the business of issuing Insurance Surety Bonds should be submitted physically in the office of RMSCL on 05.06.2025 up to 6:00 PM. The bidders shall submit/upload scanned copy of all the receipts, D.D./BC/NEFT/RTGS/IMPS/BANK CHALLAN/ BG/ e-BG/ of a scheduled bank or Insurance Surety Bonds issued by Insurer registered with the Insurance Regulatory and Development Authority of India (IRDA) for transact the business of issuing Insurance Surety Bonds in Technical Bid. Bids will be opened only after ensuring receipt of Bid document fees along with processing fees and Bid Security Deposit. In the absence of Bid document fees and processing fees and Bid Security Deposit the Bids will be rejected and will not be opened. The validity of Bank Guarantee/e-BG should be for 6 months from the date of issuance of BG/e-BG.

- (d) Click on offline mode (either DD or BC) on e procurement portal for the purpose of bid uploading only. For Empanelment as supplier for drugs and medicines, bidders are required to deposit separately an Empanelment Fee (Optional) of Rs 5900 (inclusive of GST @18%) (Five Thousand Nine Hundred rupees only) as mentioned above in condition no. 1(c). Please see clause 20 and Annexure-XI in this regard.
- (e) DD/ BC/ NEFT/RTGS/IMPS/BANK CHALLAN/BG/e-BG submitted by bidder should have been purchased/transferred/deposited from the account of the bidder only. If it is found that such fee have been paid from any bank account / person other than the bidder, than such fee would not be considered and such bids would be rejected.

### 2. ELIGIBILITY CRITERIA

(a) Bidder should be a manufacturer having valid manufacturing license/loan license or direct importer holding valid import license. Distributors/ Suppliers / Agents are not eligible to participate in the Bids.

For patented / proprietary imported items manufactured outside India, Comarketers having sole marketing rights in India are also eligible to participate.

- (b) In Case of Manufacturer The bidder must have a valid manufacturing license issued by the State Licensing Authority / Central Licensing Authority.
- (c) In Case of Importer Bidder should have a valid import license for the quoted item (s) issued by the Central Licensing Authority. Importer should also have a valid sale license (On form no. 20B, 21B also as applicable.)
- (d) Bidder should have valid Product Permission to manufacture the item /drug quoted as per specification given in the Bid from the State Licensing Authority / Central Licensing Authority produce Sermission of brands shall be accepted in the Bid submitted.

Digitally signed by Maroj Kumar Designation, Executive Director Date: 2025.05.06 17:53:38 IST

Reason: Approve

- (e) Bidder must have WHO-GMP (WHO Good manufacturing practices Certificate) Certificate issued by the State Licensing Authority / Central Licensing Authority.
- (f) Bidder must have Non-conviction Certificate issued by the State Licensing Authority/Central Licensing Authority. It should be recent and not more than one year old.
- (g) Bidder must have Market Standing as per required in technical bid.
  - Note: (i) The Market Standing Certificate issued by State Licensing Authority/Central Licensing Authority should not be more than 2 years old from the last date of bid submission.
  - (ii) The period of Market Standing will be reckoned from the date of issue of Product Permission.
- (h) Annexure-VII as per bid document. (Declaration & Undertaking on Non-Judicial Stamp Paper of Rs. 500/-).
- Bidder should have Average Annual Turnover (for Drugs & Medicines including Surgical and sutures or medical devices business) as per technical bid. (Clause 5(m))
- (j) Bidder must have submitted GST registration Certificate and its GST returns for the last three months form the last date of bid submission.
- (k) Bidder must have committed monthly supply of 5% of the tendered quantity for each item.

## (l) Debarring/Banned/Blacklisting/ Not of Standard Quality etc.:-

- I. Bid should not be submitted for the product/products for which the concern/company stands blacklisted /banned/debarred on the date of bid submission either by Bid inviting Authority or Govt. of Rajasthan or its departments on any ground. The Bid should not be submitted for those for which products also the concern/company stands blacklisted/banned/debarred on the date of bid submission by any other State/Central Govt. or it's any agencies (central Drugs procurement agencies) on the ground of conviction by court of law or the products being found Not of Standard Quality. (NoSQ)
- II. The concern/company/firm which stands blacklisted/banned/debarred on any ground either by Bid Inviting Authority (RMSCL) or Govt. of Rajasthan or its departments on the date of bid submission, shall not be eligible to participate in the Bid. The concern/company/firm which stands blacklisted/banned/debarred on the ground Significantly read of the the products being found Not of Standard Quanty (NoSQ) by a ther

Digitally signed by Maroj Kumar Designation, Execute Director Date: 2025.06.06 1 .53:38 IST

Reason: Approve

State /Central Government or it's any agencies (central Drugs procurement agencies) shall also not be eligible to participate in the Bid. For Specific cases regarding other quality issues the purchase committee of RMSCL may decide the case on merit basis.

- III. If any product/products of a company/firm have been declared as not of standard quality, as per Drugs & Cosmetics Act 1940 and Rules 1945 during last 2 years anywhere, such concern/company/firm shall not be eligible to participate in Bid for such product/products. If any company/firm is found to have any such product quoted in the Bid, the product shall be blacklisted for 2 years and Bid security of that item shall be forfeited
- IV. The concern/firm/company whose product has been declared as of spurious or adulterated quality and any criminal case is filed and pending in any court shall not be eligible to participate for that particular product, in the Bid. Similarly convicted firm/company shall also not be eligible to participate in the Bid.

## 3. PURCHASE PREFERENCE

- Price preference is not applicable as GST has been made effective from 01.07.2017 in place of VAT.
- Purchase preference shall be given to MSME's unit of Rajasthan as per notification of Finance (GF&AR Division) Department, Government of Rajasthan notification S.O.165 dated 19.11.2015).

## 4. GENERAL CONDITIONS

- (a) At any time prior to the date of submission of Bid, Bid Inviting Authority may, for any reason, whether on his own initiatives or in response to a clarification requested by a prospective Bidder, modify the condition in Bid documents by way of amendment. In order to provide reasonable time to take the amendment into account in preparing their bid, Bid Inviting Authority can at his discretion, extend the date and time for submission of Bids.
- (b) Interested eligible Bidders may obtain further information in this regard from the office of the Bid Inviting Authority, i.e RMSCL.
- (c) In case any document submitted by the bidder or his authorized representative is found to be forged, false or fabricated, the bid will be rejected and Bid Security/Performance Security will be forfeited. Bidders or their representative may also be blacklisted/banned/debarred. Report with police station can also be filed.

## 5. TECHNICAL BID

The Bidder should furnish the following in technical bid along with relevant documents:-

(a) Bidders are allowed the option to quote for Symptotic mentioned in bid (list of drugs and medicines proposed to be pured at the control of the control o

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 11.53:38 IST

Reason: Appro

Annexure-VIII). The amount of Bid Security Deposit shall be @ 2% of Estimated Bid value for each quoted item as per Annexure – VIII

- (b) The bidders shall submit/upload scanned copy of all the copy of receipts, NEFT/RTGS/IMPS/BANK CHALLANS, D.D. / BC/BG/e-BG annexed with Technical Bid as proof of deposition/ submission of Bid document fees, RISL processing fee and Bid security. The required Bid Security Deposit / Bid document fees may be in form of physical D.D./ BC and should be in favour of M.D. RMSCL. The Bid Security may be given in the form of bank guarantee or electronic bank guarantee (e-BG) also in specified format of a scheduled bank in case the amount exceeds Rs 5 lac. For amount of up to Rs 5 lac, it should be deposited through D.D./ BC/ NEFT/RTGS/IMPS. The validity of bank guarantee / e-BG should be for 6 months from the date of issuance of BG / e-BG. RISL fee should be paid in form of DD/BC only in favour of M.D. RISL. D.D./ BC submitted by the bidder should have been paid from any bank account / person other than the bidder, than such fee would not be considered and such bids would be rejected.
- (c) Those who Bidders which are found responsive on technical grounds would be empanelled also on submission of Annexure-XI and payment of empanelment fee of Rs. 5000 +GST@18% for supply of drugs and medicines item (s) mentioned in Annexure-VIII for one year. The empanelment would entitle a firm to participate in limited bids invited by the RMSCL. Such situations may normally arise when the open bid for drugs and medicines item (s) fails and there is an urgency to purchase it, or when the L-1 bidder has fail to supply, or the rate contract of an item ceases to exist for any reasons. The Bidder has to submit an undertaking in the format given at Annexure –XI, The Bidder who have already paid empanelment fee earlier (within a year), need not to submit the empanelment fees for the item (s) being quoted in this bid. However the required Annexure-XI must be submitted.
- (d) Documentary evidence for the constitution of the company / firm such as Memorandum and Articles of Association with certificate of incorporation issued by registrar of companies, Partnership Deed, Self declaration on letter head in case of proprietor ship firm etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director/Partners/Proprietor.
- (e) The instruments such as power of attorney, resolution of board etc., authorizing an officer of the Bidder should be enclosed. (Annexure XVII). One person can only be authorized by one bidder for a particular item. In case, it is found that one person is authorized representative of more than one bidder for a particular item then all such bidders shall be disqualified on the ground of conflict of interest.
- (f) Bidder have to submit following valid licenses:-

Signature yalid

Digitally signed by Mar of Kumar Designation, Executive Director Date: 2025.05.06 1 .53:38 IST Reason: Approve

i) For Manufacturer:- The bidder must submit a valid manufacturing license / loan license issued by the State Licensing Authority/Central Licensing Authority under Drugs & Cosmetic Act 1940 and Rules 1945 there under wherever applicable for each quoted item (s).

In case bidder has submitted expired manufacturing license, then a copy of acknowledgment of renewal application issued by the State Licensing Authority/Central Licensing Authority or copy of original treasury challan regarding manufacturing license retention fees shall also be enclosed.

ii) For Importer:- In case of importers, Bidder should have a valid import license for the quoted item (s)issued by the Central Licensing Authority.

In case bidder has submitted expired Import license, then a copy of acknowledgment of renewal application issued by the Central Licensing Authority or copy of original treasury challan regarding Import license retention fees shall also be enclosed.

Importer should have to submit valid sale license (On form no. 20B, 21B also as applicable.)

# iii) For Co -marketer\_:- Bidder should have to be submitted following documents -

- Import license of principle manufacturer of patented/proprietary imported items.
- WHO- GMP / COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US- FDA approval, etc.
- Sale license of co-marketer firm.
- Non conviction certificate of both firms i.e. importer and co-marketer firm. (Condition no. 5 (k) shall be applicable)
- 5. Market standing certificate for quoted item as per tender conditions. (condition no. 5 (j) (2) shall be applicable)
- Market standing certificate of co-marketer firm as per tender conditions. (condition no. 5 (j) (2) shall be applicable)
- Undertaking that the Co-marketing firm shall be accountable towards all responsibilities/ liabilities as per tender terms and conditions and full fil all such requirements.
- (g) If a company has two or more separate manufacturing units at different sites/states, the company will be allowed to submit only one Bid for all units but necessary documents related to each manufacturing unit shall have to be submitted as a separate set with the same Bid. A bidder shall be allowed to submit only one offer for one bided item.
- (h) Bidder should have valid Product Permission of the state licensing a per specification given in the Bid from the state licensing a perity of the state licensing a perity of the state licensing and the state licensing a perity of the state licensing and the state licensing a perity of the state licensing and the s

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 11.53:38 IST Reason: Approve

Central licensing authority. Product permission of brands shall be accepted in the Bid submitted.

(i) WHO-GMP (WHO - Good manufacturing practices Certificate) Certificate issued by the State licensing authority / Central licensing authority. The WHO-GMP certificate must not be older than one year from the due date of Bid submission in the case where validity is not mentioned in the certificate. The WHO-GMP certificate of all the manufacturing plants, of which products have been quoted, should be submitted. The Bidder shall also furnish an undertaking in the format given in Annexure-VII point no.8 declaring that the Bidder complies with the requirements of WHO-GMP.

The Importer should produce WHO- GMP / COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US-FDA approval, etc.

The Firm will continue to hold WHO-GMP Certificate for the product during entire rate contract period of the product. If WHO-GMP certificate expires, it is firm's responsibility to inform RMSCL about the same and not to accept any further purchase order till re-issue /renewal of WHO-GMP certificate. During the period of non validity of WHO-GMP certificate of the firm the rate contract will deemed to be suspended. If the firm fails to inform RMSCL about the expiry of WHO-GMP certificate and accept purchase order of RMSCL and later on it comes to the knowledge of RMSCL, in this situation firm shall be liable for a panel action.

- (j) Bidder have to submit Marketing Standing of the bided item (s) as below:-
  - 1. For Manufactured Item (s):- Bidder must have Market Standing Certificate for last three years from the last date of bid submission, issued by the State Licensing Authority/Central Licensing Authority under Drugs & Cosmetic Act 1940 and Rules 1945 there under wherever applicable for the quoted item (s)from the last date of bid submission.

### 2. For imported item (s):-

- (i) The importer should have at least 3 years standing as manufacturer/ importer of drugs in general.
- (ii) In the case of imported products, the product should have minimum 3 years standing in the market.

For which following documents should be submitted:-

(a) Bills of lading / Bills of entry and Sale invoices for last three years along with CA certificate with UDIN verifying details of bills of lading / bills of entry and sales invoices of bidder. (As per Annexure-XVIII) Signature valid

OR

Digitally signed by Markj Kumar Executi Designation Date: 2025.05 Reason: Appro

(b) Market Standing Certificate issued by the Central Licensing Authority/ State Licensing Authority under Drugs & Cosmetic Act 1940 and Rules 1945 for last three years.

OR

- Market standing for the product in international market would be considered for establishing eligibility regarding this particular clause of the bidding document. Also if a bidder is manufacturing a product abroad at various locations/countries and participating in the bid quoting a product being manufactured at a particular place, market standing of the product manufactured at other than particular place would be considered." In such case Market Standing for the quoted item (s) in international market issued by competent authority of manufacturing country / country of origin or Bills of lading / Bills of entry and Sale invoices for other than manufacturing country / country of origin for last three years should be submitted. If submitted bills of lading / bills of entry and sale invoices are issued in other than English language than verified translated (in English language), self-attested copies of the same should be submit along with original ones.
- (k) Bidder must submit Non-conviction Certificate issued by the State Licensing Authority/Central Licensing Authority for all manufacturing licenses / Import licenses as mentioned in Annexure VII. In case of Importer firm, Non- conviction certificate issued for all sale licenses (as mentioned in Annexure VII) of firm may also be acceptable. Submitted Non-conviction Certificate should be recent and not more than one year old form the last date of bid submission.
- In case of proprietary item (s) of a particular firm / bidder, the bidder (I) should submit its proprietary certificate along with detail of validity period.
- (m) Average Annual turnover (for Drugs & Medicines including Surgical and sutures or medical devices Business) in the last three financial years.

Average Annual turnover (for Drugs & Medicines including Surgical and sutures or medical devices Business) in the last three financial years [2021-22, 2022-23 & 2023-2024 or 2022-2023, 2023-2024 and 2024-2025 (Audited Final Accounts) shall not be less than Rs. 20 Crore and for MSME Units of Rajasthan, the average annual turnover in the last three financial years [2021-22, 2022-23 & 2023-2024 or 2022-2023, 2023-2024 and 2024-2025 (Audited Final Accounts)] shall not be less than Rs. 10 Crore.

For drug items falling in the category of Disinfectants & Antiseptics, Eye preparations and Ear drops etc. bidder's firms average annual turnover of last three financial years should not be less than Rs. 2 Crore.

The same should be supported by audited annual accounts & certified by a Chartered Accountant, based on audited accounts. No provisional accounts shall be accepted/considered.

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 1 .53:38 IST Reason: Appro

### Annual Turnover Statement without UDIN number shall not be considered.

## Explanatory Note:-

The merger / amalgamation / transfer of business / transfer of assets of a firm affect the bid condition relating to 'Turnover' / 'Past Performance' / 'Market Standing Certificate' in preceding years. The eligibility of a bidder in this regard shall be ascertained by the Purchase Committee on the basis of the above stated agreement / BOD resolution / CA certificate or any other document(s) / certificates which shall be annexed with the tender documents.

- (n) Details of GST registration. The industries situated in GST free zones will produce the copy of appropriate notification. Bidders has to submit GSTIN number and state where GSTIN registered for every quoted item (s) for which supply will be made (Annexure VII at point no.3).
- (o) GST returns file of last 3 months from last date of bid submission
- (p) Undertaking (as in Annexure-VII) for embossment of logo on packing of drugs and medicines as the case may be, as per conditions specified at Clause 14 herein.
- (q) The bidder who are manufacturing firm should have its own in-house testing laboratory wherein all the tests required with respect to the quality standards of quoted products are carried out. An undertaking be submitted in Annexure-VII.
- (r) Undertaking that the manufacturer has not been debarred/banned, the product never been declared as Not of Standard Quality (NoSQ) during last two years, it's manufacturing capacity and other details required on a format mentioned at Annexure- VII.
- (s) List of item (s) quoted to be shown in the Annexure- VII point number 6 with license number (manufacturing/Import/Sale license) written on it.
- (t) A Checklist (Annexure-V) for the list of documents enclosed with their page number. The documents should be serially arranged as per Annexure-V. Every bidder shall also be required to submit details of product permission of the quoted item (s) and the desired market standing, in Annexure-VI.
- (u) An undertaking that the bidder complies with all the terms, conditions, amendments (if any) of bid document and quoted item (s) confirm all parameters of specification and required standards to be submitted in **Declaration & Undertaking** (Annexure-VII point no.12)
- (v) Certificate that bidders with beneficial ownership from countries sharing land border with India, for participation in any public procurement in the State, shall only be allowed after prior registration with the authority as per Rule 13 of RTPP Rules and Government of Rajasthan Notification No. F.2(1)FD/G&T-SPFC/2017 dated 01.01.2021, 15.01.2021 and 30.03.2021 (Annexure XV)
- (w) A copy of PAN issued by Income Tax Department, GoI

Note:-

Signature yalid

Digitally signed by Mar of Kumar Designation Executive Director Date: 2025.05.06 17:53:38 IST Reason: Approve

 The bidder must highlight the quoted item(s) in submitted documents to support the technical evaluation of the bid.

## Special Note to bidder:-

- 1. Bidders are again advised to fill the Annexure -VII very carefully as after bid opening any amendment in Annexure-VII would not be allowed in any case. Bidders should ensure that all relevant documents i.e. Product Permission, WHO-GMP certificate, Market standing certificate, Non Conviction Certificate should be in accordance with the license no. / Product Permission mentioned in the Annexure VII. Bids Submitted without duly filled Annexure-VII would be declared Non-Responsive.
- Bidders who fail to submit documents as under, would summerly declared as non-responsive:-
  - (a) In case Product Permission either not submitted or not as per tender conditions/specifications of the item; If Product Permission is as per specifications of item mentioned in the tender but it's for export purpose, the Product Permission for domestic manufacturing would be accepted only when asked through clarification and provided that such Product Permission for domestic manufacturing has been issued on or before the last date of bid submission.
  - (b) If WHO-GMP certificate and/or Non-Conviction certificate and/or Market Standing Certificate have not been submitted in main bid or not as per tender condition/item specifications. It has also been observed that in certain cases, licensing authority takes time in issuance / renewal of aforesaid certificates, in such cases bidders have to invariably enclose expired documents/certificates along with copy of acknowledgment of application for renewal of such documents filed with licensing authority. In such cases bidders would be allowed to submit renewed documents at the time of clarification sought by the RMSCL, provided that the renewed documents should have been issued on or before the date of submission of clarifications as sought by the RMSCL.

## 6. PRICE BID -

The price bid will also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). BOQ template must not be modified/replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bidder is liable to be rejected for this bid. Bidders are allowed to enter the bidder name and values only.

The bidder should quote rate for the mentione Signature valid

Digitally signed by Maroj Kumar Designation, Executive Director Date: 2025.05.06 17:53:38 IST

Reason: Approv

#### 7. OPENING OF TECHNICAL AND FINANCIAL BID

- (a) The Technical Bid will be scrutinized by Bid evaluation committee.
- (b)Technical Evaluation of the Bid will be done on the basis of documents submitted by the bidder.
- (c) Price Bid (BOQ) of the Bidder found eligible on satisfying the criteria for technical evaluation, will only be opened.

#### 8. BID SECURITY

The Bid Security shall be @ 2% of Estimated Bid value for each quoted item as per Annexure - VIII. In case Bid Security submitted by the bidder is Less than the required bid security as per total no. of quoted item (s), the quoted items by the bidder will be counted in sequence up to the number matching the Bid Security deposited.

Bid Security will not be taken from undertakings, corporation of GoI & GoR. Further, Bid Security will be taken @ 0.5% of Estimated Bid value for each quoted item as per Annexure - VIII from MSME Units of Rajasthan. They will furnish copy duly attested by gazetted officer of the registration of MSME units of Rajasthan issued by the Director of Industries in respect of the stores for which they are registered. Duly attested copy of Acknowledgement of EM-II issued by DIC with an affidavit worth Rs.100 as per Annexure-II under preference to Industries of Rajasthan rules 1995 in respect of stores for which they are registered. (Annexure-II(B)).

The Bid Security shall be paid through separate prescribed challan (format enclosed in Annexure-I) in any branch of the BANK OF MAHARASHTRA Account no.-60460019022 & IFSC Code no.MAHB0000389 throughout country upto 05.06.2025 or through D.D. / bankers cheque in favour of M.D. RMSCL or may be given in the form of bank guarantee (e-BG) (for amount above Rs 5 lac) also in specified format (Annexure-XIX) of a schedule bank or Insurance Surety Bonds issued by Insurer registered with the Insurance Regulatory and Development Authority of India (IRDA) for transact the business of issuing Insurance Surety Bonds. For amount of bid security up to Rs. 5 Lac, it should be deposited through DD/Banker cheque/Challan/ NEFT/RTGS/IMPS. The validity of bank guarantee/e-BG should be for 6 months from the date of issuance of BG/e-BG. (As per Annexure-XIX).

receipts. D.D. BC/BG/e-BG, copy of all the NEFT/RTGS/IMPS/BANK CHALLAN/ should be submitted physically in the office of RMSCL on 05.06.2025 upto 06.00 PM. Bid security Deposit in Signature valid any other form will not be accepted.

> Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05 Reason: Appro

The Bids submitted without sufficient Bid Security will be summarily rejected. The Bid Security will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails within specified time to sign the contract agreement or fails to furnish the performance security. Other actions would also be taken as per RTPP Act 2012 & Rules 2013 and guidelines for blacklisting/debarring of RMSCL.

## 9. OTHER CONDITIONS

- The orders will be placed by the Managing Director or any officer designated, Rajasthan Medical Services Corporation Ltd, (hereinafter referred to as Ordering Authority).
- 2. The details of the required drugs, medicines, etc., are shown in Annexure-VIII. The quantity mentioned is only the tentative requirement and may increase or decrease as per the decision of Ordering Authority. The rates quoted should not vary with the quantum of the order or the destination. The commitment quantity for an item submitted by the bidder (in Annexure VII) shall be taken into account. The whole commitment quantity to be supplied during contract period should not be less than estimated bid quantity. As well, the monthly commitment quantity should not be less than 5% of the whole commitment qty. A bidder having manufacturing capacity less than commitment quantity (either monthly or for whole contract period) may be technically disqualified.
- 3. Bid has been floated with the generic names of drugs. The Bidders should quote the rates for the generic products. The composition and strength of each product should be as per details given in Annexure-VIII. Any variation, if found, will result in rejection of the Bid. The products should conform to the specified standards IP/BP/USP. In case the product is not included in the said compendium, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing.
- 4. Rates (inclusive of <u>all expenses / charges but exclusive of GST</u>) should be quoted for each of the required drugs, medicines etc., separately on door delivery basis according to the unit ordered. Bid for the supply of drugs, medicines, etc. with conditions like "AT CURRENT MARKET RATES" shall not be accepted. Handling, clearing, transport charges etc., will not be paid. The delivery should be made as stipulated in the purchase order placed with successful Bidders. No quantity or cash discount should be offered.
  - To ensure sustained supply without any interruption, the Bid Inviting Authority reserves the right to fix more than one supplier to supply the requirement among the qualified Bidders

Signature yalid

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 17.53:38 IST Reason: Approver

- b) Orders will be placed periodically during rate contract period based on the RMSCL's requirement to the firms approved for rate contract as per above clause no. 3.
- c) After the conclusion of Price Bid opening, the lowest offer of the Bidder, if required will be considered for negotiations, and rate arrived after negotiations will be L-1 rate and L-1 supplier for an item of drugs/medicines for which the Bid has been invited.
- d) The Bidder who has been declared as L-1 supplier for certain item or items of drugs/medicines shall execute necessary agreement for the supply of the Bided quantity of such drugs/medicines as specified in the Bid document on depositing the required amount as performance security and on execution of the agreement, such Bidder is eligible for the placement of purchase orders. Moreover, purchase order can be placed after the issue of letter of acceptance, pending the execution of agreement and issuance of rate contract for an item.
- e) RMSCL will inform the L1 rate to the Bidders who qualified for Price Bid opening, through RMSCL web site or e-mail; willing bidders may inform in their consent to match with the L-1 rate for the item of the Drugs/Medicines quoted by them and the Bidders who agree to match L1 rate, will be considered as Matched L1.
- f) The Bidder, who agrees to match L-1 rate shall furnish the breakup detail (Rate, GST etc.) of price (L-1 rate).
- g) The supplier upon receipt of the purchase order finds that the purchase orders exceeds the production capacity declared in the Bid documents and the delay would occur in executing the order, shall inform to the RMSCL immediately without loss of time and the purchase order shall be returned within 7 days from the date of the order, failing which the supplier is stopped from disputing the imposition of liquidated damages, fine for the delayed supply.
- h) If the L1 supplier has failed to supply /intimated RMSCL about his inability/delay in supply as per the purchase order, the required Drugs/ Medicines within the stipulated time or as the case may be, RMSCL may also place purchase orders with the L1 Rate Matched Bidder for purchase of the Drugs/Medicines, provided such rate matched Bidders shall execute necessary agreement indicating the production capacity Specified in the Bid document

Digitally signed by Maroj Kumar Designation Execut Date: 2025.06

Reason: Appro

- on depositing the required amount. Such Bidder is eligible for the placement of purchase orders for the item or items of Drugs/Medicines quoted by them.
- i) Subject to Para (h) above, while RMSCL has chosen to place purchase orders with Matched L1 supplier and there are more than one such matched L1 suppliers, then the purchase orders for the requirement of Drugs/Medicines will be placed with L-2 first on matched rates of L-1 and in case L-2 does not have the required capacity than L-3 would be considered on matched L-1 rates and the same order would be followed in case of L-3, L-4 etc.
- The matched L1 supplier, on placement of purchase orders, will be deemed as L-1 rate supplier for the purpose of the Bid and all provisions of the Bid document applicable to L-1 rate Bidder will apply mutatis mutandis to the matched L1 supplier.
- k) If the purchase order quantity is very less (which do not make even a normal small batch size; order quantity is less than 1 lac Tab/Cap, or less than 10,000 injections/ bottles/ tubes), the supply may be allowed in brand name to ensure uninterrupted sustained supply. However, the label should possess the required logogram, and the price should not appear on the label.
- 5. The rates quoted and accepted will be binding on the Bidder during validity period of the bid and any increase in the price (except increase in GST rate or any other statutory taxes) will not be entertained.
- No Bidder shall be allowed to claim revision or modification of bid after opening of bid. If any bidder withdraws or modifies its bid after opening of bid the Bid security of that item taken from the bidder shall be forfeited. Representation to make correction in the Bid documents on the ground of Clerical error, typographical error, etc., committed by the Bidders in the Bids shall not be entertained after submission of the Bids. Conditions such as "SUBJECT TO AVAILABILITY" "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the Bids of those who have given such conditions shall be treated as incomplete and accordingly the Bid will be rejected.
- The rates should be quoted only for the composition stated in the Bid.
- Supplies should be made directly by the bidder and not through any other agency.
- 9. The Bidder shall allow inspection of the factory at any time by a team of Experts/Officials of the Bid Inviting Authority and or of the Govt. of Rajasthan. The Bidder shall extend all facilities to the team to enable to inspect the manufacturing process, quality control measures adopted etc., in the manufacture of the items Signature valid

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 11.53:38 IST Reason: Appro

quoted. If a Company/Firm does not allow for any such inspection, its Bid / contract may be rejected.

## 10. ACCEPTANCE OF BID

- The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria.
- Bid Inviting Authority reserves the right to accept or reject the Bid for the supply of all or any one or more items of the drugs Bided for in a Bid without assigning any reason.
- 3. Bid Inviting Authority, or his authorized representative (s) has the right to inspect the factories of Bidders, before, accepting the rate quoted by them, or before releasing any purchase order(s), or at any point of time during the continuance of Bid and also has the right to reject the Bid or terminate/cancel the purchase orders issued and or not to reorder, based on adverse reports brought out during such inspections.
- 4. The acceptance of the Bids will be communicated to the successful Bidders in writing/through E-mail by the Bid inviting authority. Immediately after receipt of acceptance letter, the successful Bidder will be required to deposit performance security and the agreement within 15 days from issuance of Letter of Acceptance.
- The approved rates of the successful Bidders would be valid up to 30.09.2027 (w.e.f date of letter of acceptance) and extendable up to 3 months, if required.
   Firm shall be bound to accept the extension period of Rate Contract.
- Moreover, purchase order can be placed after the issue of letter of acceptance, pending the execution of agreement and issuance of rate contract for an item.

## 10.PERFORMANCE SECURITY

The Successful Bidders shall be required to pay performance Security Deposit @ 5 % of the Contract value. Performance security will not be taken from undertaking, corporation of Gol & GoR. They have to submit a declaration as per Annexure-XVI for performance security. The MSME Units of Rajasthan shall be required to pay Performance security @ 1% of the contract value.

The performance security shall have an upper limit of Rs. 25 Lac to be deposited by a bidder at the time of signing of agreement (For one or many item). However, when the actual purchase orders cross a threshold for requiring additional security, the same will be required to be deposited by the supplier.

The performance guarantee should be paid upfront in respect of each contract on or before the due date fixed by Bid inviting authority in the form of Bank Guarantee or electronic bank guarantee (e-BG). (Performa given in Annexus in the form of Bank Guarantee)

Digitally signed by Mar of Kumar Designation, Executive Director Date: 2025.05.06.11.53:38 IST Reason: Approver

Bonds issued by Insurer registered with the Insurance Regulatory and Development Authority of India (IRDA) for transact the business of issuing Insurance Surety Bonds. In case the amount exceeds Rs. 5 Lac. For amount of up to 5 Lac, it should be deposited in the form of demand draft/bankers cheque issued by a scheduled bank or may be deposited through challan annexure-1 (the validity of bank guarantee should be for a period of Twenty four month from the date of issuance of Bank Guarantee) in favour of the Managing Director, Rajasthan Medical Services Corporation Ltd, Payable at Jaipur before releasing the purchase order by the ordering authority. In case Rate Matched Bidders who have agreed to supply at L-1 price, then the performance security Deposit of such bidders will be 5% of value of quantity fixed for them. (Upper limit Rs 25 Lac). Performance Security shall remain valid and refunded 60 days beyond the date of completion of all contractual obligations or after 36 months from the date of issuance of letter of acceptance, whichever is later.

#### 12. AGREEMENT

- a) The successful Bidder shall execute an agreement on a non-judicial stamp paper of value mentioned in the Acceptance Letter (stamp duty to be paid by the Bidder) within 15 days period from the date of Letter of acceptance / Letter of intent or within extended period by the Bid Inviting Authority, i.e. the Managing Director, Rajasthan Medical Services Corporation Ltd. The Specimen form of agreement is available in Annexure-IV. Failing to submission of performance security and execution of agreement within stipulated period as above, will result in forfeiture of Bid Security Deposit & other consequential action. A bidder who is found successful in more than one product; he will be intimated through LOA / LOI to execute agreement for all the products / drugs / items. If such bidder will not execute agreement for one or more items, in such situation Bid security of that item shall be forfeited and the product for which agreement is not executed shall be debarred for a period of not less than 3 years as per guidelines for blacklisting/debarring of RMSCL.
- b) The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any person or persons whatsoever.
- c) All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or left at the premises, places of business or abode.

#### 13. SUPPLY CONDITIONS

(a) Purchase orders along with the delivery destinations will be placed on the successful Bidder at the discretion of the Ordering Authority. Drugs and Medicines will be Signature valid

> Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 1 .53:38 IST Reason: Appro

- supplied at 34 district drug ware houses and 6 Medical College Warehouses of Rajasthan.
- (b) Purchase orders will be placed on the successful Bidder at the discretion of the Ordering Authority.
- (c) The supplier shall supply the entire ordered quantity before the end of 60 days from the date of issue of purchase order at the destinations mentioned in the purchase order, if the above day happened to be a holiday for RMSCL, the supply should be completed by 5.00 p.m. on the next working day. For drug items requiring sterility test and imported ones, the supply period will be 75 days from the date of issue of purchase order.
- (d) All supplies will be scheduled for the period from the date of purchase order till the completion of the bid in installments, as may be stipulated in the purchase order.
- (e) Shelf Life: The labeled shelf life of drugs supplied should be not less than the period mentioned against each item in list of Drugs (Annexure-VIII). The remaining shelf life of the drugs at the time of delivery should not be less than ¾ of the labeled shelf life. Only those bidders shall quote who can manufacture and supply the product with the required shelf life. The product of labeled shelf life lesser than required shelf life will not be accepted. The product should not have such storage condition requiring it to be stored below 2°C.

# For all imported items ± one month relaxation in the labelled shelf life is permissible.

Quality Assurance: The supplier shall guarantee that the products as packed for shipment (i) comply with all provisions of specifications and related documents (ii) meet the recognized standards for safety, efficacy and quality; (iii) are fit for the purpose made; (iv) are free from defects in workmanship and in materials and (v) the product has been manufactured as per WHO-GMP.

In case of imported items the remaining shelf life of 60% or more may be accepted with an undertaking that the firm will replace the unused expired stores with fresh goods. However, firms supplying drugs with remaining shelf life of 75% or more need not submit such undertaking.

those required specifically for the product specifications. The Bidder must submit its Test/ Analysis Report for every batch of drug along with invoice. In case of failure on the part of the supplier to furnish such report, the batch of drugs will be returned back to the supplier and he is bound to replenish the same with approved laboratory test report. The supplier shall provide the validation data of the analytical procedure used for assaying the components and shall provide the protocols of the tests applied and the placebo material when demanded for the purpose of testing.

Digitally signed by Maroj Kumar Designation, Execut e Director Date: 2025.05.06 17:53:38 IST Reason: Approve

1873

- (g) The Drugs and medicines supplied by the successful Bidder shall be of the best quality and shall comply with the specification, stipulations and conditions specified in the Bid documents.
- (h) If supplies are not fully completed in 60 days from the date of the Purchase Order (75 days for drugs of the category of serum, vaccine, enzymes, blood grouping reagents, biological products, powder for injections and imported drugs), the provisions of liquidated damages of Bid conditions will come into force. The Supplier should supply the drugs at the Warehouse specified in the Purchase Order and if the drugs supplied at a designated places other than those specified in the Purchase Order, transports charges will be recovered from the supplier.
- (i) If the supplier fails to execute at least 50% of the quantity mentioned in a purchase order and such part supply is come into existence in three Purchase orders during the currency of contract period, then supplier shall be liable for debarment for the particular product for two years. Two years period will be reckoned from the date of issuance of such debarment order.
- (j) If the Bidder fails to execute the supply within the stipulated time, the ordering authority is at liberty to make alternative purchase of the items of drugs and medicines for which the Purchase orders have been placed from any other sources (such as Public Sector undertakings at their rates, empanelled bidders, and bidders who have been technically qualified in the said bid) or in the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the Ordering Authority/Bid inviting authority has every right to recover the cost and impose penalty as mentioned in Clause 19, apart from terminating the contract for the default.
- (k) The order stands cancelled after the expiration of delivery period, and if the extension is not granted with or without liquidated damages. Apart from risk/alternate purchase action, the Bidder shall also suffer forfeiture of the performance security and shall invite other penal action like blacklisting/Debarring disqualification from participating in present and future Bids of Bid Inviting Authority/ordering authority. . (As per guidelines for blacklisting/ debarring at annexure- IX including amendment)
- It shall be the responsibility of the supplier for any shortage/damage at the time of receipt at the designated places.
- (m) If at any time the Bidder has, in the opinion of the ordering authority, delayed in making any supply by reasons of any riots, mutinies, wars, fire. storm, tempest or other exceptional cause, on a specific request made by the Bidder before expiring of supply period, the time for making supply may be extended by the ordering authority at its discretion for such period as may be considered reasonable. The exceptional causes do not include the scarcity of raw material, Power cut, labour disputes. Reasons must be beyond control of supplier.
- (n) The supplier shall not be in any way interested in oscincerned directly or indirectly with, any of the officers, subordinates or servants in the officers of the officers

Digitally signed by Mar of Kumar Designation Executive Director Date: 2025.05.06 1 .53:38 IST Reason: Approve

any trade or business or transactions nor shall the supplier give or pay promise to give or pay any such officers, subordinates or servants directly or indirectly any money or fee or other considerations under designation of "Customs" or otherwise, nor shall the supplier permit any person or persons whom so ever to interfere in the management or performance hereof under the power of attorney or otherwise without the prior consent in writing of the Bidder Inviting Authority.

- (o) If the supplier or any of its approved items gets debarred/banned/blacklisted in any state after entering into agreement with RMSCL, it shall be the responsibility of the supplier to inform RMSCL without any delay about the same.
  - i. In case the Firm is black listed/debarred/banned after submission of bid document, it should inform the RMSCL within 15 days of blacklisting/debarring/banning. If the blacklisted/debarred / banned firm does not inform the RMSCL within stipulated time, a penalty amounting to @ two per cent of purchase orders issued between the date of blacklisting /debarring/banning and the date of informing to RMSCL, both dates inclusive, shall be imposed, subject to a minimum penalty of Rs 20,000 and a maximum penalty up to Rs 2,00,000 only.
  - ii. If it is brought to the notice of RMSCL that the similar drug of the supplier firm has been found spurious / adulterated in any other state (whether the firm / product has been blacklisted/ debarred/ banned or not); then no further purchase orders shall be issued for the product and the rate contract with the firm for the product shall be cancelled.
- (p) If a supplier does not supply any quantity against two successive purchase orders then supplier shall be liable for debarment for the particular product for one year. One year period will be reckoned from the date of issuance of such debarment order.
- (q) If a supplier fails to execute first order, without proper justification, a show cause notice may be given to him to respond within 7 days. If it does not respond or does not give reasonable justification, the corporation may order to L-2 and L-3, for entire failed supply on L-1 matched rate. If L-2 and L-3 matched rates are not available, then only purchase may be made on 'Risk and cost basis' as being done presently subject to other condition of Bid documents.
- (r) The supplier of sevoflurane anesthetic (Item code no. 491) shall install vaporizers on loan basis free of cost, in required numbers, as per the need of the Healthcare facilities/ institutions. The installation report of the vaporizers should be submitted along with the invoice.
- (s) If the supplier fails to execute full supply of the quantity mentioned in a purchase order then a penalty of 15 % of Value of unsupplied quantity shall be charged. Cases of zero supply against a purchase order shall also be dealt with in same manner.
  Signature valid

Digitally signed by Mar of Kumar Designation Executive Director Date: 2025.05.06 17:53:38 IST Reason: Approve

## 14. LOGOGRAMS / Markings

Logogram means, wherever the context occurs, the design as specified below:-

## DESIGNS FOR LOGORAMS



## INJECTIONS

Injection in ampoule form should be supplied either in Double constricted neck ampoules or snap off type ampoules with the label bearing the words "Rajasthan Govt. Supply- Not for sale निःशुल्क वितरण हेतु, QC – Passed" overprinted and the following logogram which will distinguish from the normal trade packing. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



The vials should be supplied with aluminum seals containing the following logogram:

Signature yalid

Digitally signed by Mar of Kumar Designation, Executive Director Date: 2025.05.06 1 .53:38 IST Reason: Approve



## LIQUIDS

Liquid preparations should be in bottles with pilfer-proof caps bearing the following logogram:

Logogram for item code except 448W,	Logogram for item code 448W, 489B,
489B, 490W, 490R	490W, 490R
RIMSC NOW SERVICES CORPORD	THEALTH MISSION

The top of the cap and the label to be affixed on the containers should bear a distint colour different from the colour of the label of the trade packs and they should be overprinted in red colour with the words "Rajasthan Govt. Supply- Not for Sale नि :शुल्क वितरण हेतु, QC – Passed" and the logogram. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.

## OINTMENTS & CREAMS

Ointments & Creams should be supplied in tubes bearing the following logograms and the words "Rajasthan Govt. supply- Not for sale नि:शुल्क वितरण हेत, QC – Passed" overprinted. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently Storage directions should be clear, legible, preferably with yellow highlighted background.

Digitally signed by Mar of Kumar Designation, Executive Director Date: 2025.05.06 17:53:38 IST Reason: Approve



## TABLETS & CAPSULES

Tablets and Capsules should be supplied in Strips or Blisters or as mentioned in the list of items for bid. The strip, etc, should bear the following logograms and the words "Rajasthan Govt. supply- Not for sale निःशुल्क वितरण हेतू. QC - Passed" overprinted. Name of drug should be printed in English and Hindi languages and should be legible and be printed more prominently. Storage directions should be clear, legible, preferably with yellow highlighted background.



## SPECIMEN LABEL FOR OUTER CARTON

SHALL BE OF DIFFERENT COLOURS FOR DIFFERENT CLASS OF DRUGS

RAJASTHAN GOVT. SUPPL NOT FOR SALE	LY
(Name of Drugs etc.)	91
CONSTITUENTS OF	
Name of the Drug, Manufactured by, Batch no	
Mfg.Date, Exp. Date, Quantity/Kit	
Net. Weight:Kg	
Manufactured by/Assembled by	Signature yali

Digitally signed by Mayoj Kumar Designation Execution Date: 2025.05.06 53:38 IS Reason: Appro

The name of the drug shall be mentioned in Hindi and English and should be legible and be printed more prominently. A uniform colour theme and artwork will be necessary. Apart from this "For Govt. of Rajasthan - Not for Sale नि:शुल्क वितरण हेत्, QC - Passed" along with logo of RMSCL will be printed on each strip/label of the bottle. The storage directions should be clear, legible and preferably with yellow highlighted background.

- 1. Bids for the supply for Drugs and medicines etc., shall be considered only if the Bidder gives undertaking in his Bid that the supply will be prepared and packed with the logogram printed on the strips of tablets and capsules and labels of bottles, ampoules and vials etc., as per the design mentioned above.
- 2. All tablets and capsules have to be supplied in standard packing in aluminum strip or blisters with aluminium foil back with printed logogram and shall also conform to schedule P1 of the Drugs & Cosmetics Act & Rules wherever it applies. Affixing of stickers and rubber stamps shall not be accepted.
- 3. Labels of Vials, Ampoules and Bottles containing the items Bided for should also carry the logogram.
- 4. Failure to supply Drugs etc., with the logogram will be treated as breach of the terms of agreement and liquidated damages will be deducted from bills payable as per conditions in Clause 18.2 Bidders who are not willing to agree to conditions above will be summarily rejected.
- 5. In case of imported drugs affixing rubber stamp on the original label is allowed with indelible ink on inner most and outer packing.

Note: For all imported items, logo and logogram printing on inner packing is exempted however, henceforth stamp of logo and logogram is mandatory on outer packing. Sticker of logo and logogram not allowed.

Signature valid

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 17:53:38 IST Reason: Appro

## 15. PACKING

- The item shall be supplied in the package schedule given below and the package shall carry the logogram specified in clause -14. The labeling of different packages should be as specified below. The packing in each carton shall be strictly as per the specification mentioned. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties.
- The pediatric drops should always be supplied with dropper. A measuring cap with suitable markings must be provided for other paediatric oral liquid preparations.
- The labels in the case of injectables should clearly indicate whether the preparations are meant for IV, IM, SC, etc.
- 4. Injection vials should have flip off seals.
- All plastic containers should be made of virgin grade plastic.
- The name of the drug should be printed in clearly legible bold letters (It is advisable
  that the colour of font be different from other printed matter to make the name
  highly conspicuous.
- It should be ensured that only first hand fresh packaging material of uniform size is used for packing. All packaging must be properly sealed and temper proof.
- All packing containers should strictly conform to the specifications prescribed in the relevant pharmacopoeia/Act.
- 9. Packing should be able to prevent damages or deterioration during transit.
- 10. In the event of items supplied found to be not as per specifications in respect of their packing, the Ordering Authority is at liberty to make alternative purchase of the item for which the purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier. In such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 18.2, 19 and 21.

# I. SCHEDULE FOR PACKAGING OF DRUGS AND MEDICINES GENERAL SPECIFICATIONS

No corrugate package should weigh over 15 kgs (i.e. product + inner carton + corrugated box).

All items should be packed only in first hand strong boxes only.

Every corrugated box should preferably be of single joint and not more than two joints.

Every box should be stitched using pairs of metal pins with an interval of two inches between each pair.

The flaps should uniform meet but should not overlap each other. The flap when turned by 45-60 should not crack.

Every box should be sealed with gum tape running along the top and lower opening.

CARRY STRAP:

Signature yalid

Digitally signed by Mar of Kumar Designation, Executive Director Date: 2025.05.06 11.53:38 IST Reason: Approve

Every box should be strapped with two parallel nylon carry straps (they should intersect.)

For item code 310 Every box should be strapped with two parallel nylon carry straps / BoPP Taped Packing (they should intersect.)

### LABEL:

Every corrugated box should carry a large outer label clearly indicating that the product is for "Rajasthan Govt. Supply-Not for Sale".

The Product label on the cartoon should be large, at least 15 cms x 10 cms dimension. It should carry the correct technical name, strength or the product, date of manufacturing, date of expiry quantity packed and net weight of the box.

### OTHERS:

NO box should contain mixed products or mixed batches of the same product.

# II. SPECIFICATION FOR CORRUGATED BOXES HOLDING TABLETS/CAPSULES/PESSARIES

1. The total weight of the box should be approx of 7-8 Kgs.

# III. SPECIFIATION FOR LARGE VOLUME BOTTLE i.e., ABOVE 100 ml AND BELOW 1 LIT.

 All these bottles should be packed only in single row with partition between each and also with top and bottom pad of 3 ply.

### IV. SPECIFICATION FOR IV FLUIDS

Each corrugated box may carry maximum of only 24 bottles of 500 ml in a single row or 50 bottles of 100 ml in 2 rows with individual sealed polythene cover and centre partition pad, top and bottom pads of 3 ply.

## V. SPECIFICATION FOR LIQUID ORALS

100 bottles of 50 ml or 60 ml may be packed in a single corrugated in 2 rows with top, bottom and centre pad of 3 ply.

50 bottles of 100 ml - 120 ml may be packed in a similar manner in a single corrugated box.

If the bottles are not packed in individual carton, 3 ply partition should be provided between each bottle. The measuring device should be packed individually.

## VI. SPECIFICATION FOR OINTMENT/CREAM/GELS PACKED IN TUBES:

No corrugated box should weigh more than 7-8 Kgs.

Every Ointment/Cream/Gel tube should be individually packed in carton and then packed in 20's in a grey board box, which may be packed in a corrugated box.

## VII. SPECIFICATIONS FOR INJECTION (IN VIALS AND AMPOULES)

Vials may be packed in corrugated boxes weighing upto 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 Kgs.

In the case of 10 ml Ampoules or 50 ampoules may be packed in a grey board box. Multiples of grey board boxes packed in CB. In case of ampoules larger than 10 ml only 25 ampoules may be packed in a grey board box with partition.

If the vial is packed in individual cartoon, there is necessity for grey board box packing. The individual cartoon may be packed as Sugnature control of the control of the

Digitally signed by Maroj Kumar Designation, Executive Director Date: 2025.05.06 11:53:38 IST Reason: Approve

In case of ampoules every grey board box should carry 5 amps alongwith Cutters placed in a polythene bag.

Vials of eye and ear drops should be packed in a individual cartoon with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a grey board box.

Cutters are not required with ampoules in the case of snap off type ampoules.

## VIII. SPECIFICATION FOR ORS

Primary Packing:- The pouches/sachets of ORS should be three layered with following composition

Site	Material	Micron	MM	g/m²
Inner	Polyethylene	50	0.040-0.050	36.9-46.1
Middle	Aluminium	09	0.009-0.015	24.3-40.5
Outside	Polyester	12	0.012-0.015	12.9-20.9

Secondary Packages and Tertiary package:-

50 sachets may be packed in grey board boxes and 10 grey board boxes in a C.B.

## IX. LYSOL

Not more than four 5 liters cans may be packed in a single Box.

## 16. QUALITY TESTING

- Sampling of supplies from each batch will be done at the point of supply or distribution/storage points for testing. (The samples would be sent to different empanelled laboratories for testing by the ordering authority after coding). The RMSCL will deduct a sum of 1.5% from the amount of bill payable to supplier on account of handling and testing charges.
- 2. The Drugs shall have the active ingredients within the permissible level throughout the shelf life period of the drug. The samples may also be drawn periodically during the shelf life period. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirements shall render the relevant batches liable to be rejected. If the sample is declared to be Not of Standard Quality or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.
- 3. In the event of the samples of the Drugs and medicines supplied failing quality tests or found to be not as per specification the ordering authority is at liberty to make alternative purchase of items of drugs and medicines for which the Purchase orders have been placed from any other sources or from the open market or from any other Bidder who might have quoted higher rates at the risk and the cost of the supplier and in such cases the ordering authority has every right to recover the cost and impose penalty as mentioned in Clause 19.
- If there is any problem in the field the B.M.R/B.P.R for the particular batch shall also be supplied when demanded.
- 5. The products should conform to the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the received and of the standards of IPS in the standards of IPS in the received and the standards of IPS in the standards of IPS in the standard of the standards of IPS in the standard of the standard of

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 1 .53:38 IST

Reason: Approv

- the contract, must provide the reference standards and testing protocols for quality control testing. For imported drugs respective countries pharmacopeia standards shall be acceptable (even if the product is official in IP)
- 6. The supply of any item shall be considered complete for the purpose of calculation of liquidated damages only when reference standards/ standard testing procedure or test protocol/placebo materials are made available to the corporation along with the supply of items as per the purchase order. However these materials and documents shall be made available by supplier to Quality Cell of RMSCL Headquarter. Such requirement will however be indicated in the purchase order.

#### 17. PAYMENT PROVISIONS

- 1. No advance payment towards costs of drugs, medicines etc., will be made to the Bidder.
- 2. On receipt of the prescribed consolidated invoice duly stamped and signed by authorized signatory and analytical laboratory report regarding quality, the payment would be made as soon as possible. (Annexure- XII & XIII)
- 3. The in charge of district drug warehouse (DDW) will acknowledge the drugs received & ensure entry in e- Aushadhi software online. .
- 4. All bills/ Invoices should be raised in triplicate and in the case of excisable Drugs and Medicines; the bills should be drawn as per GST Rules / other applicable Rules if any in the name of the authority as may be designated. The supplier will deliver following document at the time of delivery at DDW/MCDW.
  - a. In house test report of drug.
  - b. The challan / invoice copy pertaining to DDW/ MCDW
- 5. Payments for supplies will be considered after receipt of reports of standard quality on samples having been tested by approved laboratories of ordering authority.
  - (i) Payments can be initiated if 50 % supply has been made against a purchase order by a supplier before expiry of supply period/extended supply period.
  - (ii) After expiry of supply period/extended supply period payments for actual supplies made against a purchase order will be made although supplies are less than 50 %.
- 6. If at any time during the period of contract, the price of Bided items is reduced or brought down by any law or Act of the Central or State Government or by the Bidder himself, the Bidder shall be bound to inform ordering authority immediately about it. Ordering authority empowered to unilaterally effect such reduction as is necessary in rates in case the Bidder fails to notify or fails to agree for such reduction of rates.
  - In case the price of a drug fixed by NPPA (Govt of India) under applicable DPCO is less than the RMSCL contract price, the supplier shall be bound to make the supplies of such items at price fixed by the Govt.
- 7(a) In case of any enhancement in GST as per notification of the G date of submission of Bids and during the Bid per Government after the

Digitally signed by Maroj Kumar Designation Executive Director

Reason: Appro

GST so levied will be allowed to be charged extra as a separate item without any change in the basic of the price structure price of the Drugs approved under the Bid. For claiming the additional cost on account of the increase in GST, the Bidder should produce a letter from the concerned Excise authorities / GST authorities (Central and State) for having paid additional GST on the goods supplied to ordering authority and also must claim the same in the invoice separately. In case of reduction in rates of GST price will be\_reduced accordingly.

Similarly if there is any reduction in the rate of essential drug, as notified by the Govt. (Including NPPA), after the date of submission of Bid, the quantum of the price to the extent of reduction of essential drug will be deducted without any change in the basic price of the price structure of the drugs approved under the Bid.

- 7(b) In case of successful bidder has been enjoying GST exemption or any criteria of Turnover etc., such bidder will not be allowed to claim GST at later point of time, during the tenure of contract, when the GST is chargeable on goods manufactured/Supplied.
  - (i) If the supplier requires an extension in time for completion of contractual supply, on account of occurrence of any hindrance he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of completion of supply.
    - (ii) The purchase Officer may extend the delivery period with or without liquidated damages in case they are satisfied that the delay in the supply of goods is on account of hindrances. Reasons shall be recorded.
    - (iii) Extension in delivery period:- In case of extension in the delivery period with liquidated damages the recovery shall be made on the basis of following percentages of value of stores which the Bidder has failed to supply:-
  - a) Delay up to one fourth period of the prescribed delivery period; 2.5%
  - b) Delay exceeding one fourth but not exceeding half of the prescribed delivery period; 5%
  - Delay exceeding half but not exceeding three fourth of the prescribed delivery period; 7.5%
  - d) Delay exceeding three fourth of the prescribed delivery period; 10%
    - Note 1:- Bidder should apply for extension before expire of original supply period mentioned in purchase order. No request will be considered after the expiry of supply

period.

**Note 2:-** Fraction of a day in reckoning period of delay in supplies shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.

**Note 3:-** In specific condition, permission for additional delay of 10 days may be granted for supply, in such a case an additional penalty of 5% shall be levied.

Note 4:- If a supplier seeks extension in supply period beyond two times the time indicated in purchase order, the supply period shabbe extended with the condition

Digitally signed by Mar of Kumar Designation, Executive Director Date: 2025.05.06.11:53:38 IST Reason: Approver

ricason. Appro

that if the rate received in new bid(s) invited are lower than the rate contract in operation, then the supplier shall be entitled to the lower rates so received.

- 9. If, at any time during the continuance of this Agreement, the Supplier has, in the opinion of the Purchaser, delayed in making any supply ordered, by the reasons of any riots, mutinies, wars, fire, storm, tempest or other exceptional cause, on a specific request made by the Supplier before expiry of supply period indicated in P.O, the time for effecting delivery may be extended by the Purchaser surely at his discretion for such period as may be considered reasonable by the Purchaser. No further representation from the Supplier will be entertained on this account.
- 10. If the firm is Blacklisted/Debarred by State Govt. of Rajasthan during rate contract period/ after rate contract period, the firm has to follow below mentioned conditions:-
  - Further Purchase orders should not be placed to firm.
  - Purchase orders in process shall be cancelled.
  - All unconsumed stock from DDWs should be lifted on the cost of firm.
  - If payment is made for unconsumed stock it should be recovered from firm.
  - All rate contracts should be cancelled.

## 18. DEDUCTION IN PAYMENTS:

- 1. If the supply is received in damaged conditions it shall not be accepted.
- 2. All the Bidder are required to supply the product with logogram and with prescribed packing specification. If there is any deviation in these Bid conditions a separate damages will be levied @ 2% irrespective of the ordering authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause No.15.10.

## 19. QUALITY CONTROL DEDUCTION & OTHER PENALTIES:

- 1. If the successful Bidder fails to execute the agreement and/or to deposit the required performance security within the time specified or withdraws his Bid after the intimation of the acceptance of his Bid has been sent to him or owing to any other reasons, he is unable to undertake the contract, his contract will be cancelled and the Bid security Deposit deposited by him along with his Bid, shall stand forfeited by the Bid Inviting Authority and he will also be liable for all damages sustained by the Bid Inviting Authority apart from blacklisting/ debarring the supplier. (As per guidelines for blacklisting/ debarring at annexure IX)
- 2. (i) If the samples drawn from supplies do not conform to statutory standards, the supplier will be liable for relevant action under the existing laws and the entire stock in such batch should be taken back by the supplier within a period of 30 days from the issue of letter from ordering authority the information of which may be communicated by e- mail. The stock shall be taken back at the expense of the supplier. Ordering authority has the right to destroy such NOT OF STANDARD DRUGS IF THE SUPPLIER does not take back the goods within the stipulated time. Ordering authority will arrange to destroy in the standards.

Digitally signed by Mar of Kumar Designation Executive Director Date: 2025.05.06.11.53:38 IST Reason: Approver

within 90 days after the expiry of 30 days mentioned above, without further notice, and shall also collect demurrage charge calculated @ 2% per week on the value of the drugs rejected till such destruction.

The Supplier shall replace the stock of NOSQ goods with fresh goods upon intimation to do so by the ordering authority.

- (ii) If RMSCL decides not to return the NOSQ drugs to supplier and decides to destroy NOSQ drugs at its level, then provision of demurrage charge will not apply. Means, if RMSCL writes to supplier to take back NOSQ drugs, then demurrage provision as per 19(2)(i) will be applied and if does not write to take back and decides to destroy drugs at its own level, then demurrage charge provision as per 19(2)(i) will not be applied.
- 3. The supplier will not be entitled to any payment whatsoever for Items of drugs found to be of NOT OF STANDARD QUALITY whether consumed or not consumed and the ordering authority is entitled to deduct the cost of such batch of drugs from the any amount payable to the Bidder. On the basis of nature of failure, the product/supplier will be moved for Black Listing / debarring. (As per guidelines for blacklisting/ debarring at annexure IX including amendment)
- 4. For supply of drugs of NOT OF STANDARD QUALITY the respective Drugs Controller will be informed for initiating necessary action on the supplier and that the report of product shall be sent to the committee for appropriate action including blacklisting/ debarring. (As per guidelines for blacklisting/ debarring at annexure IX)
- The decision of the ordering authority or any Officer authorized by him as to the quality of the supplied drugs, medicines etc., shall be final and binding.
- Ordering Authority will be at liberty to terminate without assigning any reasons thereof the contract either wholly or in part on 30 days notice. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.
- 7. For infringement of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the ordering authority, and the supplier shall be liable for all losses sustained by the ordering authority, in consequence of the termination which may be recovered personally from the supplier or from his properties, as per rules.
- Non performance of any contract provisions shall be examine and may disqualify the firm to participate in the future Bids.
- 9. In the event of making ALTERNATIVE PURCHASE, as specified in Clause 13.10, Clause 15.10 and in Clause 16.3 the penalty will be imposed on supplier apart from forfeiture of Security Deposit. The excess expenditure over and above contracted process incurred by the ordering authority in making such purchases from any other sources or from the open market or from any other Bidder who has quoted higher rates and other losses sustained in the process, shall be recovered from the performance security or from any other money due and become due to the supplier and in the security of from any other money due.

Digitally signed by Maroj Kumar Designation, Executive Director Date: 2025.05.06 11:53:38 IST Reason: Approve insufficient, the balance will be recovered personally from the supplier and provided further that such amount to be levied as per penalty from supplier on account of non-supply shall not be less than 15% of the value of non-supplied even when rates in alternative purchase method are lower / equivalent to rates in original tender.

- 10. In all the above conditions, the decision of the Bid Inviting Authority, viz Managing Director, Rajasthan Medical Services Corporation Ltd, would be final and binding; in case of any dispute regarding all cases under Bid procedure or in any other non-ordinary situation and would be acceptable to all.
- 11. All litigations related to the supplier for any defaults will be done by Bid Inviting Authority and his decision will be final and binding.
- 12. In the case of litigation as per court decision/award by arbitrator, if any amount of interest is payable/receivable etc. then RMSCL will charge interest@9% per annum simple interest and it will be payable @ 6% per annum simple interest only.

### 20. EMPANELMENT OF BIDDERS (OPTIONAL)

Bidders which are found eligible / responsive on technical grounds / criteria would be empanelled for those item for which they have bided in the NIB as per Annexure VIII. A The empanelment would entitle a firm to participate in RMSCL's limited bids. Such situations may normally arise when the open bid for a Drugs & Medicines fails and there is an urgency to purchase it, or when the L-1 bidder has fail to supply or the rate contract of an item ceases to exist for any reason. The Bidder has to submit an undertaking in the format given at Annexure-XI.

The empanelment can be renewed for the next one year term on payment of the empanelment fee as applicable at the time of renewal.

### 21. SAVING CLAUSE

No suit, prosecution or any legal proceedings shall lie against Bid Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of Bid.

### 22. JURISDICTION

In the event of any dispute arising out of the Bid or orders such dispute would be subject to the jurisdiction of the Courts of Jaipur or Honorable High Court (Jaipur Bench only).

### 23. CORRECTION OF ARITHMETIC ERRORS:

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

(i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;

Digitally signed by Maroj Kumar Designation, Executive Director Date: 2025.05.06 1 .53:38 IST Reason: Approve

- If there is an error in a total corresponding to the addition or subtraction (ii) of subtotals, the subtotals shall prevail and the total shall be corrected; and.
- If there is a discrepancy between words and figures, the amount in (iii) words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.

If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

#### 24. PROCURING ENTITY'S RIGHT TO VARY QUANTITY:

- At the time of award of contract, the quantity of Drugs, specified in the bidding documents may be increased or decreased. There will not be any minimum quantity guaranteed against bid quantity. The bid quantity is only indicative. Actual purchase can be more or less than the bid quantity based on actual consumption in the hospitals during Rate Contract period.
  - The supplier shall submit the supply commitment quantity" in Annexure VII at point no. 3 which will be used for the cases where the actual purchase quantity tends to increase substantially from the bid quantity.
- If the procuring entity does not procure any subject matter of procurement (ii) or procures less than the quantity specified in the bidding documents due to change in circumstances, the bidder shall not be entitled for any claim or compensation except otherwise provided in the conditions of contract.
- (iii) However a bidder is bound to supply up to quantity indicated in bid document, considering the total production capacity & capacity dedicated to RMSCL. Moreover, the actual purchases beyond Bid quantity may be made keeping in view the supply commitment of bidder to corporation.

#### 25. DIVIDING QUANTITIES AMONG MORE THAN ONE BIDDER AT (IN CASE OF PROCUREMENT OF GOODS):

The bid quantity shall be fixed in following manner-L-1(Single Bidder) 100%

Between L-1 and Rate Matched Firm-1in the ratio of 60:40

Among L-1, Rate Matched Firm-1 and 2in the ratio of 50:25:25

Purchase preference shall be given to MSME's unit of Rajasthan as per notification of Finance (GF&AR Division) Department; Government of Rajasthan notification S.O.165 dated 19.11.2015).

The supply orders for quantity fixed as above may be issued as and when required. RMSCL has full rights to increase or decrease the bid quantity upto any limit during the contract period.

GRIEVANCE REDRESSAL DURING PROCUNSIGNATURES VAIID 26.

Digitally signed by Markj Kumar Designation Executive Director Date: 2025.05.06 1 .53:38 IST Reason: Appro

The Designation and address of the First Appellate Authority is MD, NHM, Rajasthan Jaipur.

The Designation and address of the Second Appellate Authority is The Additional Chief Secretary / Principal Secretary / Secretary Department of Medical Health & Family Welfare, Govt. of Rajasthan.

### i. Filling an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:

Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

- ii. The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.
- iii. If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of receipt of the order passed by the First Appellate Authority, as the case may be.

#### iv. Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

- (a) Determination of need of procurement;
- (b) Provision limiting participation of Bidders in the Bid process; (c) The decision of whether or not to enter into negotiations;
- (d) Cancellation of a procurement process;
- (e) Applicability of the provisions of confidentialisignature valid

v. Form of Appeal (Annexure X)

Digitally signed by Maroj Kumar Designation, Execut e Director Date: 2025.05.06 17:53:38 IST Reason: Approver

- (a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.
- (b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.
- (c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.

#### Fee for filling appeal vi.

- (a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.
- (b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

#### vii. Procedure for disposal of appeal

- (a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.
- (b) On the date fixed for hearing, the First Appellate Authority or Second Appellate

Authority, as the case may be, shall,-

- (i) Hear all the parties to appeal present before him; and
- (ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.
- (c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.
- (d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

#### 27. COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:

Any person participating in a procurement process shall-

- a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;
- b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation:
- Not indulge in any collusion, Bid rigging Signature elacitic impair the transparency, fairness and progress of the procuren

Digitally signed by Man Designation Executive Director Date: 2025.05 Reason: Appro

- d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;
- e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;
- f) Not obstruct any investigation or audit of a procurement process;
- g) Disclose conflict of interest, if any; and
- h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

#### Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest. A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.

- A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to;
- a. Have controlling partners/shareholders in common; or
- b. Receive or have received any direct or indirect subsidy from any of them; or
- c. Have the same legal representative for purposes of the Bid; or
- d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or
- e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or
- f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or
- g. Bidder or any of its affiliates has been hired (or is proposed to be hired0 by the Procuring Entity as engineer-in charge/ consultant for the contract.

28. FALL CLAUSE

Signature yalid

Digitally signed by Maroj Kumar Designation, Executive Director Date: 2025.05.06 17.53:38 IST Reason: Approve

The prices under a rate contract shall be subject to price fall clause. If the rate contract holder quotes / reduces its price to render similar goods, works or services at a price lower than the rate contract price to anyone in the State at any time during the currency of the rate contract, the rate contract price shall be automatically reduced with effect from the date of reducing or quoting lower price, for all delivery of the subject matter of procurement under that rate contract and the rate contract shall be amended accordingly. The firms holding parallel rate contracts shall also be given opportunity to reduce their price by notifying them the reduced price giving them fifteen days time to intimate their acceptance to the revised price. Similarly, if a parallel rate contract holding firm reduces its price during currency of the rate contract, its reduced price shall be conveyed to other parallel rate contract holding firms and the original rate contract holding firm for corresponding reduction in their prices. If any rate contract holding firm does not agree to the reduced price, further transaction with it, shall not be conducted.

### 29. APPLICABILITY OF RULES

Besides above conditions the provisions of RTPP Act 2012 & RTPP Rules 2013 and Drugs and Cosmetic Act 1940 and Rules 1945 will be applicable.

Managing Director
Rajasthan Medical Services Corporation Ltd

Signature yalid

Digitally signed by Maroj Kumar Designation, Executive Director Date: 2025.05.06 1 .53:38 IST

Reason: Approv

Type of Deposit Scient any one out of Tender Fees/EMD/SD/ Tender Processing  Matrix Deposit  Chapter Chapter Deposit  Chapter Deposit  Chapter Deposit  Chapter Deposit  Chapter Deposit  Chapter Deposit  Total the payable Total second Total	50 *  20 *  10 *  Cainy *  Total amount ₹  Total amount ₹  Name of the Depositor  Signature  Address for continual cation  Nor Rank ase only	Amutan (in words):  Name of the Depositor Signature Address for communic
Type of Deposit  Mobile No. Cash Deposit: Demonstrating 1900 * 1900 * 1900 * 29 * 29 * 194 * Total Amount (in words): Address for community		Attruent (in Name of the Signature Address for
Type of Deposit  Mabile No. Cash Deposit: Demonstration 1000 * 50 * 50 * 100 *		Amount (in Name of the
Type of Deposit  Mabile No. Cash Deposit: Demonstration 1000 * 1000 * 20 * 20 * 100		Amount (in
Type of Deposit  Mobile No.  Chair Deposit  Demontherinin  1000 *  100 *  20 *  20 *  10 *  5 *  Cours *		
Type of Deposit  Mobile No.  Cash Deposit:  Democritearing 0  1000 *  100 *  100 *  100 *  100 *  100 *		Cuits *
Type of Deposit  Mobile No.  Cash Deposit:  Demonstreamin 1900 *  1000 *  100 *		·, 15
Type of Deposit  Mobile No.  Cash Deposit:  Demonstranting  1000 *		50 t
Type of Deposit  Mobile No.  Can Deposit  Deposit		* 00¢
Type of Deposit  Mobile No.	Chi No Data of Chig Name of Book	oblination 1000
Type of Deposit		Cush Dennitr
DED/Tender Processing	Type of Deposit Scient my and out of - Teindar FeedRMD/SD/Tender Processing	Type of
	Tender Ref. No.	Tender
WW OG XX NOT THE STATE OF THE S	SECOLOR SUPPLIER	Supplier Name
Date of Deposit	Date of Deposit	
Institute ID RMSCJ - Air No. 60	_	lastiture 10
Corporation, Jaipur Invitute Name Rajasthan Medical Services Compression Jainur	Rajasthan Medical	lustitats Name
DIST. NO.	5PZT of	Branch
	TAHORASHTA Bank Copy	

# Signature yalid

Digitally signed by Maroj Kumar Designation, Executive Director Date: 2025.05.06 17.53:38 IST Reason: Approve

#### Form A

### Application by MSME for price preference or Purchase Preference or both in Procurement of Goods

10,		
The	General Manager	
DIC	, District	ė:
4	NI	

- Name of Applicant with Post
- Permanent Address
- Contact Details
  - a) Telephone No.:
  - b) Mobile no.:
  - c) Fax no .:
  - d) Email Address:
- 4. Name of micro & small enterprise:
- 5. Office Address:
- 6. Address of Work Place:
- No. & Date of Entrepreneurs Memorandum-II/Udyog Aadhaar Memorandam (enclose photo copy)
- Products for which Entrepreneurs Memorandum-II/ Udyog Aadhaar Memorandum availed:
- 9. Products for which are at present being produced by the enterprise:
- 10. Products for which price preference or Purchase preference or both has been applied for:
- Production capacity as per Capacity Assessment Certificate (enclose photocopy of Capacity Assessment Certificate)

Serial No	Product	Production	Capacity
		Quantity	Value
1			
2			
3			
4			

### 12. List of Plant & Machinery installed

Serial No	Name of Plant & Machinery	Quantity	Value	
1	907	Sid	nature y	alid
2		1		
3		Digita	ally signed by Mar gnation Execut	oj Kumar e Director
	707	Date	2025 05 06 17 5	3:38 IST

Reason: Approve

13. List of Testing Equipments installed

Serial No	Name of Plant & Machinery	Quantity	Value
1			
2			
3			
4			

- Benefits availed as per price preference certificate in last financial year and current financial year
  - a. Benefits depositing Bid Security and Performance Security:

Last financial year			nancial year
Bid Security	Performance Security	Bid Security	Performance Security
		Bid Security   Performance	Bid Security Performance Bid

b. Details of Supply orders received:

	Curre	ent financia	l year			
Departments	No. & Date of purchase order	Amount for which purchase order received	Amount of goods supplied	No. & Date of purchase order	Amount for which purchase order received	Amount of goods supplied
		received				received

I declare that the above all facts given in the application are correct and my enterprise is producing the items mentioned in column No. 10

Date

Signature (Name of the applicant along with seal of post)

Signature yalid

Digitally signed by Mar of Kumar Designation Executive Director Date: 2025.05.06 1 .53:38 IST Reason: Approve

Signature valid

Digitally signed by Maroj Kumar
Designation, Executive Director
Date: 2025.05.06 17:53:38 IST
Reason: Approve

### CERTIFICATE

(See clause 3(ii))

File no.		-
Date		
It is certified that M/s		was inspected by
	on dated	and
the facts mentioned by the enterprise applicant. The enterprise is eligible both under this notification. The cert	for Price Preference or	Purchase Preference or
issue.		y control of the state of the s
Office Seal	Sign	nature
		of the Officer)
		ıl Manager
		ustries Centre
	Rubber	Seal/Stamp
Enclosure- (1) Application		
(2)		
(3)		

Signature valid

Digitally signed by Maroj Kumar
Designation, Executive Director
Date: 2025.05.06 17.53:38 IST
Reason: Approve

### ANNEXURE-II (B) Ref. Clause No.8 & 3(ii)

### Form-'B' Format of Affidavit (On Non Judicial Stamp Paper of Rs. 10/-)

IS/o	AgeYrs residing
atProprie	tor/Partner/Director of M/sdo hereby
solemnly affirm and declare that:	
(a) My/Our above noted ente	erprises M/s has been issued
acknowledgement of Entrepren	eurial Memorandum Part-II by the Districts Industries
CenterThe	acknowledgement No.
isdated	and has issued for Manufacture of following
items.	
(i) (ii) (iii) (iv) (v) (b) My/Our above noted acknow	ledgement of Entrepreneurial Memorandum Part-II has not
been cancelled or withdrawn by t	he Industries Department and that the enterprise is regularly
manufacturing the above items.	
(c) My/Our enterprise is having a	Il the requisite plant and machinery and is fully equipped to
manufacture the above noted item	s.
Place	Signature of Proprietor/Director Authorized Signatory with Rubber Stamp and date
	VERIFICATION
Proprietor/Partner/Director of M	Yrsresiding atverify and confirm that the re true and correct to the best of my knowledge and nothing

ANNEXURE-III

(Ref. Clause No. 2 (i), 5 (n))

### ANNUAL TURN OVER STATEMENT

The	Annual Turnover (for D	rugs & Medicines includi	ng Surgical and sutures of
medical devic	es business) of M/s		for the
past three year	ars are given below and o	ertified that the stateme	nt is true and correct.
0 #4			
S.No.	Years	Turnover	in Crore (Rs)
1	2021-22		
2	2022-23		
3	2023-24		
	Total	Rs.	Crore
Averag	e turnover per annual	Rs.	Crore

OR

S.No.	Years	Turnov	ver in Crore (Rs)
1	2022-23		
2	2023-24		
3	2024-25		
6.5	Total	Rs.	Crore
Avera	ge turnover per annual	Rs.	Crore

Date:

Signature of Auditor/ Chartered Accountant

Seal:

(Name in Capital)

(Name in Capital)

UDIN:

Signature yalid

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 17:53:38 IST

Reason: Appro

### ANNEXURE-IV

Ref. Clause No.12(a)

day of

### **AGREEMENT**

This Deed of Agreement is made on this

Proprietor/Managing partner/Managing Director having its Registered Office at and its Factory  Premises at			2	025 by	M/s.			represe	ented by	its
(hereinafter referred to as "Supplier" which term shall include its successors, representatives, heirs, executors and administrators unless excluded by the Contract) on one part and Rajasthan Medical Services Corporation Ltd, represented by its Executive Director (P) having is office at Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur (hereinafter referred to as "The Purchaser" which term shall include its successors, representatives, executors assigns and administrator unless excluded by the Contract) on the other part.  Where as the Supplier has agreed to supply to the Purchaser, the Drugs and Medicines with specifications mentioned in the Schedule attached here to at the prices noted there in and in the manner and under the terms and conditions here in after mentioned and where as the Supplier has deposited with the Purchaser a sum of Rs	Proprietor/	Managing				having	its F	Registered		
heirs, executors and administrators unless excluded by the Contract) on one part and Rajasthan Medical Services Corporation Ltd, represented by its Executive Director (P) having is office at Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur (hereinafter referred to as "The Purchaser" which term shall include its successors, representatives, executors assigns and administrator unless excluded by the Contract) on the other part.  Where as the Supplier has agreed to supply to the Purchaser, the Drugs and Medicines with specifications mentioned in the Schedule attached here to at the prices noted there in and in the manner and under the terms and conditions here in after mentioned and where as the Supplier has deposited with the Purchaser a sum of Rs.  (Rupees only) as Performance Security for the due and faithfully performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd. (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated: ) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreem	Premises a	t						7.55	<u></u>	
Rajasthan Medical Services Corporation Ltd, represented by its Executive Director (P) having is office at Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur (hereinafter referred to as "The Purchaser" which term shall include its successors, representatives, executors assigns and administrator unless excluded by the Contract) on the other part.  Where as the Supplier has agreed to supply to the Purchaser, the Drugs and Medicines with specifications mentioned in the Schedule attached here to at the prices noted there in and in the manner and under the terms and conditions here in after mentioned and where as the Supplier has deposited with the Purchaser a sum of Rs (Rupees only) as Performance Security for the due and faithful performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated: ) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of	(hereinafte	r referred t	o as "Supplier	" which	term sha	ll include i	ts succ	essors, rep	resentativ	ves,
having is office at Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur (hereinafter referred to as "The Purchaser" which term shall include its successors, representatives, executors assigns and administrator unless excluded by the Contract) on the other part.  Where as the Supplier has agreed to supply to the Purchaser, the Drugs and Medicines with specifications mentioned in the Schedule attached here to at the prices noted there in and in the manner and under the terms and conditions here in after mentioned and where as the Supplier has deposited with the Purchaser a sum of Rs.  (Rupees only) as Performance Security for the due and faithful performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated: ) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance no	heirs, exec	cutors and	d administrate	rs unle	ss exclud	ed by the	Cont	ract) on o	ne part	and
as "The Purchaser" which term shall include its successors, representatives, executors assigns and administrator unless excluded by the Contract) on the other part.  Where as the Supplier has agreed to supply to the Purchaser, the Drugs and Medicines with specifications mentioned in the Schedule attached here to at the prices noted there in and in the manner and under the terms and conditions here in after mentioned and where as the Supplier has deposited with the Purchaser a sum of Rs (Rupees only) as Performance Security for the due and faithful performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated: ) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance no	Rajasthan	Medical S	Services Corpo	oration	Ltd, repr	esented by	its I	Executive	Director	(P)
where as the Supplier has agreed to supply to the Purchaser, the Drugs and Medicines with specifications mentioned in the Schedule attached here to at the prices noted there in and in the manner and under the terms and conditions here in after mentioned and where as the Supplier has deposited with the Purchaser a sum of Rs (Rupees only) as Performance Security for the due and faithful performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated:-) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the Schalur stacked by Firm shall be bound to accept the extension period	having is o	office at Sw	vasthya Bhawa	ın, Tilal	k Marg, C	-Scheme, .	Jaipur	(hereinafte	r referred	l to
Where as the Supplier has agreed to supply to the Purchaser, the Drugs and Medicines with specifications mentioned in the Schedule attached here to at the prices noted there in and in the manner and under the terms and conditions here in after mentioned and where as the Supplier has deposited with the Purchaser a sum of Rs (Rupees only) as Performance Security for the due and faithful performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated:-) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the Schgdul stated by Fries of Culrical College of the Extension period o	as "The Pu	rchaser" w	hich term shal	l includ	e its succe	essors, repr	esenta	tives, exec	utors assi	gns
with specifications mentioned in the Schedule attached here to at the prices noted there in and in the manner and under the terms and conditions here in after mentioned and where as the Supplier has deposited with the Purchaser a sum of Rs (Rupees only) as Performance Security for the due and faithful performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated: ) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the Sugulary Stacked Processing Stacked Firm shall be bound to accept the extension period of Rate Contract.	and admin	istrator unle	ess excluded b	y the Co	ontract) or	the other	part.			
in the manner and under the terms and conditions here in after mentioned and where as the Supplier has deposited with the Purchaser a sum of Rs (Rupees only) as Performance Security for the due and faithful performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated: ) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the Sengular stacked berger of included in Clause (b) above. Date: 40.26 item of the Director Agreement Period indicated in Clause (b) above.								7		
Supplier has deposited with the Purchaser a sum of Rs (Rupees only) as Performance Security for the due and faithful performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated: ) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the segular stageted here a fixeling only the probable total requirements of the Purchase beginning transcript of the Cales of the Contract.										
Rs (Rupees only) as Performance Security for the due and faithful performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated: ) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the seighby stageted between the only the probable total requirements of the Purchase designations (executive Director Agreement Period indicated in Clause (b) above. Data: 2025i is 506 in 52638 IST								oned and	where as	
Performance Security for the due and faithful performance of this Agreement, to be forfeited in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated:-) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance no	Spin	has	deposited	with	the	Purch	aser			of
in the event of the Supplier failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd., (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated: ) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance no	SS 22	2 V			307 8	87	V57 12			
witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd., (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated: ) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance no		경기 시기가 있었다면 되었다. 특히								
carrying out the said Agreement in this behalf into execution the Supplier and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated:-) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance no									25	
do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,  1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated:-) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance no		Annual Control of Control	and the contract of the contra				Condition			
1. The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated: ) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance no and dated and it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the selection of the probable total requirements of the Purchase period by a like a large to be or each of the period indicated in Clause (b) above. Date: 40.25 item of iscales and included in Clause (b) above.										
<ol> <li>The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug &amp; Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated:-) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.</li> <li>(a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.</li> <li>(b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.</li> <li>(c) The Bid quantity noted against each item in the selection of the probable total requirements of the Purchas Designation (Security of Indianal Security) in Security of Indianal Security of In</li></ol>	53	93			ract and ag	gree each o	f them	with the o	ther of th	iem
terms and conditions contained in the invitation to E-Bid floated for the rate contract cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated: ) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the selegital stage of the probable total requirements of the Purchase Designation Factor of 163.238 IST					10/8: 1/0/35			200		. 120
cum supply for Drug & Medicines For Rajasthan Medical Services Corporation Ltd, (Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated:-) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the selecture of the Director Agreement Period indicated in Clause (b) above. Date: 2025ii 15.06 1 in 52638 ST		()								
(Rate Contract for the period ending on 30.09.2027) (No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated:-) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the selection female of incompanies of the Purchase period of the probable total requirements of the Purchase period of the Director Agreement Period indicated in Clause (b) above. Date: 20.25i p. 5.06 1 in 53.638 ST										
F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated: ) and technical bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the selecture attached here; a dicates only the probable total requirements of the Purchas Designation. Executive Director Agreement Period indicated in Clause (b) above. Date: 20.25(1):0.02176(1):0.0217			in a single and the single and a					**************************************		
bid opened on 06.06.2025 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance no					100					
acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the selecture attached here a dicates only the probable total requirements of the Purchas Designation Calculated Director Agreement Period indicated in Clause (b) above. Date: 2025ity 5.06 1 in Seas Selecture.		1 - 1						S		
conditions that may be added from time to time.  2. (a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the sengular attached berging for the only the probable total requirements of the Purchase period indicated in Clause (b) above. Date: 20.25it 5.06 1 153:238:157		a said and said and the								
<ul> <li>(a) The Agreement is for the supply by the Supplier to the Purchaser of the Drug and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.</li> <li>(b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.</li> <li>(c) The Bid quantity noted against each item in the selectule attached here discussed in the probable total requirements of the Purchase period particle. Supplied by the Director Agreement Period indicated in Clause (b) above. Data: 20.25 in 52.23 lines.</li> </ul>							d thos	se general	and spe	cial
and Medicines specified in the agreement on the terms and conditions set forth in the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the selection attack. Signed bereit a discussionly the probable total requirements of the Purchase period particles. Agreement Period indicated in Clause (b) above. Pate: 20.25 in 23.28 Interest.							1	D	64 - D	S
the Agreement.  (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the selectule attached here a lightly attached here a lightly storied by the probable total requirements of the Purchase period										A
(b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the splightly stigned bergin only the probable total requirements of the Purchas Designation Careboat Agreement Period indicated in Clause (b) above. Pate: 2025 155.06 1 in Sec. 2027			2.	the agi	reement o	n the term	is and	conditions	set forti	ı ın
of issuance of letter of acceptance noand datedand it shall remain in force up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the selectule attached here adjusted only the probable total requirements of the Purchase period perio				d	Lto bosson	americate C	4	in account		1
up to 30.09.2027 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the splightly stacked here discussed only the probable total requirements of the Purchas Designation Calebra Director Agreement Period indicated in Clause (b) above. Data: 2025 155.06 1 in 2228 157	3700.70	[강영화 보고 1762] [1								
accept the extension period of Rate Contract.  (c) The Bid quantity noted against each item in the selection at the probable total requirements of the Purchase period particle. The Director Agreement Period indicated in Clause (b) above. Path: 2025115.061162638181										
(c) The Bid quantity noted against each item in the selectule attached here; a dicates only the probable total requirements of the Purchas Designation (Executive Director Agreement Period indicated in Clause (b) above. Data: 2025:155 06 1 152:38 IST							an	ature	: Val	Бi
only the probable total requirements of the Purchas Designation Facture Director Agreement Period indicated in Clause (b) above. Data: 2025;195.06 1 inclais SIST										
Agreement Period indicated in Clause (b) above. Pate: 4025i05.06 1762638 IST	(c)	the probe	ahle total recu	gamst e iromont	e of the D	urchase 3	itally s	signed by	Mar of K	uma
Reason: Approve										
decrease at the discretion of the Purchaser. The Supplier shall make applies of the	dec	rease at the	e discretion o	f the Pu	rchaser T	he Suppli	son:	Approve	onlies of	

Drugs and Medicines on the basis of the Purchaser Orders placed on him from time to time by the ordering Authorities of the purchaser specifying the quantities required to be supplied required to be supplied at the specific location in the state of Rajasthan.

### TERMINATION OF CONTRACT ON BREACH OF CONDITION

- 1 (a) In case the Supplier fails or neglects or refuse to faithfully perform any of the Covenants on his part herein contained, it shall be lawful for the Purchaser to forfeit the amount deposited by the Supplier as PERFORMANCE SECURITY and cancel the Contract.
  - (b) In case the Supplier fails, neglects, or refuse to observe, perform, fulfill and keep, all or any one or more or any part of any one of the Covenants, stipulation and provisions herein contained, it shall be lawful for the Purchaser
  - on any such failure, neglect or refusal, to put an end to this Agreement and thereupon every article, cause and thing herein contained on the part of the Purchaser shall cease and be void, and in case of any damage, loss, expenses, difference in cost or other moneys from out of any moneys for the time being payable to the Supplier under this and/or any other Contract and in case such last mentioned moneys are insufficient to cover all such damages, losses, expenses, difference in cost and other moneys as aforesaid, it shall be lawful for the Purchaser to appropriate the Performance Security made by the Supplier as herein before mentioned to reimburse all such damages, losses, expenses, difference in cost and other money as the Purchaser shall have sustained, incurred or been put to by reason of the Supplier having been guilty of any such failure, negligence or refusal as aforesaid or other breach in the performance of this Contract.
  - (c) If at any time during the course of the Contract, it is found that any information furnished by the Supplier to the Purchaser, either in his Bid or otherwise, is false, the Purchaser may put an end to the Contract/Agreement wholly or in part and thereupon the provisions of Clause (a) above shall apply.
- 2 The Purchaser reserves the right to terminate without assigning any reasons therefore the Contract/Agreement either wholly or in part without any notice to the Supplier. The Supplier will not be entitled for any compensation whatsoever in respect of such termination of the Contract/Agreement by the Purchaser.

#### NOTICE ETC, IN WRITING

3 All Certificates or Notice or orders for time or for extra, varied or altered supplies which are to be the subject of extra or varied charges whether so described in the Agreement or not, shall be in writing, and unless in writing, shall not be valid, biding or be of any effect whatsoever.

# SUPPLIERS NOT HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATES

4 The Supplier shall not be in any way interested in or concerned directly or indirectly with, any of the Officers, Subordinate or Servants of the Purchaser. In any trade, business or transactions nor shall the Supplier give or pay or promise to give or pay any such Officer, Subordinate or Servant directly or indirectly any money or the or other consideration until designation of "Custom" or otherwise; nor shall the Supplier point any person of a sons whomsoever to interfere in the management or performance Digitally unique by the point of the period of th

BANKRUPTCY OF THE SUPPLIER

5 In case the Supplier at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of bankruptcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the Purchaser to put an end to the Agreement, and thereupon every article, clause and thing herein contained to be operative on the part of the Purchaser, shall cease and be void and the Purchaser shall have all the rights and remedies given to him under the preceding clauses.

### SERVING OF NOTICE ON SUPPLIER

- 6 All notice or communication relating to or arising out of this Agreement or any of the terms thereof shall be considered duly served on or given to the Supplier if delivered to him or left at his premises, place of business or abode.
- 7 And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any of clause herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of the Managing Director, Rajasthan Medical Services Corporation Ltd in the matter shall be final and binding.
- 8 All disputes arising out of this agreement and all questions relating to the interpretation of this agreement shall be decide by the Govt. and the decision of the Govt. shall be final. SUPPLIER (Signature, Name EXECUTIVE DIRECTOR (P), & Address With Stamp) RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

Witness (Signature, Name & Address)	Witness
1.	1.
2	2

Signature yalid

Digitally signed by Mar of Kumar Designation, Executive Director Date: 2025.05.06 11:53:38 IST Reason: Approve

### ANNEXURE – V Ref. Clause No. 5 (t)

### **Check List**

Section	Details of requirement	Document Type	Yes/No If Yes Pag No.
A	BID SECURITY DEPOSIT, RISL Fess, Bid Processing Fees, Empanelment Fees.	Challan/DD/ e-deposit generated receipt of Bid Security Deposit, bid fee, RISL fee, empanelment fee and SSI certificate for exemption with Annexure-II	
В	Mandatory documents	Manufacturing Licence/loan licence (as per point 2 (b) of eligibility criteria)/ Manufacturing Licence renewal/Retention /validity certificate	
		For co-marketer- Import license of principle manufacturer of patented/proprietary imported items with other relevant documents (as per point 5(f)(iii))	
		Non Conviction Certificate issued by the Drugs Controller((as per point 2 (f) of eligibility criteria)	
		WHO-GMP Certificate (as per point 2 (e) of eligibility criteria)	
		Import License/ renewal/Retention /validity certificate, if imported. ((as per point 2 (c) of eligibility criteria)	
		Sale License renewal/Retention /validity certificate, in the case of imported drugs ((as per point 2 (c) of eligibility criteria)	
		Record of import/ Market Standing Certificate to establish 3 years market standing, if imported. ((as per point 5 (j)(ii) of eligibility criteria)	
		Product Permissions by the State Licensing Authority / Central Licensing Authority for each and every product quoted. ((as per point 2 (d) of eligibility criteria)	
		Market Standing Certificate issued by the State Licensing Authority / Central Licensing Authority ((as per point 2 (g) of eligibility criteria)	
		Annexure-VII Declaration and Undertaking (as per 2 (h) of eligibility criteria)	
		The instruments such as power of attorney resolution of board etc bidder authorization Certificate (As per 5 (e)	
С	Other Documents	Annexure-III -Annual Turnover Statement (as per 2 (i), 5(n) of eligibility criteria)	
		GST registration and GST Return (as per 2 (i) of eligibility criteria)	
		Annexure-VI Check List Of Details Regarding Products Quoted	
		Documentary evidence for the constitution of the company / concern	
		Copies of balance sheet & profit loss account for three years	
		Copy of PAN	
		Annexure-XI Undertaking For Empanelment	
		Annexure -XV Land Border County Registration Requirement Annexure -XVI Performance Security Declaration Digitally signed by Mark	alid

Note:-In case of non-submission of above mentioned besignation. Executed Director the original bid, the firm will be treated as Non-responsive 2019 of the street of queries / clarifications will not be sought.

### Annexure – VI Ref. Clause No. 5 (h)(i)(j)(k)(t)

### Check list of details regarding quoted products

Quoted Item /Code	Product permission	Date of product permission	WHO-GMP certificate Issue date and	Non Conviction certificate	As per MSC prod Mfg & Mkt since las years	
no.	on page no.	/ Approval	page no.	and enclosed on page no.	Page No.	Date of Issue
						-
		11				
						-
	Item	Item /Code no. enclosed on page	Tem	Tem	Item /Code no. enclosed on page no. enclosed no. enclosed on page no. enclosed no.	Item permission product permission lssue date and enclosed on page no.    The permission product permission on page no.   Conviction certificate lssue date and enclosed on page no.   Page No.   Page No.

Signature yalid

Digitally signed by Maroj Kumar Designation, Executive Director Date: 2025.05.06 17.53:38 IST Reason: Approve

#### Annexure – VII

Ref. Clause No. 2 (h) (k), 5 (q)( r)(s)(t)(v), 24(i)

### **Declaration & Undertaking**

(For No.: F.02(422)/RMS	CL/PROCUREMENT/DRUG/NIB-01/2025/	Dated

### (On Non-Judicial Stamp Paper of Rs 500/-)

I	Name	S/o	Age	Prop./Partner/Director/Power	of	attor	mey
holde	r/Authorize	d person of fir	m M/s	situated at (Comp	lete	address	s of
Mfg.	unit)		*************	bearing drug license on Form	25,	28, 10	etc
bearin	ng Numbe	r	&	respectively	y, i	issued	on
dated		valid/Renev	wed up to	do here by declare on oatl	h as	follows:	-

- 1. That none of the quoted Drug and Medicines manufactured / imported/co-marketed by us since grant of above drug license have been found as of spurious or adulterated quality and no case in this regard is pending in any court.
- 2. That the quoted product is manufactured/imported/ co-marketed by us, and none has been declared as "Not of standard quality" during last two years.
- 3. That we have following Commitment of quantity in our plant at above address [Ref. Clause No. 9(2) & 24 (i)]:-

S. No.	Quoted item Code No. & Name of Drugs	Monthly Capacity in all shifts in nos.	Annual Productio n Capacity	Supply Commitm ent quantity during rate contract period(no t be less than estimated bid quantity)	Estimated Bid Quantity as per Annexure VIII	Bid security deposited @ 2% of estimated bid value as mentioned in Annexure VIII. (In Rs.)	GSTIN Number & Name of State where GSTIN registered
1.							
2.		3				(3)	

Bidder is bound to supply minimum 5% of bid quantity on monthly basis and entire bid quantity within the contract period as per Purchase order.

4. That concern/company/firm does not stand blacklisted/banned/debarred on any ground by Bid Inviting Authority or Govt. of Rajasthan or its departments on the date of bid submission.

The concern/company/firm does not stand blacklisted/banned/debarred on the ground of conviction by court of law or the products being found spurious or adulterated by any other State /Central Government or its any agencies (central Drugs procurement agencies). But my firm is blacklisted/banned/debarred on a different ground by a procurement agency, the details of which are given belowno such matter exists)

5. That our Firm/Company and its Proprietor/Partner/Direc Signature howald not been convicted for contravention of any provisions of the many signed by Marsh Kamar rules made there under since grant of license.

Designation Executi Date: 2025.06

Reason: Appro

6. That we have been granted product permission by the State Licensing Authority for manufacture of quoted products as per the details given below:-

S. No.	Cod e No.	Name of the Product	Date of product permission obtained from the Licensing Authority	Whether Endorsement is in Generic or Trade Name	Issuing Licensing Authority	Sale License no. (in case of imported item(s))	Manufacturing /loan/Import License Number for quoted items
1.							
2.							

- That we have over three years' experience in the manufacture of the quoted product, or the quoted imported product has over 3 years market standing.
- That we have own in-house testing laboratory wherein all the tests required w.r.t. the quoted products are carried out.
- a. That we have approved qualified staff, machines & equipments along with capacity to manufacture above category of drugs
   b. For drug items our unit have been issued WHO-CMP\* by State Licensing Authority /
- 11. That I will supply the Drug and Medicines as per the designs given in Bid and as per the instructions given in clause No. 14.
- 12. That I/We have carefully read all the conditions of e- Bid in Ref. no No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/ Dated:- for Rate Contract cum Supply, of Drugs and Medicines (Rate Contract for the period ending on 30.09.2027) for Rajasthan Medical Services Corporation Ltd and accept all conditions of Bid, including amendments if any. If case of typographical error found in submitted documents / affidavits, in this case we accept all the Terms and conditions of bid documents.
- 13. I/We agree that the Bid Inviting Authority forfeiting the Bid security Deposit and or Performance Security and blacklisting /Debarring/Banning me/ us for a period of 5 years or as deemed fit if, any information furnished by us proved to be false/fabricated at the time of inspection and not complying the conditions as per Schedule M of the said Act or at any time during the Bid process.
- 14. I/ we hereby declare under Section 7 & 11 of Rajasthan Transparency in Public Procurement Act, 2012. that:
  - a. I/we possess the necessary professional, testing natural management resources and competence required by the Procuring Entity;

    Bidding Document issued, the Digitally signed by Mar of Kuma Designation Execute Director
  - b. I/we have fulfilled my/our obligation to pay such at the State Government or any local aut Resistors: Approve the Bidding

Document;

- c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;
- d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
- e. I/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition.
- f. I/we have complied and shall continue to comply with the Code of Integrity as specified in the Rajasthan Transparency in Public Procurement Act, the Rajasthan Transparency in Public Procurement Rules and this Bidding Document, till completion of all our obligations under the Contract.
- 15. The quoted rates of any items is not more than the price fixed by the govt. under the current drugs (Price control) order.
- 16. I/We undertake that I/We shall strictly adhere to the provisions of clause number 28 "Fall clause" of Bid document.
- 17. The submitted Average Annual Turnover certificate is related to (for Drugs & Medicines including Surgical and sutures or medical devices business).

18. Our	complete	address	ior
communication			******
***************************************		**********	
Pin	***********		
Pan No			
E-mail address:			
Phone No. /Mob	ile No		
19. Bank detail for	e banking :-		
Name of accou	nt holder		
Full name of Ba	ank with Branch	********	
Address of Ban	k	Pin	
A/c no. with fu	ll digits		
IFSC code			

Signature yalid

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 11.53:38 IST Reason: Approve Verification

(Name of Deponent & Signature)

Witness:- (Name, Address & Signature)
1
2

\*Certificates on which validity period has not been mentioned, such certificate should not be older than one year from the last date of submission of application/ bid.

Signature yalid

Digitally signed by Maroj Kumar Designation Execute Director Date: 2025.05.06 17.53:38 IST

Reason: Appro

### Annexure - VIII

Ref. Clause No. 5(a), 9 (2, 3)

## List of Drugs with Specifications

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
1	6	Halothane BP [6]	250 ml in Amber Colour Bottle (Rate should be quoted for single unit)	36	3740	4260010	85200	,0
2	32	Tramadol Cap IP 50 mg [32]	10x10 Cap Strip/Blister (Rate should be quoted for 100 Cap)	36	48652980	17927650	358553	
3	37	Chlorpheniramine Maleate Tab IP 4mg [37]	10 x 10 Tab Strip/Blister (Rate should be quoted 100 Tab Strip/Blister)	30	32761393 0	23850294	477006	
4	116	Gentamicin Injection IP 80mg/2ml (IM/ IV use) [116]	2 ml amp(50 Ampoules)(Rate Should be quoted for 50 Amp.)	24	8531574	22837317	456746	
5	136	Chlorambucil Tab IP 5 mg [136]	30 Tab Bottles (Rate Should be quoted for 30 Tab)	24	15074	147725	2955	
6	141	Cytarabine Injection BP 500mg [141]	5 ml Vial (Rate should be quoted Single unit)	24	30166	3455286	69106	
7	148	Fluorouracil Inj IP 250 mg/ 5ml [148]	5 ml Ampoule (Rate should be quoted Single Unit)	24	87806	848206	16964	
8	159	Vincristine Injection IP 1 mg [159]	Vial / Amp (Rate should be quoted Single Unit)	24	29728	1155557	23111	
9	163	Acenocoumarol Tab IP/ Nicoumalone Tab IP 2 mg [163]	10x10 Tab Strip (Rate should be quoted 100 Tab Strip)	24	3361318	1761868	35237	
10	173	Ethamsylate Inj 250 mg/ 2ml (IM/IV) [173]	2 ml Amp (10 ampoules) (Rate should be quoted for 10 amp)	24	2951710	8430084	168602	
11	183	Amiodarone Hydrochloride Inj 50 mg/ml [183]	3 ml Amp(10 ampoules) (Rate should be quoted for 10 amp.)	24	180286	3998022	79960	
12	209	Streptokinase Injection 15 lac units IP [209]	Vial (Rate Should be quoted for single vial)	24	28870	17715048	354301	
13	218	Liquid Paraffin IP [218]	400 ml Bottle (Rate should be quoted Single Unit)	24	CONTONIO	iature		123
14	246	Gentian Violet Topical Solution USP 10/o [246]	200 ml Bottle (Rate should be quoted for Single unit)	24	Designa	signed by tion Exec 25.05.06	uti e Dire	ctor
15	248	Hydrogen Peroxide Solution	400 ml bottle with	24	Resson	Approved	252511	

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
		IP 6 o/o (20 Vol) [248]	inner cap (Rate Should be quoted for single unit)			***		
16	270	Metoclopramide Injection IP 10mg/2ml [270]	2 ml Amp (Amber colour) (25 ampoules) (Rate Should be quoted for 25 amp)	24	8420716	12260562	245211	0
17	282	Clomifene Tablets IP 25 mg[282]	10 x10 Tab strip (Rate Should be quoted for 100 Tab )	24	546584	501922	10038	0.
18	283	Clomiphene Tablets IP 50 mg[283]	10 x10 Tab Strip (Rate should be quoted for 100 Tab.)	24	656394	727148	14543	
19	293	Hydroxyprogesterone Injection IP 250mg/ ml [293]	1 ml Amp(25 ampoules) (Rate Should be quoted for 25 amp)	24	848190	8198265	163965	
20	295	Metformin Tab IP 500 mg [295]	I0X10/ I5x10/ Tab Blister (Rate should be quoted 100 Tab Blister)	36	15452364 2	35997828	719957	
21	333	Isoxsuprine Injection IP 5mg/ml [333]	2 ml Amp (10 Ampoules) (Rate Should be quoted for 10 amp)	24	193830	1276487	25530	
22	334	Isoxsuprine Tab IP 20 mg [334]	10x10 Tab Strip (Rate should be quoted for 100 Tab)	36	4136612	2409163	48183	
23	376	Theophylline Tablet 400mg Sustained Release/ Controlled Release (Theophylline Prolonged Released Tablet IP) [376]	10 X 10 Tab Blister (Rate should be quoted for 100 Tab)	24	10668866	13250390	265008	
24	388	Calcium Gluconate Inj IP 10% (IV use) [388]	10 ml Amp (25 Amp) (Rate should be quoted 25 amp)	36	1650448	7763707	155274	
25	399	Concentrated Solution for Haemodialysis B.P Acetate concentrate in 10 Litre Cans. [399]	10 Ltrs Plastic Can (Rate should be quoted for 10 Ltrs Plastic Can) (Rate Should be quoted for single unit)	24	23482	7416555	148331	
26	401	Peritonial Dialysis Solution IP [401]	1000 ml FFS/ BFS Pack(Rate should be quoted for single unit)	24	33556	1259021	25180	
27	419	Vecuronium Bromide for Injection 4mg ( Freeze Dried /lyophilized) [419]	Vial/Ampoule (Rate should be quoted Single unit)	24	150956	2956096	59122	
28	420	Phenobarbitone Inj IP 200mg/ml [420]	I ml Amp/Vial (Rate should be quoted for Single Unit)	24	317098	3228311	64566	a l
29	423	Hyaluronidase Injection IP Each vial contains Hyaluronidase IP 1500 I.U. [423]	Vial (Rate should be quoted Single Unit)	24	Sign 94490 Digitally	signed by	Mar Si Ku	ımar
30	430	Tinidazole Tab IP 300 mg (Film Coated) [430]	10x10 Tab Blister (Rate should be quoted for 100 Tab)	36	Date: 20	25.05.06 Approve	.53,38	ST

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
31	453	Glibenclamide and Metformin Hydrochloride (SR) Tablets [Glibenclamide 5mg, Metformin Hydrochloride 500 mg (Sustained Release)] [453]	10x10 Tab Blister (Rate should be quoted 100 Tab Blister)	24	10048480	3680155	73603	
32	457	Amlodipine and Enalapril Maleate Tablets (Amlodipine Besilate equivalent to Amlodipine 5 mg, Enalapril Maleate 5 mg) [457]	10x10 Tab Strip (Rate should be quoted for 100 Tab)	24	6815112	60300	1206	
33	466	Lisinopril Tablets IP 2.5 mg [466]	10 x 10 Tab strip/ blister (Rate should be quoted for 100 Tab)	24	2465282	603304	12066	
34	509	Aztreonam Injection USP 500 mg [509]	Vial (Rate should be quoted Single unit)	24	60272	2540875	50817	
35	525	Alpha Interferon Injection Interferon Alpha 2 concentrated Solution IP 3 Million Unit[525]	Vial(Rate should be quoted for single unit)	24	1094	355331	7107	
36	529	Dacarbazine Injection 500 mg IP [529]	Vial (Rate should be quoted for Single unit)	24	6082	1079677	21594	
37	557	Urokinase Injection 5 Lac Unit (Lyophilized) [557]	Vial (Rate should be quoted for Single Vial)	24	12190	24959025	499181	
38	559	Betamethasone Lotion IP 0.05 o/o [559]	50ml (Rate should be quoted Single unit)	24	2807994	26983699	539674	
39	619	Terbutaline Tablets IP 2.5 mg[619]	10x10 Tablet(Rate Should be quoted for 100 Tablet)	24	2875390	1094949	21899	
40	632	Mannitol with Glycerin Injection 10% +10% w/v (For Intravenous Infusion) [632]	100 ml FFS/BFS Bottle(Rate should be quoted for Single unit)	24	47780	1257034	25141	
41	646	Each Combi Blister Pack Containing 3 tablets of Artesunate (50mg each) and 1 tablet of Sulphadoxine Pyremethamine (500+25) mg	One Combi Blister Pack (Rate should be quoted for One Combi Blister Pack)	24	259494	4054334	81087	15
42	648	Each Combi Blister Pack Containing 3 tablets of Artesunate (150 mg each) and 2 tablets of Sulphadoxine Pyremethamine (500mg+25mg)	One Combi Blister Pack (Rate should be quoted for One Combi Blister Pack)	24	258992	7209172	144183	
43	649	Each Combi Blister Pack Containing 3 tablets of Artesunate (each 200 mg) and 2 tablets of Sulphadoxine Pyremethamine(750+37.5)m g each or 3 tablets Sulphadoxine	One Combi Blister Pack (Rate should be quoted for One Combi Blister Pack)	24	Digitally Designa Date: 20	signed by tion Exec 25.05.06 Appro	Maroi Ku	ımar

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
		Pyremethamine(500+25)mg						
44	663	Clobazam Tablet/Capsule 10 mg [663]	10 x 10 Tablet/Capsule Blister (Rate should be quoted 100 Tab/cap blister)	24	9294970	6454427	129089	
45	668	Gabapentine Tablet/Capsule 300mg [668]	10 x 10 Tablet/Capsule Blister/Strip (Rate should be quoted 100 Tab/cap blister)	30	25378030	12790527	255811	
46	677	Cyclosporin Capsule IP 50 mg [677]	50 Capsule Pack (Rate should be quoted for 50 cap)	24	747686	77722	1554	
47	687	Concentrated Solution for Hameodialysis BP Sodium Hydrogen Carbonate Concentrate in 10 Litre Cans [687]	Part A (10 Ltrs Plastic Can) Part B (One Packet of 820 to 900 gm) ((Rate should be quoted for Part A (10 Ltrs Plastic Can) & Part B (One Packet of 820 to 900 gm))	24	59564	20680621	413612	
48	736	Tab Cyclophosphamide IP 50 mg (Each Sugar Coated Tablet contains Cyclophosphamide IP 53.5 mg equivalent to Anhydrous Cyclophosphamide 50 mg) [736]	10X10 Tablets (Rate Should be quoted for 100 Tablet)	24	276010	521659	10433	
49	742	Tab. 6 Thioguanine IP 40 mg (Each Uncoated Tablet contains 6 Thioguanine IP 40 mg) [742]	10X10 Tablets(Rate Should be quoted for 100 Tablet)	24	6986	1604	32	
50	749	3rd Generation Recombinant F VIII 250 IU with diluent [749]	Vial with diluents (Rate should be quoted for Single unit)	24	15146	24610357	492207	
51	785	Tab Levamisol Hydrochloride IP 50 mg (Each Uncoated tablet conatin levamisol Hydrochloride IP 50 mg) [785]	10 X 10 Tab (Rate should be quoted 100 Tab)	24	127420	54230	1085	
52	792	Tab Pyridostigmine IP 60 mg (Each Tablet contains Pyridostigmine IP 60 mg) [792]	10X10 (Rate should be quoted for 100 Tab)	24	566246	1600491	32010	
53	NRD -5	Racecadotril 100mg Cap. IP [NRD-5]	10x10 / 15 Cap (Rate should be quoted 100 Cap)	24	1051402	1813458	36269	100 <b>T</b> 11
54	NRD -7	Acitretin 10 mg Cap. IP [NRD-7]	10x10 (Rate should be quoted 100 Cap)	24	Sign			125
55	NRD -8	Acitretin 25 mg Cap. IP [NRD-8]	10x10 (Rate should be quoted 100 Cap)	24	Designa Date: 20	signed by tion Exec 25.05.06	9 Dire	ctor ST
56	NRD	Aprepitant 125 / 80 mg	10x10 / strip of 3 tab /	24	Reason	Approxe	181796	14

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
	-12	Capsule / Tablet kit (each kit contains 1 Capsule / Tablet of 125 mg and 2 Capsule / Tablet of 80mg) [NRD-12]	Cap (Rate should be quoted for each kit)					
57	NRD -14	Calcium Dobesilate 500MG Cap. [NRD-14]	10x10 (Rate should be quoted 100 Cap)	24	251220	419236	8385	
58	NRD -19	Clomipramine IP 25 mg Capsule / Tablet IP [NRD- 19]	10x10 (Rate should be quoted 100 Cap/tab)	24	594800	546398	10928	(1)
59	NRD -21	Dacarbazine 200 mg Inj. USP [NRD-21]	vial / Amp (Rate should be quoted Single Unit)	24	18634	1612631	32253	
60	NRD -24	Formetrol 12mcg and Budesonide 400 mcg. Powder for Inhalation [NRD-24]	30 Cap (Rate should be quoted 30 Cap)	18	15510204	19282286	385646	
61	NRD -26	Isotretinoin 10mg Cap. IP [NRD-26]	10x10 / 15 strip/blister of Cap (not more than 100± 10 in a box) (Rate should be quoted for 100 cap)	24	836020	575851	11517	
62	NRD -27	Isotretinoin 20 mg Cap. IP [NRD-27]	10x10 / 15 strip/blister of Cap (not more than 100± 10 in a box) (Rate should be quoted for 100 cap)	24	1004620	1125174	22503	
63	NRD -30	Mycophenolate Mofetil 500MG Capsule / Tablet [NRD-30]	10x10 (Rate should be quoted 100 Cap/Tab)	24	746800	4939925	98799	
64	NRD -32	Ramipril IP 5 mg Capsule / Tablet IP [NRD-32]	10x10 (Rate should be quoted 100 Cap/Tab)	24	5603332	2070992	41420	
65	NRD -35	Silodosin 4 mg Tablet / Capsule [NRD-35]	10x10 (Rate should be quoted 100 Cap/Tab)	24	1112440	1021665	20433	
66	NRD -36	Silodosin 8 mg Tablet / Capsule [NRD-36]	10x10 (Rate should be quoted 100 Cap/Tab)	24	1663140	2849957	56999	
67	NRD -37	Temozolamide 250 mg Cap. IP [NRD-37]	10x10 (Rate should be quoted 100 Cap)	24	19880	1420991	28420	
68	NRD -38	Vitamin A 25000 IU Cap. IP [NRD-38]	10x10 (Rate should be quoted 100 Cap)	24	327500	289002	5780	
69	NRD -46	Amorolfine 0.25% Cream [NRD-46]	15 gm (Rate should be quoted Single Unit)	24	118040	991536	19831	
70	NRD -48	Benzoyl Peroxide Gel 2.5 % IP [NRD-48]	20 gm (Rate should be quoted Single Unit)	24	466322	2966554	59331	٦
71	NRD -51	Glycolic Acid 6% Cream [NRD-51]	30 gm (Rate should be quoted Single Unit)	24	Sigr 74762 Digitally	lature 1230882 signed by		<b>d</b> ımar
72	NRD -52	Hydrocortisone 1% Cream IP [NRD-52]	15 gm (Rate should be quoted Single Unit)	24	Designa Date: 20	tion Execution 25.05 06	e Dire .53:38 I	ctor ST
73	NRD	Hydroquinone 2% Cream	20 gm	24	ryeason:	Approxes	35456	

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
	-53	USP [NRD-53]	(Rate should be quoted Single Unit)					
74	NRD -55	Luliconazole 1% Cream IP [NRD-55]	30 gm (Rate should be quoted Single Unit)	24	2045604	22910765	458215	
75	NRD -56	Mometasone 0.1 % Cream IP [NRD-56]	10 gm (Rate should be quoted Single Unit)	24	984328	5401992	108040	U.
76	NRD -58	Neomycin Sulphate 0,5% Cream [NRD-58]	10 gm (Rate should be quoted Single Unit)	24	32272	178916	3578	
77	NRD -60	Adaplene (0.1% W/W) Gel [NRD-60]	15 gm (Rate should be quoted Single Unit)	24	131882	1053157	21063	
78	NRD -65	Salmetrol 50mcg and Fluticasone 500 mcg DPI IP [NRD-65]	30 Capsule / 60 Capsule (Rate should be quoted 30 Cap/Tab)	24	1392082	1637088	32742	
79	NRD -66	Budesonide 400 mcg DPI IP [NRD-66]	30 Capsule / 60 Capsule (Rate should be quoted 30 Cap/Tab)	24	153062	245716	4914	
80	NRD -70	Levosalbutamol 100mcg and Ipratropium Bromide 40mcg DPI [NRD-70]	30 Capsule / 60 Capsule (Rate should be quoted 30 Cap/Tab)	24	3208844	2120404	42408	
81	NRD -71	Diastase, Pepsin with simethicone 15ml DropEach ml contains Diastase (1:1200) 33.33mg, Pepsin (1:3000) 5mg & Simethicone emulsion 40mg [NRD-71]	15 ml(Rate Should be quoted for Single unit)	18	275550	3360828	67217	
82	NRD -76	Hydroxyzine Hydrochloride Oral Solution / Drop 6mg/ml [NRD-76]	15 ml (Rate should be quoted Single Unit)	24	238128	1520209	30404	
83	NRD -77	Ambroxol Drop 7.5mg/ml 15ML [NRD-77]	15 ml (Rate should be quoted Single Unit)	24	176880	956850	19137	
84	NRD -78	Anticold Drop (Each ml contains Paracetamol 125mg, Chlorpheniramine Maleate Img and Phenylepherine hydrochloride 2.5 mg) 15 ml [NRD-78]	15 ml (Rate should be quoted Single Unit)	24	4039606	22124114	442482	
85	NRD -81	Ferrous Ascorbate and Folic acid Drops 15ml (each ml contains Ferrous Ascorbate 10mg and Folic acid 100mcg) [NRD-81]	15 ml (Rate should be quoted Single Unit)	18	78200	500980	10020	
86	NRD -83	Vitamin – E 50mg/ml Drops 15ml [NRD-83]	15 ml (Rate should be quoted Single Unit)	18		lature 879754 signed by	Marsi Kı	ımar
87	NRD -84	Vitamin D3 400IU/ml Drop [NRD-84] Vitamin D3 800IU/ml Drop	15 ml (Rate should be quoted Single Unit)	18	Designa Date: 20	tion Execution Execution 15.05 06	.53:38 I	ctor ST

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
	-85	[NRD-85]	(Rate should be quoted Single Unit)					
89	NRD -87	Lactulose Enema 20% [NRD-87]	100 ml (Rate should be quoted Single Unit)	24	70640	2139120	42782	
90	NRD -94	Natamycin Opthalmic Suspension 5% Eye Drop IP [NRD-94]	5 ml (Rate should be quoted Single Unit)	24	57406	1626656	32533	
91	NRD -95	Olapatadine 0.1% and Ketorolac 0.4% Ophthalmic Solution [NRD-95]	5 ml (Rate should be quoted Single Unit)	24	169084	1325619	26512	
92	NRD -100	Cyclopentolate 1% Eye Drop IP [NRD-100]	5 ml (Rate should be quoted Single Unit)	24	24970	335597	6712	
93	NRD -101	Dorzolamide 2% Eye Drop IP [NRD-101]	5 ml (Rate should be quoted Single Unit)	24	95874	3060298	61206	
94	NRD -104	HPMC 0.3% Eye Drop [NRD-104]	5 ml (Rate should be quoted Single Unit)	24	97060	1195779	23916	6
95	NRD -105	Itraconazole 1% Eye Drop [NRD-105]	5 ml(Rate should be quoted Single Unit)	24	9960	97608	1952	
96	NRD -107	Moxifloxacin 0.5% and Ketorolac Tromethamine 0.5% Eye Drop [NRD-107]	5 ml (Rate should be quoted Single Unit)	24	120140	928442	18569	1.72
97	NRD -108	Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops [NRD-108]	5 ml (Rate should be quoted Single Unit)	24	269640	1808961	36179	
98	NRD -110	Nepafenac 0.1% Eye Drop [NRD-110]	5 ml (Rate should be quoted Single Unit)	24	112580	769147	15383	
99	NRD -114	Proparacaine 0.5% W/v Eye Drop USP [NRD-114]	5 ml (Rate should be quoted Single Unit)	24	59380	1017536	20351	
100	NRD -115	Sodium Chloride 5 % Eye Drop BP [NRD-115]	5 ml (Rate should be quoted Single Unit)	24	70672	791526	15831	
101	NRD -118	Tropicamide 0.8% w/v and Phenylphrine HCl 5% w/v Eye Drop [NRD-118]	5 ml vial (Rate should be quoted Single Unit)	24	221062	3094868	61897	
102	NRD -120	Azithromycin 1% Eye Ointment [NRD-120]	5 gm (Rate should be quoted Single Unit)	24	17912	270829	5417	
103	NRD -123	Chloramphenicol 1%, Polymyxin B Sulphate (10000 Units) and Dexamethasone 0.1% Sodium Phosphate Eye Ointment [NRD-123]	5 gm (Rate should be quoted Single Unit)	24	49624	917052	18341	
104	NRD -125	Itraconazole 1% Eye Ointment [NRD-125]	5 gm (Rate should be quoted Single Unit)	24		ature		
105	NRD -126	Moxifloxacin 0.5% Eye Ointment [NRD-126]	5 gm (Rate should be quoted Single Unit)	24	Digitally Designa	signed by	Maroj Ku ur e Dire	mar ctor
106	NRD -128	Povidone iodine Gargle 0.5% w/v [NRD-128]	50 ml bottle (Rate should be quoted	24	Reason:	25.05.06 Approve	573:38 I	01

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
			Single Unit)					
107	NRD -129	Gatifloxacin 0.3% Eye Drop [NRD-129]	5 ml (Rate should be quoted Single Unit)	24	34442	196733	3935	
108	NRD -141	Metoprolol Img/ml Inj. [NRD-141]	5ml vial / Amp (Rate should be quoted Single Unit)	24	8690	107061	2141	
109	NRD -143	Docetaxel Injection 80 mg/4ml [NRD-143]	vial / Amp (Rate should be quoted Single Unit)	24	12104	3768701	75374	
110	NRD -156	Artesunate Injection 120 mg Each Combo Pack contains Artesunate Inj 120mg Vial, Sodium Bicarbonate Inj IP 5% (2ml Amp), Sodium Chloride Inj IP 0.9%(10ml Amp) [NRD-156]	Combo Pack (Rate should be quoted Single Pack)	24	447550	9273236	185465	
111	NRD -160	Azacitidine 100mg Inj. [NRD-160]	vial / Amp (Rate should be quoted Single Unit)	24	45230	31559685	631194	
112	NRD -161	Azithromycin 10 ml vial equaivelent to 500 mg Inj. [NRD-161]	vial / Amp (Rate should be quoted Single Unit)	24	276340	8047021	160940	
113	NRD -163	Bortezomib 2.5mg Inj. [NRD-163]	vial / Amp (Rate should be quoted Single Unit)	24	3614	1234542	24691	
114	NRD -164	Botulinum Toxin Type A for injection 100 IU [NRD-164]	vial / Amp (Rate should be quoted Single Unit)	24	2388	19306980	386140	
115	NRD -165	Botulinum Toxin Type A for injection 50 IU [NRD-165]	vial / Amp (Rate should be quoted Single Unit)	24	2592	14832720	296654	
116	NRD -167	Cabazitaxel Injection 60 mg [NRD-167]	vial / Amp (Rate should be quoted Single Unit)	24	1094	2695616	53912	
117	NRD -169	Inj.Caffeine Cirate 20mg/ml [NRD-169]	1 ml vial / Amp (Rate should be quoted Single Unit)	24	39830	2672115	53442	
118	NRD -176	Caspofungin 50 mg Inj. [NRD-176]	vial / Amp (Rate should be quoted Single Unit)	24	4220	3601517	72030	
119	NRD -177	Caspofungin 70 mg Inj. [NRD-177]	vial / Amp (Rate should be quoted Single Unit)	24	1890	2095632	41913	
120	NRD -179	Cefoperazone Igm and Tazobactum 125mg Inj. [NRD-179]	vial / Amp (Rate should be quoted Single Unit)	24	51650	1576358	31527	
121	NRD -180	Cefoperazone 500mg Inj. IP [NRD-180]	vial / Amp (Rate should be quoted Single Unit)	24	16960	225093	4502	100
122	NRD -181	Ceftazidime Igm and Sulbactam500 mg Inj. [NRD-181]	vial / Amp (Rate should be quoted Single Unit)	24	Sign	ature	yali	d
123	NRD -184	Ceftriaxone IP 125 mg Inj. IP [NRD-184]	vial / Amp (Rate should be quoted Single Unit)	24	Desidoa	signed by	out e Dire	ctor
124	NRD -188	Inj. Cefuroxime Sodium 750mg (each vial contains	vial (Rate should be quoted	24	Reason:	25.05.06 Approve	:5 <sub>8</sub> 3;38 I	31

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
		Cefuroxime Sodium 750mg) [NRD-188]	Single Unit)					
125	NRD -189	Cetrorelix Acetate 0.25 mg Inj. [NRD-189]	vial / Amp (Rate should be quoted Single Unit)	24	220	39424	788	
126	NRD -194	Clarithromycin 500mg Inj. BP [NRD-194]	vial / Amp (Rate should be quoted Single Unit)	24	15262	1337562	26751	
127	NRD -195	Clindamycin 600mg/4ml Inj. IP in 4 ml vial [NRD-195]	vial / Amp (Rate should be quoted Single Unit)	24	409122	6164446	123289	
128	NRD -199	Cytarabine 1000 mg Inj. IP [NRD-199]	vial / Amp (Rate should be quoted Single Unit)	24	13800	2921184	58424	)
129	NRD -204	Darbepoietin Alfa 100mcg Inj. [NRD-204]	vial / Amp/ PFS (Rate should be quoted Single Unit)	24	6488	10739976	214800	
130	NRD -205	Darbepoietin Alfa 200 mcg Inj. [NRD-205]	vial / Amp/ PFS (Rate should be quoted Single Unit)	24	8164	18442803	368856	
131	NRD -209	Degarelix 80 mg Inj. [NRD- 209]	vial / Amp (Rate should be quoted Single Unit)	24	3118	17600486	352010	
132	NRD -214	Detemir Insuline 1001U/ml Injection 3ml [NRD-214]	Vial / Pre Filled Pen / Pen alongwith 03 Cartridge and 05 needles(Rate should be quoted Single Unit)	24	7800	6142500	122850	
133	NRD -220	Docetaxel 120 mg Inj. IP [NRD-220]	vial / Amp (Rate should be quoted Single Unit)	24	11970	4464331	89287	
134	NRD -221	Doxycycline for Injection 100 mg Inj. USP [NRD-221]	vial / Amp (Rate should be quoted Single Unit)	24	357562	7328591	146572	
135	NRD -224	Enalaprilat Injection 1.25mg/ml in 1ml Ampoule [NRD-224]	vial / Amp (Rate should be quoted Single Unit)	24	2080	16307	326	
136	NRD -225	Ephedrine 30 mg/ml Inj. BP in 1ml Ampoule [NRD-225]	vial / Amp (Rate should be quoted Single Unit)	24	5170	36595	732	05
137	NRD -229	Eribulin 1 mg Inj. [NRD- 229]	vial / Amp (Rate should be quoted Single Unit)	24	3084	23625907	472518	
138	NRD -230	Ertapenem sodium 1.046gm=Ertapenem 1gm Inj.[NRD-230]	vial/Amp	24	20680	16861645	337233	
139	NRD -236	Fluconazole 200 mg lnj. [NRD-236]	100 ml Bottle (Rate should be quoted Single Unit)	24	137306	2920334	58407	
140	NRD -238	Fludarabine Phosphate Injection 50mg Inj. IP [NRD-238]	vial / Amp (Rate Should be quoted for Single vial / Amp)	24	Sian	atüre	· ţali	d
141	NRD -241	Folic Acid Cynocobalamine and Nicotinamide Injection (Each ml contains Folic Acid 15mg/ml Cynocobalamine 500 mcg/ml	10 ml (Rate should be quoted for single unit)	24	Digitally Designa Date: 20	signed by tion Exec 25.05.06 Appro	Mar oj Ku	imar ctor

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
		and Nicotinamide 200 mg/ml) in 10 ml [NRD-241]						
142	NRD -242	Fondaparinux 2.5mg Inj. USP [NRD-242]	vial / Amp / PFS (Rate should be quoted Single Unit)	24	3820	802200	16044	
143	NRD -244	FSH 75 IU Inj. [NRD-244]	vial / Amp (Rate should be quoted Single Unit)	24	12420	2907274	58145	
144	NRD -246	Fulvestrant 250mg Inj. [NRD-246]	vial / Amp (Rate should be quoted Single Unit)	24	10230	23820350	476407	
145	NRD -249	Goserelin Acetate implant 3.6 mg Inj. BP [NRD-249]	PFS / Vial / Amp (Rate should be quoted Single Unit)	24	6178	22704150	454083	
146	NRD -252	Horse ATG(Anti Thymocyte Globulin) 250 mg Inj. [NRD-252]	vial / Amp (Rate Should be quoted for Single Unit)	24	4500	36855000	737100	
147	NRD -253	HP HMG (Highly Human Menopausal parodied Gonadotropin) 150 IU Inj. IP [NRD-253]	vial / Amp (Rate should be quoted Single Unit)	24	17540	4862088	97242	
148	NRD -255	Hydralazine 20mg/ml Inj. IP 1ml vial/ampoule	vial / Amp (Rate should be quoted for single unit)	24	1540	9021	180	11
149	NRD -260	Insulin Glulisine (Monocomponent Insulin Glulisine) 100 IU/ml Injection 3 ml [NRD-260]	Vial / Pre Filled Pen / Pen alongwith 03 Cartridge and 05 needles (Rate should be quoted Single Unit)	24	15810	10433912	208678	
150	NRD -264	Invert Sugar Injection IP 10% w/v [NRD-264]	500ml Bottle (Rate should be quoted Single Unit)	24	8860	246492	4930	
151	NRD -267	Irinotecan Injection 40mg/2ml 2 ml vial [NRD- 267]	vial / Amp (Rate should be quoted Single Unit)	24	10290	1452125	29042	11
152	NRD -268	Irinotecan 100 mg/5ml Inj. IP 5ml vial [NRD-268]	vial / Amp (Rate should be quoted Single Unit)	24	16950	4512497	90250	
153	NRD -273	Levofloxacine 500mg/100 ml Inj. IP 100ml infusion [NRD-273]	vial / Amp (Rate should be quoted Single Unit)	24	519866	8937536	178751	
154	NRD -274	Levosulpride 12.5 mg/ml Injection 2ml [NRD-274]	vial / Amp (Rate should be quoted Single Unit)	24	259180	1015986	20320	
155	NRD -275	Inj. Lignocaine (preservative free) (Each ml contains Lignocaine IP 21.3 mg sodium chloride IP 6.0 mg 50 ml vial) [NRD-275]	50 ml vial(Rate Should be quoted for Single Vial)	24	66988	1919876	38398	AI.
156	NRD -278	Lignocaine Hydrochloride 2% 50ml vial Inj. IP [NRD- 278]	vial / Amp (Rate should be quoted Single Unit)	24	Sigr	signed by		2.5
157	NRD -279	Liposomal Doxorubicin Hydrochloride 20mg/10ml Injection 10ml vial/Ampoule [NRD-279]	vial / Amp (Rate should be quoted Single Unit)	24	Designa Date: 20	tion Execution 25:05 06 Approve	utile Dire	ctor

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
158	NRD -280	Liposomal Doxorubicin Hydrochloride 50mg/25ml Injection 25ml vial/Ampoule [NRD-280]	vial / Amp (Rate should be quoted Single Unit)	24	2400	5286960	105739	
159	NRD -284	Enoxaparin Sodium Injection (Low Molecular Wt. Heparin) 40mg/0.4ml 0.4ml injection [NRD-284]	Vial/ PFS (Rate should be quoted Single Unit)	24	68340	3229065	64581	
160	NRD -285	Mephentermine 30mg/ml Injection 10ml vial [NRD- 285]	10 ml vial (Rate should be quoted Single Unit)	24	58272	3628061	72561	
161	NRD -287	Mesna 200 mg/2ml (Sod. Mercaptoethane Sulphate) Inj. 2 ml ampoule [NRD- 287]	vial / Amp (Rate should be quoted Single Unit)	24	116340	2517656	50353	0.
162	NRD -288	Inj. Methotrexate 250 mg (each ml contain Methotrexate 25 mg in 10ml vial) [ NRD-288]	10ml vial (Rate should be quoted Single Unit)	24	7040	780595	15612	
163	NRD -291	Methylprednisolon Acetate 40mg Inj. IP [NRD-291]	vial / Amp (Rate should be quoted Single Unit)	24	68316	612111	12242	
164	NRD -292	Inj. Methylprednisolone Acetate 125 mg I.P. (Each vial contains Methylprednisolone Acetate 125 mg) [NRD-292]	vial / Amp (Rate should be quoted for single unit)	24	28332	727294	14546	
165	NRD -293	Inj. Metotrexate 15mg/ml (Each ml contains Metotrexate 15mg) [NRD- 293]	Ampoule (Rate Should be quoted for one amp. )	24	3780	40325	807	
166	NRD -294	Midazolam 5mg/ml Injection 10 ml vial [NRD- 294]	10 ml vial (Rate should be quoted Single Unit)	24	208480	3082168	61643	
167	NRD -297	Mitomycin 40 mg Inj. IP [NRD- 297]	vial / Amp(Rate should be quoted Single Unit)	24	2688	4606157	92123	
168	NRD -301	Moxifloxin 400mg/100ml Inj. [NRD-301]	100 ml bottle (Rate should be quoted Single Unit)	24	111660	2988915	59778	
169	NRD -303	Nabpaclitaxel / Paclitaxel Nano Particle Injection 100 mg [NRD-303]	vial / Amp (Rate should be quoted Single Unit)	24	14180	15389270	307785	
170	NRD -304	Nandrolone Decanoate 100mg Inj, IP [NRD-304]	vial / Amp (Rate should be quoted Single Unit)	24	8990	80550	1611	
171	NRD -305	Nandrolone Decanoate 50 mg Inj. IP [NRD-305]	vial / Amp (Rate should be quoted Single Unit)	24	78466	465774	9315	
172	NRD -306	Natalizumab 300 mg Inj. [NRD-306]	vial / Amp (Rate should be quoted Single Unit)	24	Siar	ature	366912 Vali	d
173	NRD -308	Netilmycin 300mg/3ml Inj. IP 3ml vial/Ampoule [NRD- 308]	vial / Amp (Rate should be quoted Single Unit)	24	Diditally	sidfred by	Mar 36Ki	ımar
174	NRD -311	Nimodipine Infusion 10mg/50 ml Inj. BP 50ml [NRD-311]	vial / Amp (Rate should be quoted Single Unit)	24	Date; 20 Reason:	tion Exec 25,05.06 Appro e	.53;38	ST

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
175	NRD -316	Inj. Sodium Chloride 0.9% 1000 ml Glass Bottle Inj. IP [NRD- 316]	1000 ml Glass Bottle (Rate Should be quoted for Single unit)	24	43984	2364580	47292	
176	NRD -321	Omalizumab 150 mg vial Inj. [NRD-321]	vial / Amp (Rate should be quoted Single Unit)	24	1938	16584435	331689	
177	NRD -322	Ornidazole 500mg Inj. IP [NRD- 322]	vial / Amp (Rate should be quoted Single Unit)	24	32290	559831	11197	) <u>2</u>
178	NRD -323	Palonosetron 0.25mg Inj. [NRD-323]	vial / Amp (Rate should be quoted Single Unit)	24	114890	4632365	92647	
179	NRD -326	Peg Asparaginase 3750 IU 5 ml Inj. [NRD-326]	vial / Amp (Rate should be quoted Single Unit)	24	2324	20302464	406049	
180	NRD -327	PEG filgrastim injection 6mg Inj. [NRD-327]	vial / Amp / PFS (Rate should be quoted Single Unit)	24	14290	14084224	281684	
181	NRD -330	Pemetrexed 100mg Inj. IP [NRD-330]	vial / Amp (Rate should be quoted Single Unit)	24	8190	1265846	25317	
182	NRD -331	Pemetrexed 500 mg Inj. IP [NRD-331]	vial / Amp (Rate should be quoted Single Unit)	24	17260	9182320	183646	
183	NRD -335	Piperacillin 1 gm and Tazobactum 125 mg Inj. IP [NRD-335]	vial / Amp (Rate should be quoted Single Unit)	24	194660	3488307	69766	
184	NRD -336	Piracetam 200mg Inj. [NRD- 336]	15 ml Amp (Rate should be quoted Single Unit)	24	56552	760059	15201	
185	NRD -338	Plerixafor 24 mg Inj. [NRD- 338]	vial / Amp (Rate should be quoted Single Unit)	24	284	1972096	39442	
186	NRD -346	Ranibizumab Injection (10mg/ml) 2.3mg/0.23ml per vial [NRD-346]	vial / Amp (Rate should be quoted Single Unit)	24	3880	27246912	544938	
187	NRD -347	Rasburicase 1.5 mg Inj. [NRD-347]	vial / Amp (Rate should be quoted Single Unit)	24	1158	6419952	128399	
188	NRD -351	Recombinant LH 751U Inj. [NRD-351]	vial / Amp (Rate should be quoted Single Unit)	24	3700	5801600	116032	
189	NRD -353	Risperidone prolonged released Depot/Suspension 25 mg Injection [NRD-353]	vial / Amp (Rate should be quoted Single Unit)	24	2812	9704621	194092	
190	NRD -354	Risperidone prolonged released Depot/Suspension 50 mg Injection [NRD-354]	vial / Amp (Rate should be quoted Single Unit)	24	2022	13522165	270443	
191	NRD -355	Rituximab 100 mg Inj. [NRD-355]	vial / Amp (Rate should be quoted Single Unit)	24	Sĩần	ature	yali	d
192	NRD -357	Rocuronium 100mg/10ml Inj. In 10 ml vial [NRD-357]	vial / Amp (Rate should be quoted Single Unit)	24	Digitally	sidhel@bv	Maropki	ımar
193	NRD -359	Romiplostim 250 mcg Inj. [NRD-359]	vial / Amp (Rate should be quoted Single Unit)	24	Date; 20 Reason:	tion Exec 25.05.06 Approve	.53:38	ST

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
194	NRD -360	Romiplostim 500 mcg Inj. [NRD-360]	vial / Amp (Rate should be quoted Single Unit)	24	2782	5577354	111547	
195	NRD -361	Ropivacaine 0.75% 20ml vial Inj. IP [NRD-361]	vial / Amp (Rate should be quoted Single Unit)	24	31140	2301869	46037	
196	NRD -362	Ropivacaine 0.75% 3 Ml Ampule (Heavy) Injection [NRD-362]	20 ml Amoule(Rate Should be quoted for Single amp.)	24	32860	2090054	41801	
197	NRD -363	Secukinumab 150 mg Inj. [NRD-363]	vial / Amp (Rate should be quoted Single Unit)	24	1002	14428640	288573	
198	NRD -369	Inj. Streptomycin Injection 500mg/ vial (Each Vial Contains: Streptomycin 500 mg) [NRD-369]	Vial (Rate Should be quoted for Single vial)	24	29010	1173582	23472	
199	NRD -371	Teicoplanin 200 mg Inj. IP [NRD-371]	vial / Amp (Rate should be quoted Single Unit)	24	73520	7642404	152848	
200	NRD -372	Teicoplanin 400 mg lnj. IP [NRD-372]	vial / Amp (Rate should be quoted Single Unit)	24	81440	15648696	312974	
201	NRD -379	Tigecycline for injection 50mg Inj. USP [NRD-379]	vial / Amp (Rate should be quoted Single Unit)	24	122680	10717325	214346	
202	NRD -385	t PA 20mg Alteplase for Injection [NRD-385]	vial / Amp (Rate should be quoted Single Unit)	24	1538	24938190	498764	
203	NRD -387	Trabectedin I mg Inj. [NRD- 387]	vial / Amp(Rate should be quoted Single Unit)	24	84	1401792	28036	
204	NRD -401	Vinorelbine 50mg Inj. IP [NRD-401]	vial / Amp (Rate should be quoted Single Unit)	24	4298	5772180	115444	
205	NRD -402	Vitamin D3 (600000 IU) Inj. IP [NRD-402]	I ml Amp (Rate should be quoted Single Unit)	24	86842	668197	13364	
206	NRD -409	L-Ornithine L-Aspartate (150mg) and Pancreatin (100mg) Capsule / Tablet [NRD-409]	10x10 (Rate should be quoted 100 Cap/Tab)	24	284720	475141	9503	
207	NRD -411	Clotrimazole 1% and Beclomethasone 0.025% Lotion [NRD-411]	50 ml (Rate should be quoted Single Unit)	24	180200	1961729	39235	
208	NRD -412	Ketaconazole 2% Lotion [NRD-412]	50 ml (Rate should be quoted Single Unit)	24	137840	1835588	36712	
209	NRD -418	Sunscreen Lotion SPF 30 (Octinoxate 7.5%, Avobenzone 2%, Oxybenzone 3%, Octocrylene 3% and Zinc Oxide 2%) 50ml [NRD-418]	50 ml (Rate should be quoted Single Unit)	24	447640 Sign	<sup>20555629</sup>	411113	d
210	NRD -419	Clotrimazole 10Mg Lozenses [NRD-419]	10x10 (Rate should be quoted 100 Tab)	24	Diditally	sighted by	Mar of Ku	mar
211	NRD -429	Fluticasone Propionate Nasal Spray IP 50mcg [NRD-429]	100 metered dose (Rate should be quoted 100 metered dose)	24	Date: 20 Reason:	tion Execution 25,05 06 Approve	.5,3,38	ST

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
212	NRD -431	Neomycin sulphate and Bacitracin Zinc ointment USP 5 mg and 500 IU/gm Ointment USP [NRD-431]	20 gm (Rate should be quoted Single Unit)	24	23800	535519	10710	
213	NRD -438	Ointment Neomycin, Polymyxin B and Bacitracin Zinc Ophthalmic 5 gm (Each gram contains polymyxin B sulfate usp 5000 units, Bacitracin 400 units ,Neomycin sulphate and Zinc Oxide in Ointment base ) [NRD-438]	5 gm (Rate Should be quoted for Single unit )	24	25540	3057138	61143	
214	NRD -439	Tacrolimus 0 .03% Ointment [NRD-439]	10 gm (Rate should be quoted Single Unit)	24	136520	2096292	41926	
215	NRD -440	Tacrolimus 0 .1% Ointment [NRD-440]	10 gm (Rate should be quoted Single Unit)	24	152760	4812795	96256	10
216	NRD -452	Bacillus Clausii Spores Suspension 2 Billion/5ml [NRD-452]	5 ml (Rate should be quoted Single Unit)	24	499720	5820739	116415	
217	NRD -453	Formeterol 20mcg and Budesonide 0.5mg Respitory Solution/ Suspension [NRD- 453]	2 ml (Rate should be quoted Single Unit)	18	371400	4159680	83194	0.2
218	NRD -454	Levosalbutamol 1.25mg and Ipratropium 500meg Respiratory Solution 2.5ml [NRD-454]	2.5 ml / 3 ml (Rate should be quoted Single Unit)	24	2526702	8744410	174888	
219	NRD -458	Glycopyrronium Inhalation Solution 25mcg 2 ml [NRD- 458]	2 ml (Rate should be quoted Single Unit)	24	216380	5394613	107892	
220	NRD -465	I. Arginine 3gm and Proanthocynadine 75mg Granules [NRD-465]	Sachet (Rate should be quoted Single Unit)	24	291640	2907068	58141	
221	NRD -475	Suspension Cefaclor 125 mg (Each 5 ml contain Cefaclor 125 Mg I.P.) [NRD-475]	30 ml (Rate should be quoted Single Unit)	24	2440	88543	1771	
222	NRD -477	Amlodipine oral solution 1 MG/ ML Syrup B.P. [NRD- 477]	100 ml (Rate Should be quoted for Single unit)	24	100	1445	29	
223	NRD -481	Calcium Phosphate 200 ml Syrup (each 10ml contain elemental Calcium 300mg elemental Phosphorus 150mg Elemental magnesium 75mg Elemental Zinc 4mg Vitamin D3 200 300IU.) [NRD-481]	200 ml bottle (Rate should be quoted Single Unit)	24	162800	3965808	79316	
224	NRD -484	Cefpodoxime Proxetil Oral suspension 50MG Syrup I.P. Each 5 ml contain Cefpodoxime Proxetil Oral suspension 50MG Syrup I.P. [NRD-484]	30 ml (Rate should be quoted Single Unit)	24	Digitally Designa	ature	Mar oj Ku uti e Dire	mar ctor
225	NRD -485	Cefpodoxime Proxetil Oral suspension 100MG Syrup	30 ml (Rate should be quoted	24	Reason:	25,05.06 Approve	. <del>5</del> 3;38 1	SI

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
		I.P. Each 5 ml contain Cefpodoxime Proxetil Oral suspension 100MG Syrup I.P. [NRD-485]	Single Unit)					
226	NRD -486	Cefuroxime Axetil oral suspension 125mg/5ml Syrup B.P. [NRD-486]	30 ml (Rate should be quoted Single Unit)	24	47600	919632	18393	
227	NRD -487	Clarithromycin for oral suspension / Dry Syrup 125mg/5ml [NRD-487]	30 ml (Rate should be quoted Single Unit)	24	26600	637549	12751	ů.
228	NRD -488	Cefoperazone Injection 1gm [NRD-488]	vial / Amp (Rate should be quoted Single Unit)	24	19640	384944	7699	
229	NRD -489	Cyclosporine Oral solution 100mg/ml Syrup I.P. [NRD- 489]	50 ml (Rate should be quoted Single Unit)	24	5300	5425875	108518	
230	NRD -491	Cyproheptadine HCL 2mg / 5ml Syrup I.P. [NRD-491]	200 ml (Rate should be quoted Single Unit)	24	3501658	33335784	666716	
231	NRD -504	Linezolid 100mg/5ml in 30ml Syrup [NRD-504]	30 ml (Rate should be quoted Single Unit)	24	49048	702603	14052	
232	NRD -508	Montelukast and Levocetrizine Syrup/suspension each 5ml contains Montelukast 4mg and Levocetrizine 2.5 mg [NRD-508]	60 ml (Rate should be quoted Single Unit)	24	1973068	17435607	348712	
233	NRD -510	Ondansetron oral suspension/solution/ Syrup 2mg/5ml [NRD-510]	30 ml (Rate should be quoted Single Unit)	24	3994394	18879104	377582	
234	NRD -512	Phenobarbitone 20mg/5ml in 100ml Syrup [NRD-512]	100 ml (Rate should be quoted Single Unit)	24	218304	3762862	75257	
235	NRD -514	Piracetam 500mg/5ml Suspension/Syrup [NRD- 514]	100 ml (Rate should be quoted Single Unit)	24	18690	774095	15482	
236	NRD -515	Potassium Magnesium citrate Syrup/ solution each 5ml contians Potassium citrate 1100mg and Magnesium citrate 375 mg [NRD-515]	200 ml (Rate should be quoted Single Unit)	24	44050	1230933	24619	
237	NRD -516	Ranitidine 75 mg /5ml oral suspension/Solution /Syrup I.P. [NRD-516]	100 ml (Rate should be quoted Single Unit)	24	103580	1374714	27494	
238	NRD -519	Sodium Picosulphate oral Suspension/ Solution/ Syrup 5mg/5ml [NRD-519]	100 ml (Rate should be quoted Single Unit)	24	29410	310617	6212	-
239	NRD -520	Sorbitol and Tricholine Citrate Syrup / Solution Each 10ml contains Sorbitol (70%) 7.15gm and Tricholine Citrate (66%) 0.55gm [NRD-520]	200 ml (Rate should be quoted Single Unit)	24		ature		
240	NRD -521	Sucralfate Syrup/ Suspension Each 5ml contains Sucralfate 500mg	200 ml (Rate should be quoted Single Unit)	24	Date: 20 Reason:	signed by tion Exec 25.05.06 Approve	.53:38	ST

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
		[NRD-521]					-	3
241	NRD -522	Triclofos oral suspension500 mg/ 5ml in 30ml Syrup I.P. [NRD-522]	30 ml(Rate should be quoted for Single Unit)	24	47730	1323076	26462	
242	NRD -524	Zinc Oral Syrup / Solution / Suspension 20 mg / 5ml [NRD-524]	100 ml (Rate should be quoted Single Unit)	24	2688652	20145532	402911	
243	NRD -525	Azithromycin 100mg/5ml oral Syrup /Suspension [NRD-525]	15 ml (Rate should be quoted Single Unit)	24	1891364	17899869	357997	
244	NRD -526	Azithromycin 200mg/5ml oral Syrup /Suspension [NRD-526]	15 ml (Rate should be quoted Single Unit)	24	1796538	22757106	455142	
245	NRD -532	Tacrolimus 0.25 Tab./Cap. I.P. [NRD-532]	10x10 (Rate should be quoted 100 Tab/Cap)	24	57000	35112	702	1;
246	NRD -534	Tab. 6-Mercaptopurine 20 mg I.P.[NRD-534]	10x10 Tablet (Rate Should be quoted for 100 Tablet )	24	50600	148764	2975	
247	NRD -535	Acebrophylline SR 200 Mg Tab. [NRD-535]	10x10 (Rate should be quoted 100 Tab)	24	3686000	4871418	97428	175
248	NRD -536	Aceclofenae 100mg and Thiocolchicoside 4mg Tab. [NRD-536]	10x10 (Rate should be quoted 100 Tab)	24	3569200	6503939	130079	
249	NRD -537	Aceclofenac SR 200 mg Tab. [NRD-537]	10x10 (Rate should be quoted 100 Tab)	24	986400	475050	9501	
250	NRD -542	Alendronate Sodium 70 mg Tab. I.P. [NRD-542]	10x10 / 1x4 (Rate should be quoted 100 Tab)	24	90540	405619	8112	
251	NRD -549	Apixaban 2.5 mg Tab. [NRD-549]	10x10 / 30 Tablet (Rate should be quoted 100 Tab)	24	263660	362332	7247	
252	NRD -550	Apixaban 5mg Tab. [NRD- 550]	10x10 / 30 Tablet (Rate should be quoted 100 Tab)	24	416880	689620	13792	
253	NRD -552	Aripiprazole 5 mg Tab, I.P. [NRD-552]	10x10 (Rate should be quoted 100 Tab)	24	686600	323899	6478	
254	NRD -555	Atomoxetin 10 mg Tab. [NRD-555]	10x10 (Rate should be quoted 100 Tab)	24	134300	270749	5415	
255	NRD -556	Atomoxetin 18 mg Tab. [NRD-556]	10x10 (Rate should be quoted 100 Tab)	24	98100	351590	7032	
256	NRD -557	Atomoxetin 25 mg Tab. [NRD-557]	10x10 (Rate should be quoted 100 Tab)	24	43700	234931	4699	
257	NRD -560	Bilastin 20 MG Tab. [NRD- 560]	10x10 (Rate should be quoted 100 Tab)	24	Sian	atüre	yali	d
258	NRD -562	Bosentan 62.5 mg Tab. I.P. [NRD-562]	10x10 (Rate should be quoted 100 Tab)	24	Digitally	sign <del>ted</del> lby	MaropKu	mar
259	NRD -566	Calcium Acetate 667 Tab. USP [NRD-566]	10x10 (Rate should be quoted 100 Tab)	24	Date: 20 Réason:	25.05.06 Approve	.53:38 i	ST

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
260	NRD -569	Carbimazole 10 mg Tab. I.P. [NRD-569]	10x10 (Rate should be quoted 100 Tab)	24	1493200	585334	11707	
261	NRD -570	Cefixime and Potassium Clavulanate 200 and 125mg Tab. [NRD-570]	10x10 (Rate should be quoted 100 Tab)	24	1088200	7836659	156733	()
262	NRD -571	Cefpodoxime proxetil Tablet 100mg / Cefpodoxime proxetil DispersibleTablet 100mg [NRD-571]	10x10 (Rate should be quoted 100 Tab)	24	2481860	4447493	88950	
263	NRD -573	Cefpodoxime CV 325 Tab [NRD-573]	10x10 (Rate should be quoted 100 Tab)	24	1261700	8820595	176412	
264	NRD -574	Chlordiazepoxide 25 mg Tab. I.P. [NRD-574]	10x10 (Rate should be quoted 100 Tab)	24	1261420	988106	19762	
265	NRD -575	Chlordiazepoxide 5 mg and Clidinium 2.5 mg Tablet [NRD-575]	10x10 (Rate should be quoted 100 Tab)	24	344620	208426	4169	
266	NRD -576	Chlorthalidone 6.25 mg Tab. I.P. [NRD-576]	10x10 (Rate should be quoted 100 Tab)	24	480420	171537	3431	
267	NRD -577	Cholchicine 0.5mg Tab. I.P. [NRD-577]	10x10(Rate should be quoted 100 Tab)	24	32300	71628	1433	
268	NRD -578	Cilostazol 50mg Tab. LP. [NRD-578]	10x10 (Rate should be quoted 100 Tab)	24	688000	1024845	20497	
269	NRD -579	Cilostazol 100mg Tab. I.P. [NRD-579]	10x10 (Rate should be quoted 100 Tab)	24	736600	2012980	40260	
270	NRD -582	Cilnidipine 5 mg Tab. I.P. [NRD-582]	10x10 / 15 strip/blister of Tab (not more than 100± 10 in a box) (Rate should be quoted for 100 Tab/Cap)	24	1507020	253179	5064	
271	NRD -583	Cilnidipine10 mg Tab. I.P. [NRD-583]	10x10 / 15 strip/blister of Tab (not more than 100± 10 in a box) (Rate should be quoted for 100 Tab/Cap)	24	3027620	593414	11868	
272	NRD -584	Cilnidipine 20 mg Tab. I.P. [NRD-584]	10x10 (Rate should be quoted 100 Tab)	24	786020	211282	4226	
273	NRD -585	Clonazepam 0.25 Tab. I.P. [NRD-585]	10x10 (Rate should be quoted 100 Tab)	24	2114600	378936	7579	
274	NRD -586	Clonazepam 1Mg Tab. I.P. [NRD-586]	10x10 (Rate should be quoted 100 Tab)	24	2194400	639009	12780	_I
275	NRD -587	Clozapine 25 mg Tab. I.P. [NRD-587]	10x10 (Rate should be quoted 100 Tab)	24	383000	lature		=3
276	NRD -588	Clozapine 50 mg Tab. I.P. [NRD-588]	10x10 (Rate should be quoted 100 Tab)	24	Designa Date: 20	tion Execution 25.05 06	e Dire .53:38 I	ctor ST
277	NRD	Clozapine 100 mg Tab, I.P.	10x10	24	Keasen:	Approxe	43969	

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
	-589	[NRD-589]	(Rate should be quoted 100 Tab)					
278	NRD -592	Cyproheptadine 4Mg Tab. LP. [NRD-592]	10x10 / 1x15 (Rate should be quoted 100 Tab)	24	458420	120656	2413	
279	NRD -593	Cyproterone Acetate 2 mg and Ethynil Estradiol. 035mg Tab BP [NRD-593]	1x21 Tab(Rate should be quoted for 21 Tab)	24	103250	206996	4140	
280	NRD -599	Dapagliflozin 10 MG Tab. [NRD-599]	10x10 (Rate should be quoted 100 Tab)	24	9187960	3807491	76150	
281	NRD -600	Dapoxetine 30 mg Tab. I.P. [NRD-600]	10x10 (Rate should be quoted for 100 Tab)	24	141200	166051	3321	
282	NRD -602	Deflazacort 6mg Tab. [NRD-602]	10x10 (Rate should be quoted 100 Tab)	24	8513182	8730030	174601	
283	NRD -603	Deflazacort 12 MG Tab, [NRD-603]	10x10 (Rate should be quoted 100 Tab)	24	4609824	8672296	173446	
284	NRD -604	Desvenlafaxine 50mg CR/PR/SR/ER Tablet [NRD-604]	10x10 (Rate should be quoted 100 Tab)	24	688000	742820	14856	
285	NRD -612	Disulfiram 250mg Tab. I.P. [NRD-612]	10x10 (Rate should be quoted 100 Tab)	24	52900	57471	1149	
286	NRD -613	Donepezil 5 mg Tab. I.P. [NRD-613]	10x10 (Rate should be quoted 100 Tab)	24	620000	314563	6291	
287	NRD -614	Duloxetine gastro resistant 20 mg Tab. I.P. [NRD-614]	10x10 (Rate should be quoted 100 Tab)	24	2187580	1563157	31263	
288	NRD -615	Duloxitine gastro resistant30 mg Tab. I.P. [NRD-615]	10x10 (Rate should be quoted 100 Tab)	24	1824680	1753444	35069	
289	NRD -622	Erlotinib 150 mg Tab. I.P. [NRD-622]	10x10 / 30 Tablet (Rate should be quoted 100 Tab)	24	13900	309803	6196	
290	NRD -623	Erlotinib 100mg Tab. I.P. [NRD-623]	10x10 / 30 Tablet (Rate should be quoted 100 Tab)	24	9400	173712	3474	
291	NRD -624	Esomeprazole 40 Mg Tab. I.P. [NRD-624]	10x10 / 1x15 (Rate should be quoted 100 Tab)	24	10139702	4996845	99937	
292	NRD -627	Enzalutamide 40mg Tablet / Capusle [NRD-627]	10x10 / 1x4 (Rate should be quoted 100 Tab/Cap)	24	129600	6676992	133540	
293	NRD -629	Etizolam 0.5 mg Tab. I.P. [NRD-629]	10x10 (Rate should be quoted 100 Tab)	24	1409200	506636	10133	٦
294	NRD -632	Febuxostat 40 mg Tab, [NRD-632]	10x10 (Rate should be quoted 100 Tab)	24	Olgr 1283502 Digitally	signed by		13
295	NRD -633	Febuxostat 80 mg Tab. [NRD-633]	10x10 (Rate should be quoted 100 Tab)	24	Designa Date: 20	tion Execution 25.05 06	uti e Dire	ctor
296	NRD	Fexofenadine 180 MG Tab.	10x10	24	Reason:	ABBRAZE	16375	T.

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
	-635	LP. [NRD-635]	(Rate should be quoted 100 Tab)			***		
297	NRD -640	Fluvoxamine 50 mg Tab. LP. [NRD-640]	10x10 (Rate should be quoted 100 Tab)	24	197400	305300	6106	
298	NRD -643	Furosemide 20mg and Spironolactone 50mg Tab. [NRD-643]	10x10 (Rate should be quoted 100 Tab)	24	5265464	9081872	181637	
299	NRD -649	Ivermeetin 6 mg and Albendazole 400 mg Tab. [NRD-649]	10x10 (Rate should be quoted 100 Tab)	24	87840	103192	2064	
300	NRD -650	Ivermectin 6mg Tab. I.P. [NRD-650]	10x10 (Rate should be quoted 100 Tab)	24	496920	122385	2448	
301	NRD -651	Ivermeetin 12mg Tab. I.P. [NRD-651]	10x10 (Rate should be quoted 100 Tab)	24	559220	197293	3946	
302	NRD -652	Ketoconazole 200 MG Tab. I.P. [NRD-652]	10x10 (Rate should be quoted 100 Tab)	24	207000	264298	5286	
303	NRD -654	Lamotrigine Dispersible 100MG Tab. I.P. [NRD-654]	10x10 (Rate should be quoted 100 Tab)	24	464600	930389	18608	
304	NRD -655	Lapatinib Tablet 250mg [NRD-655]	10x10 / 30 Tablet (Rate should be quoted 100 Tab)	24	138080	3247642	64953	
305	NRD -660	Levetiracetam IP 250 mg Tab. I.P. [NRD-660]	10x10/15 strip/blister of Tab (not more than 100± 10 in a box ) (Rate should be quoted for 100 Tab)	24	1292400	1085616	21712	
306	NRD -663	Levofloxacin 750 mg Tab. I.P. [NRD-663]	10x10 / 1x5 (Rate should be quoted 100 Tab)	24	844000	2599520	51990	
307	NRD -665	Levothyroxine Sodium 25 mcg Tab. LP. [NRD-665]	10x10 / 100 Tablet Bottle (Rate should be quoted 100 Tab Bottle)	24	7696336	1120587	22412	
308	NRD -666	Levothyroxine Sodium 75 mcg Tab. I.P. [NRD-666]	10x10/ 100 Tablet Bottle (Rate should be quoted 100 Tab Bottle)	24	3264800	548486	10970	
309	NRD -668	Linaglipitin 5mg Tab. [NRD-668]	10x10 (Rate should be quoted 100 Tab)	24	2083000	909854	18197	in .
310	NRD -669	Lopinavir 200Mg and Ritonavir 50 mg Tab. LP. [NRD-669]	10x10 / 30 Tablets (Rate should be quoted 100 Tab)	24	62000	729120	14582	
311	NRD -670	Loratadine 10 mg Tab. I.P. [NRD-670]	10x10 (Rate should be quoted 100 Tab)	24	Sign	atüre	v vali	d
312	NRD -674	Melatonin 3 mg Tab. [NRD-674]	10x10 / 30 Tablet (Rate should be quoted 100 Tab)	24	Digitally	sighed by	Mar of Ku	mar
313	NRD -677	Tab. Methimazole 5 mg (Each tablet contains Methimazole	10x10 Tablet (Rate Should be quoted for 100 Tablet )	24	Date: 20	25:05.06 Appro e	.53!38	ST

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
		5 mg ) [NRD-677]	10-10					0
314	NRD -678	Methimazole 10mg Tab. USP [NRD-678]	10x10 (Rate should be quoted 100 Tab)	24	99820	718864	14377	
315	NRD -682	Methylprednisolone 4mg Tab. I.P. [NRD-682]	10x10 (Rate should be quoted 100 Tab)	24	511600	246387	4928	
316	NRD -683	Methylprednisolone 16mg Tab. I.P. [NRD-683]	10x10 (Rate should be quoted 100 Tab)	24	1283000	1954266	39085	
317	NRD -684	Methylprednisolone 8mg Tab. I.P. [NRD-684]	10x10 (Rate should be quoted 100 Tab)	24	1307600	1054449	21089	
318	NRD -693	Montelukast 5 mg Tab. I.P. [NRD-693]	10x10 / 1x15 (Rate should be quoted 100 Tab)	24	136120	64336	1287	
319	NRD -694	Montclukast 10 mg Tab. I.P. [NRD-694]	10x10 / 15 strip/blister of Tab (not more than 100± 10 in a box ) (Rate should be quoted for 100 Tab)	24	15725648	7925727	158515	
320	NRD -695	Morphine 10MG Tab. I.P. [NRD-695]	10x10 (Rate should be quoted 100 Tab)	24	752580	1045183	20904	
321	NRD -698	Moxonidine 0.2 mg Tab. B.P. [NRD-698]	10x10 (Rate should be quoted 100 Tab)	24	763620	1582221	31644	
322	NRD -699	Moxonidine 0.3 mg Tab. B.P. [NRD-699]	10x10 (Rate should be quoted 100 Tab)	24	856820	2360710	47214	
323	NRD -700	N Acetylecystine effervescent form, orange flavour, 600 mg Tab. [NRD- 700]	10x10 (Rate should be quoted 100 Tab)	24	5183600	21450649	429013	
324	NRD -701	Naltrexone 50 mg Tab. I.P. [NRD-701]	10x10 (Rate should be quoted 100 Tab)	24	30400	1174656	23493	
325	NRD -702	Nebivolol 5mg Tab. I.P. [NRD-702]	10x10 (Rate should be quoted 100 Tab)	24	162000	158941	3179	
326	NRD -703	Nebivolol 10mg Tab. I.P. [NRD-703]	10x10 (Rate should be quoted 100 Tab)	24	57820	134050	2681	
327	NRD -705	Nicoumalone 1 Mg Tab. I.P. [NRD-705]	10x10 (Rate should be quoted 100 Tab)	24	934060	481228	9625	
328	NRD -706	Nicoumalone 3 Mg Tab. I.P. [NRD-706]	10x10 (Rate should be quoted 100 Tab)	24	724400	1027628	20553	12
329	NRD -707	Nicoumalone 4 Mg Tab. I.P. [NRD-707]	10x10 (Rate should be quoted 100 Tab)	24	Sign	ature	yali	d
330	NRD -709	Nifidipine 20MG SR Tab. I.P. [NRD-709]	10x10 (Rate should be quoted 100 Tab)	24	Designa	signed by	ut e Dire	ctor
331	NRD -710	Nilotinib 150 mg Tablet / Capsule [NRD-710]	10x10 / 4 Tablet (Rate should be quoted	24	Reason:	25,05.06 Approve	:53:38 1	01

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
			100 Tab/cap)					,
332	NRD -711	Nilotinib 200 mg Tablet / Capsule [NRD-711]	10x10 / 4 Tablet (Rate should be quoted 100 Tab/cap)	24	60800	2017344	40347	
333	NRD -713	Nitazoxanide 500mg Tab. [NRD-713]	10x10(Rate should be quoted for 100 Tab)	24	36000	359251	7185	
334	NRD -714	Nitrazepam 5mg Tab. I.P. [NRD-714]	10x10 (Rate should be quoted 100 Tab)	24	196300	71013	1420	
335	NRD -715	Nitrazepam 10 mg Tab. I.P. [NRD-715]	10x10 (Rate should be quoted 100 Tab)	24	110900	64700	1294	
336	NRD -718	Olmesartan medoxomil 20 MG Tab. I.P. [NRD-718]	10x10 / 15x10 (Rate should be quoted 100 Tab)	24	1109800	584199	11684	
337	NRD -722	Oxcarbazepine 450MG Tab. I.P. [NRD-722]	10x10 (Rate should be quoted 100 Tab)	24	573000	1270685	25414	
338	NRD -723	Oxazepam 15mg Tab. I.P. [NRD-723]	10x10 (Rate should be quoted for 100 Tab )	24	78600	92434	1849	
339	NRD -725	Pantoprazole 20MG Tab. I.P. [NRD-725]	10x10 (Rate should be quoted 100 Tab)	24	2250400	685562	13711	
340	NRD -726	Paracetomol 650 mg Tab. I.P. [NRD-726]	10x10/15 strip/blister of Tab (not more than 100± 10 in a box) (Rate should be quoted for 100 Tab)	24	19509800	7374704	147494	
341	NRD -727	Paroxetine 12.5 mg Control Release / Prolonged Release Tablet [NRD-727]	10x10 (Rate should be quoted 100 Tab)	24	279100	261327	5227	
342	NRD -728	Paroxetine 25 mg Control Release / Prolonged Release Tablet [NRD-728]	10x10 (Rate should be quoted 100 Tab)	24	236800	355336	7107	
343	NRD -735	Pheniramine 25 MG Tab. I.P. [NRD-735]	10x10 (Rate should be quoted 100 Tab)	24	200400	111079	2222	
344	NRD -738	Pirfenidone 400 mg Tab. I.P. [NRD-738]	10x10 / 1x15 (Rate should be quoted 100 Tab)	24	309800	4441293	88826	
345	NRD -739	Piroxicam DT 20mg Tab. I.P. [NRD-739]	10x10 (Rate should be quoted 100 Tab)	24	421820	144566	2891	ev
346	NRD -742	Posaconazole 100mg Tab. [NRD-742]	10x10 (Rate should be quoted 100 Tab)	24	110200	11108160	222163	
347	NRD -746	Prednisolone IP 40mg Tab. I.P. [NRD-746]	10x10 (Rate should be quoted 100 Tab)	24	944620	2930589	58612	٦
348	NRD -752	Propranolol 40 mg Sustained Release / Prolonged Release Tablet / Capsule [NRD-752]	10x10 (Rate should be quoted 100 Tab/cap.)	24	Designa	signed by	Mar oj Ku	mar
349	NRD -755	Ranolazine 500MG Tab. ER/PR/CR [NRD-755]	10x10 (Rate should be quoted 100 Tab)	24	Date: 20 Reason:	25,05,06 Appro e	53:38	ST

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
350	NRD -756	Rasagiline1MG Tab. [NRD- 756]	10x10 (Rate should be quoted 100 Tab)	24	82200	893021	17860	
351	NRD -757	Regorafenib 40 mg Tab. [NRD- 757]	10x10 / 28 Tablet(Rate should be quoted for 100 Tab)	18	22640	5763601	115272	
352	NRD -759	Repaglinide Img Tab. [NRD-759]	10x10 (Rate should be quoted 100 Tab)	24	86420	430717	8614	
353	NRD -763	Tab. Rifampicin 600 mg (Each capsule/ tablet contains Rifampicin IP 600 mg) [NRD- 763]	10x10 Tablet / Capsule (Rate should be quoted 100 Tab/ cap )	24	57800	533685	10674	
354	NRD -764	Rifaximin 200 Tab. B.P. [NRD-764]	10x10 (Rate should be quoted 100 Tab)	24	780600	2762700	55254	
355	NRD -766	Rivaroxaban 10mg Tab. B.P. [NRD-766]	10x10 / 1x15 (Rate should be quoted 100 Tab)	24	398700	357235	7145	
356	NRD -767	Rivaroxaban 15mg Tab. B.P. [NRD-767]	10x10 / 1x14 (Rate should be quoted 100 Tab)	24	208000	215441	4309	
357	NRD -768	Rivaroxaban 20mg Tab. B.P. [NRD-768]	10x10 / 1x14 (Rate should be quoted 100 Tab)	24	189500	247281	4946	
358	NRD -771	Rosuvastatin 10mg and Fenofibrate 160mg Tab. I.P. [NRD-771]	10x10 (Rate should be quoted 100 Tab)	24	1878480	1346494	26930	
359	NRD -777	Serratiopeptidase 10mg Tab. I.P. [NRD-777]	10x10 (Rate should be quoted 100 Tab)	24	3789640	1230875	24618	10
360	NRD -778	Serratiopeptidase 20 mg Tab. I.P. [NRD-778]	10x10 (Rate should be quoted 100 Tab)	24	857400	660294	13206	
361	NRD -779	Sevelamer Carbonate 800 mg Tab. [NRD-779]	10x10 (Rate should be quoted 100 Tab)	24	631600	2207063	44141	
362	NRD -780	Sildosin 8 mg and Dutasteride 0,5 mg Tablet / Capsule [NRD-780]	10x10 (Rate should be quoted 100 Tab/cap)	24	1310800	2451720	49034	
363	NRD -783	Sildenafil 20 mg Tab. I.P. [NRD-783]	10x10 / 1x15 (Rate should be quoted 100 Tab)	24	799600	4358383	87168	111
364	NRD -786	Sorafenib 200 mg Tab. I.P. [NRD-786]	10x10 / 30 Tablet (Rate should be quoted 100 Tab)	24	201180	2323629	46473	
365	NRD -793	Tapentadol 50mg Tab. [NRD-793]	10x10 (Rate should be quoted 100 Tab)	24	635420	1775618	35512	
366	NRD -794	Tegafur 100mg and Uracil 224mg Capsule [NRD-794]	10x10 Cap (Rate should be quoted 100 Cap)	24	_	ature		J=0
367	NRD -795	Tenofovir 300MG Tab. [NRD-795]	10x10 / 30 Tablets (Rate should be quoted 100 Tab)	24	Designa	signed by tion 25,05,06	ut e Dire	ctor
368	NRD -799	Tolvapatan 15mg Tab. [NRD-799]	10x10 (Rate should be quoted	24	Reason:	Approve	: <del>5</del> 3:38 I	01

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
			100 Tab)					,
369	NRD -800	Topiramate 50MG Tab. I.P. [NRD-800]	10x10 (Rate should be quoted 100 Tab)	24	901120	565182	11304	
370	NRD -801	Torsemide 20mg Tab. I.P. [NRD-801]	10x10 / 1x15 (Rate should be quoted 100 Tab)	24	3199800	1325997	26520	
371	NRD -802	Tramadol 37.5mg and Paracetamol 325mg Tab. [NRD-802]	10x10 (Rate should be quoted 100 Tab)	24	12545362	5592221	111844	
372	NRD -805	Trimetazidine Hydrochloride Modified Release (CR/SR/PR) 60 mg Capsule/Tablet [NRD-805]	10x10 (Rate should be quoted 100 Tab/cap)	24	307802	713608	14272	
373	NRD -806	Trypsin 48mg and Rutoside 100mg and Bromelain 90 mg Tablet [NRD-806]	10x10 (Rate should be quoted 100 Tab)	18	1064800	1787671	35753	
374	NRD -808	Ulipristal 5mg Tab. [NRD- 808]	10x10 (Rate should be quoted for 100 Tab)	24	34100	1300056	26001	
375	NRD -809	Voriconazole 200 mg Tab. I.P. [NRD-809]	10x10 / 1x4 (Rate should be quoted 100 Tab)	24	133000	3872960	77459	
376	NRD -812	Vildagliptin 50mg Tab. I.P. [NRD-812]	10x10 / 1x15 (Rate should be quoted 100 Tab)	24	5864758	3120051	62401	
377	NRD -813	Voglibose 0.2 mg Tab. I.P. [NRD-813]	10x10/15 strip/blister of Tab (not more than 100± 10 in a box) (Rate should be quoted for 100 Tab)	24	5262640	1119890	22398	
378	NRD -814	Voglibose 0.3 mg Tab. I.P. [NRD-814]	10x10 (Rate should be quoted 100 Tab)	24	7960950	2050741	41015	
379	NRD -816	Warfarin 2MG Tab, I.P. [NRD-816]	10x10 / 30 Tablet (Rate should be quoted 100 Tab)	24	638740	193441	3869	,
380	NRD -818	Zinc 50MG Tab. [NRD-818]	10x10(Rate should be quoted 100 Tab)	24	2745550	891755	17835	
381	NRD -819	Zolpidem 10mg Tab. I.P. [NRD-819]	10x10/15 strip/blister of Tab (not more than 100± 10 in a box) (Rate should be quoted for 100 Tab)	24	873600	469647	9393	
382	NRD -820	Cap. Zonisamide 50 mg (Each Capsule contains Zonisamide 50 mg)	10x10 (Rate should be quoted 100 Cap)	24	100300	687496	13750	
383	NRD -821	Zonisamide 100 mg Tab. [NRD- 821]	10x10 (Rate Should be quoted for 100 Tab)	24	Sign	atůte	yali	d
384	NRD -822	Tiotropium Inhalation 9mcg [NRD-822]	120/ 180/ 200MDI (rate should be quoted per dose)	18	Diditally	siemed by	Mar of Ku	ımar
385	NRD -828	Zideovudine 60mg+ Lamivudine 30mg, Each tablet contain Zideovudine	10X10 Tablets (Rate should be quoted 100 Tab)	24	Date: 20 Reason:	tion Exec 25.05.06 Approve	.53:38	ST

S. No	Drug Code No	Name of Drug with specification	Packing unit	Minimu m labelled Shelf life (in months)	Estimated Bid Qty. for 2years	Estimated Bid Value (Rs)	Required Bid Security @2% Estimate d Bid Value (In Rs.)	Remark s
1	2	3	4	5	6	7	8	9
		60mg+ Lamivudine 30mg [NRD-828]						
386	NRD -903	Chlorthalidone 25mg Tablet [NRD-903]	10x10 Tablet (Rate should be quoted 100 Tab)	24	633534	496620	9932	

Signature valid

Digitally signed by Maroj Kumar
Designation, Executive Director
Date: 2025.05.06 17:53:38 IST
Reason: Approve

#### Note:-

The above quantity mentioned for this supply cum rate contract is indicative and may vary as per the actual requirement of hospitals.

The bidder should quote rate for the above mentioned packing unit only.

#### General Requirement:-

- 1. The manufacturer should ensure Stability of the formulations and its ingredients in the packing supplied.
- The blister packing of tablets/Capsules should have Aluminium foil back.
- Strip packing should be of Aluminium / Alu- Alu foils.
- Aluminium foil strips refer to thickness not less than 40 microns.
- The rigid PVC used in blister packing should be of not less than 250 microns.
- Small tablets packed in blister should be packed to facilitate easy removal of a tablet without breaking/ crushing.
- Containers for 400 ml (or 400 gm) or more, should have an inner lid also.
- Syrup and Suspension should be palatable enough.
- 9. The measuring cap / dropper supplied with oral liquid formulation should have suitable marking.
- The minimum size (length x breadth) of a blister strip shall be 6.5cm X 3cm.
- 11. Generic name of a drug should be printed in clearly legible bold letters. The font size of the name of drug on any tablet strip/ blister shall not be less than '9' in bold capital letters of Times New Roman or Arial font, e.g., LOSARTAN TABLETS IP even on small strips/ blisters. The font size shall be correspondingly bigger on bigger strips / blisters. Besides this, other contents on the label should also be legible.
- 12. The stereo printing of batch no., Mfg date, Exp date on the reverse side of strip/blister should run atleast two times.
- 13. Quote rate in BOQ for the packing exactly given in annexure VIII. For example
  - If the packing unit is given for 10x10 tablets / capsule, the rate should be quoted for 10x10 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
  - If the packing unit is given for 10x10x1 tablets / capsule, the rate should be quoted for 10x10 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
  - If the packing unit is given for 10x14 tablets / capsule, the rate should be quoted for 10x14 tablets / capsule, and not for 1 tablet / capsule or 10 tablets/ capsule.
  - If the packing unit is given for 2 ml ampoule (25 ampoules), the rate should be for 25 ampoules and not for 1 sopon at the poules
  - If the packing unit is given for 2 ml ampoule (10 ampoule should be quoted for 10 ampoules and no

Date: 2025.0

Reason: Appro

# RAJASTHAN MEDICAL SERVICES CORPORATION LTD GUIDELINES FOR BLACK LISTING / DEBARRING OF PRODUCT OR COMPANY

# 1. ON SUBMISSION OF FALSE, FORGED OR FABRICATED DOCUMENTS OR CONCEALING OF FACTS:

- 1.1 The tenderer who submits false, forged or fabricated documents or conceals facts with intent to win over the tender or procure purchase order; EMD of such tenderer firm will be forfeited and firm will be liable for debarring for a period of not Less than 2 years. The firm will also be liable for Legal action depending on the facts & circumstances of the case.
- 2. ON ACCOUNT OF FAILURE TO ENTER INTO AGREEMENT OR WITHDRAWL AFTER AGREEMENT OR REFUSAL / FAILURE TO SUPPLY:
- 2.1 The successful Bidder fails to execute the agreement after being declared as L-1, L-2 or L-3 etc. to perform the obligations under the Bid conditions, Bid Security Deposit of such Bidder firm shall be forfeited.
  - If an LoA for more than one products is issued to a successful bidder and he/she/it fails to execute agreement for few item (s), in such case, Bid security of that item shall be forfeited and the product for which agreement is not executed shall be debarred for a period of not less than 3 years.
- 2.2 The successful tenderer after entering into an agreement withdraw or fail to honour commitments as per tender conditions, Security Deposit of such tenderer firm will be forfeited and firm will be liable for debarring for a period of not Less than 2 years.

#### 3. ON ACCOUNT OF NON-SUPPLY:

- 3.1 The supplier shall start to supply according to tender condition from the date of purchase order and shall complete the supplies within 60/75 days as mentioned in Purchase Order or as stated in tender condition.
- 3.2 RMSC will be at liberty to accept or reject the supply made belatedly as per the terms and conditions of the tender documents. In the event of acceptance of delayed supply the liquidated damages shall be imposed at the rate stipulated in conditions of the tender document.
- 3.3 If the supplier fails to execute the purchase order and informs RMSC about its inability to execute the order and non-compliance of the purchase order due to act of vis-majeure, then the Managing Director, RMSC will issue appropriate order on merits of case.
- 3.4 If the supplier fails to execute atleast 50% of the **Santin mentioned** in singlic purchase order and such failure in supply continues for three purchase of the supplier firm will be liable for debarring for a **Digitally signed** by the single tumar such supplier will be ineligible to participate in an Designation Execute Director Date: 2025.05.06 1 .53:38 IST item(s) of drugs / medicines for a period of 2 years. Reason: Approve

# 4. ON ACCOUNT OF QUALITY FAILURE OF DRUGS & MEDICINES:

- 4.1 The drugs supplied by the suppliers to the District Drug Warehouses are quarantined and samples of each and every batch of drugs /medicines are drawn on random basis and forwarded to Quality Control Wing of RMSC at the headquarter. The samples are then sorted; common batches pooled, coded and are sent to the empanelled laboratories for quality control test as per the QC Policy of RMSC.
- 4.2 Samples of all sterile surgicals & sutures items falling in the categories of drugs will also be drawn as per above policy and all of them will be subjected essentially for sterility testing.
- 4.3 If such samples pass quality test in all respects, RMSC will instruct its Warehouses to issue items of drugs to various hospitals / institutions
- 4.4 If the sample fails in quality test and report is received certifying that sample is not of standard quality, the drugs of the batch will not qualified for issue and supplier shall be informed to take back stocks of such batch, which failed the quality test and other consequences would follow as per the conditions in the tender documents.

#### Minor defects

- 4.5 (1) If one batch of a particular item supplied during contract period fails in any of the quality test conducted by the tender inviting authority and/or by the Drugs Control Department, then Penalty of not less than 5.0% of Purchase Order value of that particular item shall be levied."
  - 4.5 (2) If two batches of a particular item supplied during contract period fail in any of the quality tests conducted by the tender inviting authority and/or by the Drugs Control Department, then that particular product of that firm will be blacklisted for a period up to 3 years but not less than 06 months in any case.
    - (\*Tablets/Capsules failing in dissolution test and active contents found 70% and above for thermo labile products and upto 5% less than the prescribed limits for thermo stable products.)

# Grossly substandard

- 4.6 (1) If any batch of a particular item supplied under a tender tenure by the supplier is declared as Not of Standard Quality by an empanelled lab or Govt. Lab which falls in grossly substandard category and such failure is further confirmed by another empanelled lab / Govt. Lab, then the product shall be liable for debarring for a period of not Less than one (1) years.
- (2) If two or more batches supplied under a tender tenure by the supplier is declared as Not of Standard Quality by an empanelled lab or Govt. Lab, which falls in grossly substandard and such failure is further confirmed by Govt. Lab, then the Product shall be liable for debarring for a period of the less than two (2) years I
- 4.7 If the supplier supplied more than one drug (subject to minimum of 6 during a tender duration and 50% of such drugs are Digitally signed from be blacklisted for a period of 2 years from observing the procedure.

  Product shall be liable for debarring for a period of Signature ears alid

  4.7 If the supplier supplied more than one drug (subject to minimum of 6 such drugs are Digitally signature ears alid

  4.7 If the supplier supplied more than one drug (subject to minimum of 6 such drugs are Digitally signature ears alid

  4.7 If the supplier supplied more than one drug (subject to minimum of 6 such drugs are Digitally signature ears alid

  4.7 If the supplier supplied more than one drug (subject to minimum of 6 such drugs are Digitally signature ears alid

  4.7 If the supplier supplied more than one drug (subject to minimum of 6 such drugs are Digitally signature ears alid

  4.7 If the supplier supplied more than one drug (subject to minimum of 6 such drugs are Digitally signature ears alid

  4.7 If the supplier supplied more than one drug (subject to minimum of 6 such drugs are Digitally signature ears alid

  4.7 If the supplier supplied more than one drug (subject to minimum of 6 such drugs are Digitally signature ears).

# Spurious or Adulterated

- 4.8 In case, any sample (even one batch) is declared as Not of Standard Quality by an empanelled lab or Govt. Lab which falls in Spurious or Adulterated category and if such failure is further confirmed by Govt. Lab during its entire shelf life, the Company shall be liable for debarring for a period of not less than 5 years.
- 4.9 If any statutory sample of RMSC supply drug is drawn by Drugs Control Officer on suo-moto basis or on complaint and if it fails in quality parameters, the report is conclusive till it is challenged by supplier / company. If it is challenged then the report of Director, C.D.L., Kolkata shall be conclusive and action as contemplated in foregoing paragraphs will be initiated in the matter of debarring of product or company. However if failure is of such nature wherein Drugs Controller of State grants prosecution sanction under Drugs & Cosmetics Act, 1940, then even failure of such one batch shall be considered adequate for debarring the product for not less than 2 years and in case of involvement of three different products the Supplier / Company as a whole shall be liable for debarring for a period of not Less than 3years.

# 5 PROCEDURE IN THE EVENT OF QUALITY FAILURE WILL INVOLVE THE FOLLOWING STEPS:

- 5.1 On receipt of adverse quality test report from empanelled lab or Govt. Lab of a quarantined stock, instructions will be issued immediately through e-mail to the concerned District Drug Warehouses to not to release such stock and entries be made by QC Cell at headquarter in e-aushadhi software for batch rejection i.e. not to be released for distribution to institutions / DDC's.
- 5.2 Warehouse In-charge will take appropriate measures immediately to segregate such stock and label all cartons as "NOSQ Drugs-Not for release" and shift it from quarantine area to Non-Release / Rejected Drugs Area (which is under lock & key) till its lifting by the supplier.
- 5.3 Immediately on receipt of NOSQ report, the second sample should be sent to another empanelled lab / Govt. Lab by the by QC Cell.
- 5.4 The supplier shall be informed immediately about the test results and instructions be issued to lift the entire stock at supplier's expenses of such batch no. drug which is declared as "NOSQ" by the empanelled lab / Govt. Lab. However, in case of serious quality failure i.e. if drug is declared or adjudged spurious, adulterated or grossly substandard, one of drug warehouse In-charge will be directed to contact the District Drugs Control officer for drawing statutory sample of such batch as per Act. The DDW In-charge has to keep adequate quantity of such drug for statutory sampling by Drugs Control officer.
- 5.5 In case of drug declared as **Not of Standard Quality** on subsequent sampling after the batch was released the procedure given in **Special Control** in respect of stock available with the warehouse. In **Special Control** issued and drug warehouse In-charge will take im **Digitally stigned by Markov** Kumar the unused stock of such drugs from all such install patients. Execute Director Date: 2025.05.6 1.53:38 IST

Reason: Approve

possible mode and means and he/she will ensure that no such NOSQ drug is further distributed to the patients and ensure effective recall.

- 5.6 On receipt of test report from empanelled lab / Govt. Lab, show cause notice will be issued immediately to the concerned supplier calling for explanation within 3 days from the date of receipt of notice in respect of quality failure of concerned batches of drug. The supplier will be required to submit the batch manufacturing record, batch analysis report, raw material purchase record & raw material test reports etc. Opportunity for personal hearing, if desired by supplier, may also be accorded.
- 5.7 On confirmation of the test result by the second laboratory, the case will be referred to the disciplinary committee of RMSC for further action.
- 5.8 In case when the second report is contradictory to the first report, the statutory sample will be sent to Govt. Lab, whose report will be final and if the sample has been tested by the Govt. Lab at any stage, its report will be conclusive & final unless challenged as per provisions of Drugs & Cosmetics Act, 1940.

# 6. EXAMINATIONS OF ISSUES BY DISCIPLINARY COMMITTEE OF RMSC

- 6.1 Each & every case of submission of false documents, failure to execute agreement, non-supply or quality failure, etc. will be referred to disciplinary committee of RMSC for examination on a case to case basis for making appropriate technical recommendation to Managing Director for further appropriate action.
- 6.2 The recommendations of disciplinary committee will be placed before the Managing Director, RMSC who shall take appropriate action which may deem fit in the light of facts & circumstances of the case by way imposing penalty or debarring or Debarring of the particular product or supplier/company.
- 6.3 If, the quality failure is of such nature that a particular product has been blacklisted according to the procedure stated above, the supplier will not be eligible for participating in any of the tenders for the particular item floated by RMSC for the specified period. For such purpose period of debarring will be counted from date of issue of order and it will deemed to be over on completion of the period and as such no fresh orders will normally be required for re-eligibility purpose. Similarly if the supplier /company is blacklisted the supplier will not be eligible for participating in any of the tenders for any of the items during blacklisted period.

#### 7. POWER OF REVIEW:

Subsequent to the action taken on the basis of available facts if some new facts & evidences such as reversal of test results findings by Appellate Laboratories etc. are brought to the notice of the corporation, the Managing Director of RMSC will have the right to review the earlier action. He may seek advice from the disciplinary committee in such matters.

#### 8. RIGHT TO APPEAL:

Any supplier / company against whom the above actions taken may prevailed appeal within 30 days of date of debarring order to the introduction and the significant by the significant Medical & Health Department, Govt. of Rajasthan w Designation, Execute Director Date: 2025.05 15.53:38 IST

Reason: Appro

9. SAVINGS:

The debarring of particular product or supplier / firm will be done without prejudice to other penalty which may be imposed as per the conditions of tender documents and also to other actions which may be initiated under Drugs and Cosmetics Act 1940 or any other law of land. RMSC will display names of such blacklisted products and companies on its website and also circulate the same among all stakeholders viz. PSME, DM&HS, DC including respective State Drug Controllers where the supplier / company is located.

#### 10. JURISDICTION:

In the event of any dispute arising out of the orders and implementation thereof, such dispute shall be subject to the jurisdiction of the Courts of Jaipur City only or Hon'ble Rajasthan High Court, Bench at Jaipur.

#### 11. EXPLANATIONS:

- (i) Increase in the cost of raw materials, power cut, Labour strike, insolvency, closure of the factory would not be considered as act of vis-majeure.
- (ii) The Spurious, Adulterated, Grossly sub-standard drug shall have the explanation as per guidelines issued by Govt. of India for taking action on "Not of Standard quality drugs."

On the basis of quantitative analysis (Assay), the NOSQ drug shall be distinguished in the following manner:-

Category of NOSQ drugs	Active ingredient content (Assay)				
	Thermo stable	Thermolabile			
Minor	Upto 5% less than the prescribed lower limit	Above 70% to the prescribed lower limit			
Grossly Substandard	Below 5% of the prescribed lower limit to 50%	70% to 40%			
Spurious	Below 50%	Below 40%			

- (iii) Purchase Orders, if any, already issued before taking any debarring action or replacement orders given in past will not be affected in view of action taken as per above guidelines but all strict quality checks shall be observed for each supply of products.
- (iv) The action proposed as above is not in conflict to any express conditions laid down in corresponding tender and in case of any overlapping, the tender condition will prevail.

Signature yalid

Digitally signed by Mar of Kumar Designation, Executive Director Date: 2025.05.06 1 .53:38 IST Reason: Approve

ANNEXURE-X (Ref. Clause: 26)

FORM NO. 1 [See rule 83 of RTPP]

# Memorandum of Appeal under the Rajasthan Transparency in Public Procurement Act, 2012

Ap	pear No	OI					
Be	fore the	(First/Second Appellate Authority)					
1.	Particula	ars of appellant:					
-	(i)	Name of the appellant:					
	(ii)	Official Address, if any:					
	(iii)						
2.	Name ar	nd address of the respondent (S):					
	(i)						
	(ii)						
	(iii)						
off act	icer/ autho	and date of the order appealed against and name and designation of the prity who passed the order (enclose copy), or a statement of a decision, ission of the Procuring Entity in contravention to the provisions of the h the appellant is aggrieved:					
		ppellant proposes to be represented by a representative, the name and s of the representative:					
5.	Number	of affidavits and documents enclosed with the appeal:					
		of appeal:					
		(Supported by an affidavit)					
		(546)					
7.							
Pra	yer:						
	- 						
****							
Pla	ce						
Da	te						
An	pellant's S	Signature					
	provinced at the fa-	copycontains w					

Signature valid

Digitally signed by Mar of Kumar
Designation Executive Director
Date: 2025.05.06 1 .53:38 IST Reason: Approve

# ANNEXURE-XI Ref. Clause No. 1(d), 5(c)(j), 20

#### UNDERTAKING FOR EMPANELMENT

I Name	S/o	Age	Prop./Partner	/Director/ P	ower of
attorney holder	of firm M/s	situa	ted at (Compl	ete address	of Mfg.
unit)	bearing drug lie	cense on Forn	n 25 & 28 o	r form 10	bearing
Number	&	t	respectively,	issued	on
dated	valid/Renewed	up to	do	here by de	clare on
oath as follows:-					

- That I have applied for empanelment for supply of Drugs & Medicines for the items I have quoted in the bid as enlisted in Annexure –VII
- That I/We have carefully read all the conditions of E- Bid in Ref. no.
   No.: F.02(422)/RMSCL/PROCUREMENT/DRUG/NIB-01/2025/
   Dated:- for supply Cum rate contract and empanelment for supply
   of Drug and Medicines For Rajasthan Medical Services Corporation
   Ltd and accept all conditions of Bid, including amendments if any.
- That I will be considered empanelled for the items which my bid have been declared technically responsive.
- 4. That I have deposited the required fees for empanelment.

Date

Name & Signature with Seal

Signature yalid

Digitally signed by Mar of Kumar Designation Execute Director Date: 2025.05.06 1 .53:38 IST Reason: Approve

90

# Annexure-XII Ref. Clause No.17.2

Supplier Consolidated Invoice

lete Ad	dress:							****		
0.:			1	GST No						
ess: Raja ni-Block, ne, Jaipu CL GST	sthan Mo Swasthar Phone I	edical Ser iya Bhawa No. 0141- AFCR282	an, Tila 222806 <b>4M1Z3</b>	ik Marg, ( 56	<b></b>	Date:		ler No.:	SONO (1995)	0
Nam e of DDW	Odere d Qty.	Invoice / Challa n no.	Date	Packin g Size	Batch No.	Mfg. Date	Exp Dat e	Quantity Supplied in No. (Batch wise)	Basic Rate (without GST )	Basic Amount (without GST)
2	3	4	5	6	7	8	9	10	11	12
rks:						Rate Rate Rate	of (% e of (% e of (%	) GST(SG ) GST(IG	ST) ST)	
	olete Addil ID: O.: naser: M ess: Raja ni-Block ne, Jaipu CL GST of Item  Nam e of DDW	olete Address: il ID:  O.: naser: Managing ess: Rajasthan Moni-Block, Swasthane, Jaipur Phone I  CL GSTIN.08AA of Item/Descrip  Nam odere e of d Qty. DDW  2 3	olete Address: il ID:	olete Address: il ID:  O.:  naser: Managing Director ess: Rajasthan Medical Services C ni-Block, Swasthaya Bhawan, Tila ne, Jaipur Phone No. 0141- 222806  CL GSTIN.08AAFCR2824M1Z3 of Item/Description:  Nam Odere Invoice Date e of d Qty. DDW  Challa n no.  2 3 4 5	olete Address: il ID:  O.:  GST Note:  asser: Managing Director ess: Rajasthan Medical Services Corporation ni-Block, Swasthaya Bhawan, Tilak Marg, One, Jaipur Phone No. 0141- 2228066  CL GSTIN.08AAFCR2824M1Z3 of Item/Description:  Nam Odere d Qty. DDW  Nam Odere d Qty. Challa n no.  2 3 4 5 6	olete Address: il ID:  O.: GST No.: Haser: Managing Director ess: Rajasthan Medical Services Corporation Ltd, ni-Block, Swasthaya Bhawan, Tilak Marg, C- ne, Jaipur Phone No. 0141- 2228066  CL GSTIN.08AAFCR2824MIZ3  of Item/Description: Drug G  Nam Odere e of d Qty. / Challa n no.  Drug G  Challa n no.  Total E  Total E	Description:    Soft No.:   HSN Code	Detect Address:  II ID:  O.: GST No.: HSN Code  Purchase Order Sess: Rajasthan Medical Services Corporation Ltd, in-Block, Swasthaya Bhawan, Tilak Marg, Chee, Jaipur Phone No. 0141- 2228066  CL GSTIN.08AAFCR2824M1Z3  of Item/Description: Date e of d Qty. / Challa n no.  Drug Code (RMSCL)  Date Date Date Packin g Size No. Date Date e of Challa n no.  Total Basic Amount  Rate of (% Ra	rks:    Date:   Date:   Date:	O.:  O.:  O.:  GST No.:  HSN Code  Invoice No.:  Date:  Purchase Order No.:  Date:  Purchase Order No.:  Date:  Date:  Date:  Purchase Order No.:  Date:  Date:  Date:  Date:  Date:  Date:  Purchase Order No.:  Date:  Da

Signature valid
Digitally signed by Mar of Kumar
Designation, Executive Director
Date: 2025.05.06 1 .53:38 IST
Reason: Approver

# **Analytical Report Regarding Quality**

Nam	e of Supplier:-					
Add	ress:-					
PO N	No:-	Date:-				
Drug	y Name:-					
Deta	ils of in house test	report:-				
S. No.	Name of Lab.	Test report No.	Date	Batch No.	Qty. Supplied	Result
1.						
2.						
3.						
4.						
5.						
6.						
7.						
8.						
9.						
10.						
11.						
12						

Authorised Signatory

Signature yalid

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 17.53:38 IST Reason: Approver

# Performance Security form (Bank guarantee)

To,
Managing Director Rajasthan Medical Services Corporation Ltd WHEREAS(Name of Supplier)
Hereinafter called "the Supplier" has undertaken, in pursuance of Contract (Letter of Acceptance) No
AND WHEREAS it has been stipulated by you in the said Bid that the Supplier shall furnish you a bank Guarantee from a Scheduled Bank for the sum specified therein as security for compliance with the Supplier's performance obligations in accordance with the Contract.
AND WHEREAS we have agreed to give the supplier a Guarantee:
THEREFORE WE hereby affirm that we are Guarantors and responsible to you, on behalf of the Supplier, up to a total of
This Bank guarantee is payable at Jaipur Branch
This guarantee is valid until theday of
Signatures and Seal of Guarantors
Date
Address:
Signature valid

Note:- The validity of bank guarantee should be for 3 issuance of Bank Guarantee.

Digitally signed by Mar of Kumar Designation, Executive Director Date: 2025.05.06 11:53:38 IST Reason: Approver

## Land Border Country Registration Requirement

Name	(To be executed on a non-judicial stamp paper valued Rs. 50/-) of BidderNIB Number
regard	I/We have read the Rule 13 of RTPP Rules and Government of Rajasthan cation No. F.2(1)FD/G&T-SPFC/2017 dated 01.01.2021, 15.01.2021 and 30.03.2021 ing Provisions for Procurement from a Bidder which shares a land border with India, ertify that, bidder M/s (Name of Bidder) is
(i)	not from such a country
	or
(ii)	if from such a country has been registered with the Authority i.e. as specified in Rule 13 of RTPP Rules and Government of Rajasthan Notification No. F.2(1)FD/G&T-SPFC/2017 dated 01.01.2021, 15.01.2021 and 30.03.2021. (Evidence of valid registration by the Authority shall be attached).
(Bidde	er to select one option
Name:	[insert complete name of person signing the bid]
In the	capacity of [insert legal capacity of person signing the bid]
Signed	: [insert signature of person whose name and capacity are shown above]
Duly a	authorized to sign the Bid for and on behalf of [insert complete name of the bidder]
Date:	[insert date of signing]

Signature valid

Digitally signed by Mar of Kumar
Designation Executive Director
Date: 2025.05.06 1 .53:38 IST
Reason: Approve

# Performance Security Declaration (To be executed on a non-judicial stamp)

	ct Name and No.:	25	Discout masses						
			_Imsert name	and	nu	mber of	Contract]		
To:		[insert	Designation	and	c	omplete	address o	f Procuring	
Entity]									
an au	Ve, the undersigned, othentic certificate in the bidder entity is	issued by	the Administra						
(i) D	epartments/Boards	of the Sta	te Government	or Ce	ntr	ral Govern	nment; or		
(ii) G	overnment Compan	ies as def	ined in clause (	45) of	fse	ection 2 of	f the Comp	anies Act, 2013; or	
Si m an	ompany owned or tate Government or nore State Governm nd Auditor-General 013; or	Governn ents which	nents, or partly h is subject to a	by the	e C by t	Central G the Audita	overnment or appointe	and partly by one ed by the Comptroll	or er
	tonomous bodies, F	Registerea	Societies, Coo	perati	ive	Societies	which are	owned or controll	ed
	aged by the State Go								
	lerstand that we are				2.00		Securing 1	Declaration in lieu	of
177	nance Security unde		1007000T0						
	derstand that, accord								
	y Declaration as a g								ne
	et for					의 변경 경영 보이 다양 안 시해 있다.			
	cept that we will au								
	ou for the period of t								
	r which the Procu	THE STATE OF THE S				22			
7.0	formance Security								
	ition from you, t			Contraction of the Contraction o				하기 있다. 그 전에서 가게 하게 하게 되었다. 얼마 없었다.	
	nance Security Dec			we a	are	in bread	ch of any	of our performan	ce
	ion under the condit								
all obli	derstand this Perform igations under the nance, etc. in accord	Contrac	including De	efect	Lia	ability, w	varranty/ C		
Signed:	: [i	nsert sig	nature of perso	n wh	ose	e name ai	nd capacit	y are shown]	
In the	capacity of:	[inser	legal capacit	y of p	per	rson sign	ing the Pe	erformance Securi	ty
Declara		erot introduced vin		*********	*******				0.750
		[ins	sert complete r	ame	of	person si	gning the	Declaration]	
	uthorized to sign the								ıd
	s of the Bidder								
	ond	lay of		[i	inse	ert date o	of signing]		
	ate Seal							76	

Signature valid

Digitally signed by Mar of Kumar
Designation Executive Director
Date: 2025.05.06 11.53:38 IST
Reason: Approve

Annexure-XVII

(Ref. clause 5 (e))

# **BIDDER'S AUTHORIZATION CERTIFICATE**

10,	
{Procuring entity},	
~	
contact no. with mail id} is hereby auth the company/ firm in dealing with NIB He/ She is also authoriz commercial information/ clarifications	declare/ certify that <u>{Name/ Designation and horized to sign relevant documents on behalf of reference No.</u> dated ed to attend meetings & submit technical & as may be required by you in the course of f validation, his/ her verified signatures are as
Thanking you,	
Name of the Bidder: -	Signature Verified
Authorised Signatory: -	
Seal of the Organization: -	
Date:	
Place:	

Signature valid

Digitally signed by Maroj Kumar
Designation, Executive Director
Date: 2025.05.06 17.53:38 IST
Reason: Approve

# To whom so ever it may concern

	It	is	certified	that	M/s		has	imported	the
follow	ing	ite	ms throug	h the	Bills	of lading / Bills of entry	y and	Sale invo	oices
for las	t th	iree	calendar	/finar	icial y	ears.			

S.No. Item code	Item Specifications	Company of the Compan	flading / of entry	Sale	invoices
	 -cartos:	Year	Number	Year	Number
1.					
2.					
	3				
	,				
3.					
				11	

This certificate is issued on the basis of documents enclosed with this certificate.

-			
D	9	fe.	

Signature of Chartered Accountant (Name in Capital) along with Registration

Number Seal:

(Name in Capital)

UDIN:

Signature valid

Digitally signed by Mar of Kumar

Designation Executive Director

Date: 2025.05.06 1 .53:38 IST Reason: Approve

Annexure-XIX

(Ref. Clause

no. 8)

# Bank Guarantee Unconditional (To be executed on a non-judicial stamp paper) Form of Bid Security

(To be issued by a Scheduled Bank in India or other issuer, acceptable to the Procuring Entity)

[insert Bank's Name, and Address of Issuing Branch or Office)

Beneficiary: [insert name and address of the Purchaser)

Date: [Insert date)

Bid Security No. [insert number]

At the request of the Bidder, we ...[insert name of Bank] ...hereby irrevocably undertake to pay you any sum or sums not exceeding in total an amount of [insert amount in figures] [insert amount in words] upon receipt by us of your first demand in writing accompanied by a written statement stating that the Bidder is in breach of its obligation(s) under the bid conditions, because the Bidder:

- (a) Has withdrawn or modified its Bid after deadline for submission of bids, during the period of bid validity specified by you in the Bid or
- (b) Having been notified during the period of bid validity specified in the Bid document, about the acceptance of its Bid by you
- (i)Failed or refused to execute the Contract Agreement within the time period specified in the Bid Document, or
- (ii) Failed or refused to furnish the performance security, in accordance with the terms and conditions of Bid within the time period specified in the Bid Document, or
- (c) Has breached a provision of the Code of Integrity specified in the RTPP Act, RTPP Rules and the terms and conditions of Bid

This guarantee will expire: (a) if the Bidder is the successful Bidder, upon our receipt of copies of the contract signed by the Bidder and the performance security issued to you upon the instruction of the Bidder; and (b) if the Bidder is not signed the performance security issued to you upon the instruction of the Bidder; and (b) if the Bidder is not signed they was followed as a copy of your notification to the Bidder is not signed they was followed as a copy of your notification to the Bidder is not signed they was followed as a copy of your notification to the Bidder is not signed they was followed as a copy of your notification to the Bidder is not signed they was followed as a copy of your notification to the Bidder is not signed to you upon the instruction of the Bidder.

Reason: Approve

Consequently, any demand for payment under this guarantee must be received by us at the office on or before that date. Signed: [insert signature of person whose name and capacity are shown] Name: [insert complete name of person signing the Bid Security] In the capacity of: [insert legal capacity of person signing the Bid Security] Duly authorized to sign the Bid Security for and on behalf of [insert\_name of bank] Dated on Day of [insert date of signing ] Bank seal [affix seal of the Bank] Note:- The validity of Bank guarantee should be for 6 months from the date of issuance of bank guarantee.

Signature yalid

Digitally signed by Maroj Kumar Designation Executive Director Date: 2025.05.06 17.53:38 IST Reason: Approve